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1. Summary)
 
Intestinal trans-cellular amino acid and monosaccharide absorption is a two-step process 
mediated by different transport proteins located in the apical (facing the lumen of the gut) and 
the basolateral (facing the extracellular space) membrane of small intestinal enterocytes[1-3]. 
)
1.1. Human)intestine)luminal)ACE2)and)amino)acid)transporters)are)
regulated)by)ACEQinhibitors))
 
B0AT1 (SLC6A19) is a sodium-dependent neutral amino acid transporter expressed in the 
luminal membrane of small intestinal enterocytes and of proximal tubule kidney cells[1] whose 
deficiency causes Hartnup disorder[4]. Small intestinal B0AT1 expression depends on the 
presence of the carboxymonopeptidase ACE2 (angiotensin converting enzyme 2)[5], an 
enzyme that belongs to the renin-angiotensin system and whose expression is induced in 
many tissues by application of RAS-active medications including ACE-inhibitors (ACEIs) and 
angiotensin II AT1 receptor blockers (ARBs)[6-8]. A similar interaction of the IMINO 
transporter SIT1 (sodium-dependent imino transporter 1; SLC6A20) – a small intestinal and 
proximal tubule L-proline (Pro) transporter – and ACE2 has been proposed[9], but not 
demonstrated yet.  
We have shown, using the Xenopus laevis oocytes expression system, that human ACE2 
functionally interacts with SIT1 and that both amino acid transporters (B0AT1 and SIT1) co-
localize with ACE2 to the brush border membrane (BBM) of small intestinal enterocytes. In 
addition, we showed that treatment with ACEIs increases small intestinal expression of ACE2, 
of amino acid transporters B0AT1 and PAT1 (SLC36A1) and of peptide transporter PEPT1 
(SLC15A1). We further demonstrated the axial distribution of several amino acid 
transporters/transport units expressed in the luminal and basolateral enterocyte membrane in 
one single cohort of human patients.  
 
1.2. Intestinal)monosaccharide)transporter)expression)in)diabetic)patients)
–)effect)of)metformin)treatment)
 
Noninsulin-dependent diabetes mellitus (NIDDM) is a common disease of glucose 
metabolism that may result in severe morbidity[10]. The dimethylbiguanide metformin is the 
first-line antihyperglycemic medication in NIDDM treatment[11]. Metformin increases insulin-
stimulated glucose (Glc) uptake in muscle cells and decreases hepatic Glc output[12,13]. 
Furthermore, metformin treatment has an inhibitory effect on intestinal glucose absorption as 
shown in rodents[14]. Three different small intestinal hexose transporters, SGLT1 (SLC5A1), 
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GLUT2 (SLC2A2) and GLUT5 (SLC2A5) mediate intestinal monosaccharide absorption with 
SGLT1 being a sodium-dependent BBM glucose (Glu) and galactose (Gal) transporter, and 
GLUT2 and 5 being facilitated diffusion proteins with GLUT2 transporting Glu, Gal and 
fructose (Frc) and GLUT5 transporting Frc only[15-17]. Whereas GLUT5 is expressed in the 
BBM, GLUT2 is expressed in the basolateral enterocyte membrane, but shows luminal 
staining in conditions of experimental diabetes, in fructose- or glucose rich diets in 
rodents[18], as well as in morbidly obese human subjects[19]. Whereas specific fructose- and 
sucrose rich diets increase small intestinal SGLT1, GLUT2 and GLUT5 expression[17], the 
changes in small intestinal hexose transporter expression as a result of NIDDM seems to be 
more complex[16,20].  
We could show an increase in small intestinal GLUT2 mRNA expression in non-treated 
human type 2 diabetics, an effect that is abolished upon metformin treatment. Whereas 
SGLT1 expression was not affected by NIDDM, also GLUT5 gene expression was non-
significantly increased in non-treated human type 2 diabetics. We could further show the 
longitudinal gene expression of hexose transporters along the human digestive tract, as well 
as protein localization of facilitated diffusion protein GLUT5.  
 
1.3. The)molecular)mechanism)of)intestinal)levodopa)absorption)and)its)
possible)implication)on)treatment)of)Parkinson’s)disease)
 
Parkinson’s disease (PD) is a neurodegenerative disorder mainly caused by dopamine 
depletion in the substantia nigra, clinically manifesting by different symptoms including its 
hallmark, the trias of bradykinesia, resting tremor and rigidity[21]. Since its introduction in 
1968, levodopa (L-Dihydroxyphenylalanine, L-Dopa) is the major therapeutic agent in treating 
PD[22]. After passing the Blood Brain Barrier (BBB), levodopa is converted by the dopa-
decarboxylase into dopamine[23]. To prevent levodopa metabolism prior to its transport 
across the BBB, orally administered levodopa is routinely given in combination with a DDC 
inhibitor (DDCI) (as e. g. carbidopa or benserazide) that may be combined with a cathecol-o-
methyl transferase (COMT) inhibitor (such as entacapone), with the latter avoiding levodopa 
methylation into 3-0-methyldopa[22]. Levodopa is a large neutral amino acid (LNAA) showing 
structural homology to the aromatic amino acids (AAs) L-phenylalanine (Phe) and L-tyrosine 
(Tyr). Whereas levodopa is transported via the cysteine and dibasic AA exchanger b0,+AT-
rBAT (SLC7A9-SLC3A1) across the luminal enterocyte membrane[24], three different AA 
transporters were shown to carry levodopa across the basolateral membrane, namely the 
Na+-independent L-type amino acid exchangers LAT1 (SLC7A5) and LAT2 (SLC7A8)[25], as 
well as the aromatic AA uniporter TAT1 (SLC16A10)[26]. In addition to b0,+AT-rBAT, other 
luminal AA transporters including the broad neutral amino acid transporter B0AT1 (SLC6A19) 
have been proposed to transport levodopa[24]. 
Testing different candidate transporters, we could show, that levodopa transport across the 
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luminal enterocyte membrane is restricted to the neutral and dibasic AA exchanger b0,+AT-
rBAT. Luminal neutral AAs decreased intestinal levodopa absorption, whereas luminal DDC- 
(Carbidopa and Benserazide) and COMT inhibitors (Entacapone) did not affect levodopa 
transport. High intra- and extracellular AA concentrations (mimicking the postabsorptive state) 
had no effect on levodopa absorption. Basolateral TAT1 displayed a major role in levodopa 
efflux from intestinal enterocytes. Whereas no gender differences in intestinal levodopa 
transporter expression were seen, the gene- and protein expression of levodopa transporters 
followed a circadian rhythm. 
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2. Zusammenfassung)
 
Die Absorption von Aminosäuren und Monosacchariden im Dünndarm durch die apikale (dem 
Darmlumen zugewandte Seite) und die basolaterale (dem Extrazellulärraum zugewandte 
Seite) Enterozytenmembran wird durch das Zusammenspiel verschiedener Transportproteine 
gewährleistet[1-3]. 
 
2.1. ACEQHemmer)steigern)die)Expression)intestinaler)
Aminsäurentransporter)sowie)der)Peptidase)ACE2)im)menschlichen)
Dünndarm 
 
B0AT1 (SLC6A19) bezeichnet einen natriumabhängigen Transporter neutraler Aminosäuren, 
der in der luminalen Membran intestinaler Enterozyten sowie des proximalen Tubulusepithels 
exprimiert ist[1]. Die B0AT1 Defizienz führt zur Hartnup-Krankheit[4]. Die intestinale 
Expression von B0AT1 in der luminalen Enterozytenmembran bedingt das Vorhandensein der 
RAS (Renin Angiotensin System) Peptidase ACE2 (Angiotensin Converting Enzym 2)[5], 
einem Enzym, dessen Expression durch die Applikation von ACE-Hemmern oder Sartanen in 
verschiedenen Geweben induziert wird[6-8]. In ähnlicher Weise wie B0AT1 und ACE2 
scheinen auch ACE2 und SIT1 (SLC6A20) – der natriumabhängige IMINO Transporter 1 – zu 
interagieren. Diese Interaktion konnte bisher allerdings noch nicht eindeutig aufgezeigt 
werden[9]. 
Wir konnten in einem heterologen Expressionssystem (Xenopus laevis Oozyten) nachweisen, 
dass ACE2 und SIT1 funktionell interagieren. Weiter konnten wir zeigen, dass beide 
genannten Aminosäurentransporter (B0AT1 und SIT1) mit dem akzessorischen Protein ACE2 
in der Bürstensaummembran des humanen Dünndarmepithels exprimiert sind. 
Interessanterweise zeigten Patienten unter Dauermedikation mit ACE-Hemmern eine 
vermehrte intestinale Genexpression von ACE2, B0AT1, des luminalen 
Aminosäurentransporters PAT1 (SLC36A1) und des Peptidtransporters PEPT1 (SLC15A1). 
Weiter konnten wir die Genexpression mehrerer Aminosäurentransporter entlang des 
humanen Gastrointestinaltrakts innerhalb einer einzigen Patientenkohorte aufzeigen. 
 
2.2. Expression)intestinaler)Monosaccharidtransporter)bei)Typ)2)
Diabetikern)und)der)Einfluss)der)Metformintherapie))
 
Diabetes mellitus Typ 2 (= NIDDM) ist eine häufige Erkrankung des Glukosestoffwechsels, 
die mit schwerwiegenden klinischen Manifestationen einhergehen kann[10]. Das 
Dimethylbiguanid Metformin wird als Standardtherapie des NIDDM verwendet[11]. Metformin 
erhöht hierbei die Insulinvermittelte Glukoseaufnahme in die Muskelzellen und vermindert die 
hepatische Glukoseexkretion[12,13]. Des weiteren führt die Applikation von Metfmormin zu 
einer verminderten intestinalen Glukoseabsorption im Tiermodell[14]. Drei Transporter sind 
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für die intestinale Glukoseabsorption verantwortlich: SGLT1 (SLC5A1), GLUT2 (SLC2A2) und 
GLUT5 (SLC2A5). SGLT1 bezeichnet einen in der luminalen Enterozytenmembran 
exprimierten natriumabhängigen Glukose- (Glc) und Galaktose (Gal) Transporter. GLUT2 und 
-5 sind Diffusionsproteine. GLUT5 transportiert Fruktose (Frc) und ist – analog SGLT1 – in 
der luminalen Enterozytenmembran exprimiert. GLUT2 transporteriert alle drei 
Monosaccharide (Glc, Gal und Frc) durch die Basalmembran[15-17]. Eine GLUT2 Expression 
in der luminalen Enterozytenmembran konnte im Tiermodell bei Ratten mit Diabetes mellitus, 
sowie nach fruktose- oder glukosereicher Diät beobachtet werden[18]. In einer einzigen 
Humanstudie konnte ebenfalls eine apikale GLUT2 Expression bei adipösen Probanden 
gezeigt werden[19]. Während eine fruktose- und sukrosereiche Diät im Tiermodell zu einer 
vermehrten intestinalen SGLT1, GLUT2 und GLUT5 führt[17], wurde der Einfluss des Typ 2 
Diabetes auf die intestinale Hexosetransporterepression noch nicht ausreichend 
untersucht[16,20]. 
Wir konnten bei Patienten mit Typ 2 Diabetes ohne Metformintherapie eine vermehrte 
intestinale GLUT2 Genexpression im Vergleich zu Nichtdiabetikern nachweisen. Die GLUT2 
Expression bei Typ 2 Diabetikern unter Metformintherapie war interessanterweise 
unverändert zu den Nichtdiabetikern. Ein ähnlicher, allerdings statistisch nicht signifikanter 
Effekt zeigte die intestinale GLUT5 Genexpression (indem ebenfalls metformintherapierte 
Diabetiker im Vergleich zu Nichtdiabetikern und Diabetikern ohne Metformin eine Tendenz zu 
erhöhter intestinaler GLUT5 Genexpression zeigten). Im Gegensatz dazu war die SGLT1 
mRNA gleichmässig bei behandelten- und nicht behandelten Diabetikern sowie bei 
Nichtdiabetikern exprimiert. Desweiteren konnten wir die Genexpression der 
Monosaccharidtransporter GLUT2, GLUT5 und SGLT1 entlang des humanen Darms 
innerhalb einer einzigen Patientenkohorte aufzeigen.  
 
2.3. Der)molekulare)Mechanismus)der)intestinalen)Levodopa)Absorption)
und)mögliche)Auswirkungen)auf)die)Behandlung)des)Morbus)
Parkinson))
 
Morbus Parkinson ist eine neurodegenerative Erkrankung, die durch Absterben der Dopamin 
produzierenden Nervenzellen in der Substantia Nigra verursacht wird. Klinisch manifestiert 
sich die Parkinsonkrankheit typischerweise durch die Trias: Rigor, Bradykinesie und 
Ruhetremor[21]. Levodopa (L-Dihydroxyphenylalanine, L-Dopa) stellt seit seiner 
Markteinführung im Jahr 1968 das am meisten verwendete Medikament zur Behandlung der 
Parkinsonkrankheit dar[22]. Levodopa wirkt dopaminerg, indem es nach Transport durch die 
Blut-Hirn-Schranke durch die DOPA-Decarboxylase (DDC) zu  Dopamin metabolisiert 
wird[23]. Um einen vorzeitigen (vor Transport durch die Blut-Hirn-Schranke) Levodopa 
Metabolismus zu verhindern, wird Levodopa routinemässig in Kombination mit eine DDC 
Inhibitor (z.B. Carbidopa oder Benserazid) verabreicht. Diese Kombination kann weiter um 
einen Catechol-O-Metyhltransferase Inhibitor (z.B. Entacapon) ergänzt werden, der eine 
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Levodopa Methylierung verhindern soll[22]. Strukturell ist Levodopa eine unpolare 
Aminosäure, die mit den Aminosäuren Leucin, Phenylalanin und Tyrosin verwandt ist und die 
via den Aminsäurenaustauscher b0,+AT-rBAT (SLC7A9-SLC3A1) durch die luminale 
Enterozytenmembran transportiert wird[24]. Während andere neutrale Aminsäurentransporter 
(wie z.B. B0AT1 (SLC6A19)) als mögliche (zusätzliche) Levodopatransporter der apikalen 
Enterozytenmembran vorgeschlagen wurden[24], sind drei verschiedene Transporter für den 
basolateralen Levodopaefflux aus dem Enterozyten verantwortlich, nämlich die 
Aminosäurenaustauscher LAT1 (SLC7A5) und LAT2 (SLC7A8)[25], sowie der aromatische 
Uniporter TAT1 (SLC16A10)[26].  
Wir testeten verschiedene luminale Aminosäurentransporter (b0,+AT-rBAT, SIT1, PAT1, 
ASCT2 und B0AT1) auf einen möglichen Levodopa Transport. Hierbei zeigte sich, dass einzig 
der luminale Aminsäurenaustauscher b0,+AT-rBAT Levodopa tansportiert. Die gleichzeitige 
verabreichung luminaler Aminosäuren reduzierte die Levodopa absorption, wohingegen die 
zeitgleiche Gabe von DDC Inhibitoren (Carbidopa oder Benserazid) oder des COMT 
Inhibitors Entacapon keinen Einfluss auf den Levodopatransport hatten. Hohe intra- oder 
extrazelluläre Aminosäurekonzentrationen (entsprechend der postabsorptiven Phase der 
Verdauung) hatten keinen Effekt auf die Levodopaaufnahme. Der basolaterale Uniporter 
TAT1 scheint essentiell für den Levodopaefflux aus intestinalen Enterozyten zu sein. Die 
Gen- und Proteinexpression der Levodopatransporter ist geschlechtsunabhängig, zeigt aber 
eine Korrelation zum zirkadianen Rhythmus.  
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3. Nutrient)absorption)in)the)small)intestine)
 
3.1. The)small)intestine)architecture)
 
The human small intestine is characterised by an epithelium forming a continuous layer of 
cells organized into villi protruding into the lumen of the gut (Figure 1a) and crypts that 
invaginate into the underlying tissue[27]. The total surface of the small intestine is estimated 
being about 200m2[28]. Along the gastrointestinal tract, all segments are divided into four 
layers: the mucosa (epithelium, lamina propria, and muscular mucosae), the submucosa, the 
muscularis propria (inner circular muscle layer, and outer longitudinal muscle layer), and the 
serosa. The layer facing the intestinal lumen consists of epithelial cells (see below), that is 
attached to the basement membrane overlying the lamina propria, consisting of connective 
tissue and lymph nodes. The third and deepest layer of the mucosa is the muscularis 
mucosae, a continuous film of smooth muscle cells. The mucosa resides on top of the 
submucosa that contains a variety of inflammatory cells, lymphatics, autonomic nerve fibers, 
and ganglion cells, and overlies the muscularis propria. The muscularis propria consists of an 
inner circular layer and an outer longitudinal layer. In between reside autonomic neural fibers 
and ganglionic clusters that form a myenteric plexus. Peristaltic waves of the muscularis 
propria propel food along the GI tract. The serosa (consisting of an outer layer of squamous 
epithelial cells, referred to as mesothelium) or the adventitia (lacking an outer layer of 
mesothelial cells) build the outmost GI layers [29] (Figure 1b).  
 
Figure 1a        Figure 1b
 
  
 
Figure 1a. Duodenal villus. Seen is a continuous layer of enterocytes interspersed by goblet 
cells (20x magnification; hematoxylin-eosin staining) (from [30]). Figure 1b. Arrangement of 
small intestinal layers. The wall of the gastrointestinal tract is organised in a mucosal-, a 
submucosal-, a musclular and a serosal layer (from [31]). 
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3.2. The)intestinal)epithelium)
 
The intestinal epithelium is the fastest regenerating tissue within the human body, completely 
renewing within 5 days (with exception of Paneth cells)[32]. The intestinal crypts contain 
Paneth cells that synthesize antimicrobial peptides and stem cells that migrate out of the 
crypts onto the villi differentiating into enterocytes (providing inter alia nutrient absorption), 
Goblet cells (producing a protective mucus layer) and enteroendocrine cells (secreting 
intestinal hormones)[27,32-34]. Two opposing stem cell models are described in the 
literature: The ‘+4 position’ model assumes, that the crypt base is solely populated by Paneth 
Cells and the +4 stem cells locate just above the Paneth cells at the +4 position (Figure 2, ‘+4 
position’ model). Another (later described) theory assumes, that crypt base columnar (CBC) 
cells that are intercalated between Panth cells at the crypt base build the true intestinal stem 
cells (Figure 2, ‘stem cell zone’ model)[35]. 
 
Figure 2 
 
 
Figure 2. Intestinal stem cell models. Schematic representation of the crypt-to-villus axis 
(left) and of the differentiation of small intestinal stem cells (right). The upper panel depicts 
the ‘+4 position’ stem cells model and the lower panel shows the ‘Stem cell zone’ model with 
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intercalated crypt base columnar (CBC) stem cells (Figure from [35]). 
 
3.3. Intestinal)peptide)and)amino)acid)absorption)
 
Ingested proteins are hydrolyzed into small peptides (length of 2-10 amino acids) by stomach 
and pancreas proteases and finally by brush-border membrane-bound peptidases[36]. The 
only absorbable units that may pass the BBM are tri- and dipeptides (absorption mediated by 
the luminal peptide transporter PEPT1) and single amino acids (AAs) (absorption mediated 
by various AA transporters expressed in the enterocytes’ BBM (Figure 3))[37-40]. Within 
small intestinal enterocytes the absorbed tri- and dipeptides are hydrolyzed[41] and single 
AAs are released into the extracellular space by another set of AA transporters located in the 
basolateral enterocyte membrane (Figure 3) [1,37,38,40]. Interestingly, a similar set of 
transporters is used for small intestinal amino acid absorption as for amino acid re-absorption 
in proximal tubule kidney cells[1,36]. 
 
Figure 3 
 
 
Figure 3. Intestinal amino acid transport. Scematic representation of amino acid 
transporters in a small intestinal enterocyte. The names of the transport proteins and their 
human genes are given. The small intestinal lumen is depicted in light blue (left side), 
enterocytes are given in yellow and the extracellular space is shown in orange (right side). 
Adapted figure from Verrey and co-workers[1].  
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3.3.1. SLCQfamilies)and)nomenclature)of)(amino)acid))transporters)
 
Transport proteins may be categorized into active and passive transporters. Whereas the 
latter allow diffusion of solutes (as e.g. amino acids and monosaccharids) across cellular 
membranes according their electrochemical gradient, active transport systems are divided 
into primary- and secondary active systems[42]. While primary active transporters use the 
energy of ATP hydrolysis to drive molecules across membranes (as e.g. the Sodium-
potassium ATPase; see Figure 3), secondary active transporters use transmembrane ion 
gradients (established by e.g. the basolateral Sodium-potassium ATPase) as driving force to 
transport solutes[42,43].  
Since the 1990s membrane transporters in the human genome are grouped into solute carrier 
(SLC) families according to their sequence similarities (with transport proteins assigned to the 
same family sharing 20% or more amino acid sequence identity). Up to now, 52 (compared to 
initially 43 families) SLC families were identified including almost 400 human genes[42]. 
Thereof, 11 families include amino acid transporters[38].  
Following the SLC nomenclature, human genes are named using the three letters SLC, 
followed by a digit (as e.g., SLC6 designating the solute carrier family 6), followed by another 
letter defining the subfamily and another number identifying the individual transporter gene 
(as e.g., SLC6A19). Whereas human SLC transporter genes are written in upper-case letters 
(as e.g. SCL6A19), in rodent genes only the first letter is an upper-case character (as e.g. 
Slc6a19) and insect genes are designated using only lower-case letters[42]. 
 
3.3.2. Amino)acid)transporter)B0AT1)
 
B0AT1 (broad neutral amino acid transporter 1) (SLC6A19) is a sodium-dependent AA 
transporter expressed in the luminal enterocyte membrane and in kidney proximal tubule cells 
transporting neutral AAs[1,44] (with highest substrate affinity to large neutral amino acids, 
lower affinity to smaller neutral amino acids and lowest substrate affinity to amino acids L-
glycine (Gly) and L-proline (Pro)[37].  
Its defect causes Hartnup disorder, an autosomal recessive condition characterized by the 
urinary loss of neutral amino acids that is referred to as neutral aminoaciduria. First described 
in 1956[45] Hartnup disorder occurs at a frequency of about 1/30’000 in the European 
population and may cause clinical symptoms including pellagra-like light-sensitive rashes, 
diarrhea in infancies, cerebellar ataxia, and other central nervous system manifestations[4,5]. 
Efficient surface expression of B0AT1 at the apical membrane of small intestinal enterocytes 
and kidney proximal tubule cells necessitates the co-expression of accessory proteins ACE2 
(angiotensin converting enzyme 2)[5] and the type I membrane protein collectrin 
(TMEM27)[46], respectively. This interaction of B0AT1 and collectrin (exhibiting about 40% 
sequence identity with the renin-angiotensin system (RAS) enzyme ACE2[47]) has been 
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discovered while studying the collectrin knock-out mouse which was showing an absence of 
B0AT1 in the luminal proximal tubule cellular membrane that resulted in massive neutral 
aminoaciduria[46].  
 
3.3.3. Amino)acid)transporter)SIT1)
 
The IMINO transporter SIT1 (sodium-dependent imino transporter 1; SLC6A20) designates a 
high affinity L-proline transporter, expressed – among other tissues – in the luminal 
membrane of small intestine enterocytes and proximal tubule kidney cells[48].  
SLC6A20 mutations when occurring in combination with polymorphisms of other proline and 
glycine transporters may result in the metabolic disorder Iminoglycinuria, that is characterized 
by urinary loss of Pro and Gly and may be associated in some cases with hypertension, 
glycosuria, nephrolithiasis, mental retardation, deafness and blindness[49].  
A functional interaction of SIT1 and ACE2 (in the small intestine) or collectrin (in the kidney), 
respectively, has been suggested by decreased intestinal L-proline absorption in ACE2 
knock-out mice and by reduced proximal tubule SIT1 expression and prolinuria in collectrin 
knock-out mice[46].  
 
3.3.4. ACE2)–)RAS)enzyme,)accessory)protein)of)B0AT1)and)other)functions)
 
3.3.4.1. ACE2(–(RAS(enzyme(
 
The systemic (or circulating) renin-angiotensin system regulates the blood pressure and 
controls the fluid and salt homeostasis[50]. Within the bloodstream, angiotensinogen 
(produced in the liver) is converted to angiotensin I by renin (produced by juxtaglomerular 
kidney cells following low blood pressure and/or low blood volume). Angiotensin I is then 
converted to angiotensin II by the angiotensin converting enzyme ACE, a zinc 
metalloendopeptidase that acts as a dipeptidyl carboxypeptidase on the surface of endothelial 
cells lining the blood vessel walls. Angiotensin II binds to the angiotensing II AT1 (AGTR1) 
and angiotensin II AT2 (AGTR2) receptors that mediate cellular effects including 
vasoconstriction, inflammation and cell proliferation (AGTR1) and aldosterone secretion from 
the adrenal cortex (Figure 5). This classic RAS has recently been extended by the function of 
the ACE homologue ACE2 which is a structural homologue to ACE and - at its carboxy-
terminal domain - to the type I membrane protein collectrin[47] (Figure 4).  
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Figure 4 
 
 
Figure 4. Structures of ACE, ACE2 and collectrin. The transmembrane domain is shown in 
black. The zinc-binding motif (HEMGH; carboxypeptidase) is repeated twice in ACE and once 
in ACE2 and is given in yellow. Regions of structural homology are given in the same color 
(from [47]).  
 
 
ACE2 – similar to ACE – is a carboxypeptidase cleaving single C-terminal amino acids from 
angiotensin I and II thereby producing angiotensin 1-9 (Ang-(1-9)) and angiotensin 1-7 (Ang-
(1-7)), respectively. The conversion of angiotensin II to Ang-(1-7) shows an over 400 times 
stronger efficacy than the Ang-(1-9) production and therefore definines the primary role of 
ACE2 within the RAS[50]. Ang-(1-7) binds to the MAS receptor, leading to vasodilation. ACE2 
hence counteracts the RAS function by working against the AGTR1-mediated 
vasoconstriction and cellular proliferation[47,50,51] (Figure 5).  
 
Figure 5 
 
 
Figure 5. The renin-angiotensin system. ACE, angiotensin converting enzyme; ACE2, 
angiotensin converting enzyme 2; ACE-I, ACE inhibitor; ARB, angiotensin II AT1 receptor 
blocker (modified from[52]).  
 
3.3.4.2. ACE2(–(accessory(protein(of(B0AT1(
 
Brush-border membrane expression of B0AT1 in small intestinal enterocytes depends on the 
presence of intestinal ACE2[5], similar as shown for collectrin in proximal tubule kidney 
cells[46]. Hence, ACE2 knock-out mice showed an almost abolished BBM B0AT1 expression 
2 I Hamming et al
Figure 1. Schematic diagram of the renin–angiotensin–
aldosterone system which shows the role of ACE and ACE2
in the metabolism of the various angiotensin peptides. Modified
from Warner et al [101], with permission
resemble exons in the ACE gene [3]. Two alternative
transcripts of the mouse ACE2 gene have been iden-
tified which probably arise by alternative splicing [8].
Recently, an alternative 5′-untranslated exon of human
ACE2 and new polymorphisms have been reported [9].
The human ACE2 protein is a typical zinc metal-
lopeptidase, which comprises 805 amino acids and
is 40% identical in sequence with ACE, although
it only contains a single catalytic domain. Critical
active site residues, including the His-Glu-Met-Gly-
His zinc-binding motif, are highly conserved. ACE2
is a type I integral membrane glycoprotein orien-
tated with the N-terminus and the catalytic site fac-
ing the extracellular space (an ectoenzyme), where
it can metabolize circulating peptides. The small C-
terminal, cytoplasmic domain has a number of poten-
tial regulatory sites. The similarity with ACE relates
only to its topology and much of the extracellu-
lar domain (Figure 2); the juxtamembrane, transmem-
brane, and cytoplasmic domains of ACE2 share simi-
larity with the renal, transmembrane protein collectrin
[10] (Figure 2), which stimulates insulin exocytosis
and pancreatic beta-cell proliferation [11,12]. Targeted
deletion of the collectrin gene in mice suggests that it
also plays a major role in regulating renal amino acid
transport [13].
Substrate specificity of ACE2
ACE2, a strict carboxypeptidase, hydrolyses its sub-
strates by removing a single amino acid from their
respective C-termini, rather than a dipeptide, as does
ACE. ACE2 therefore has the ability to convert the
decapeptide Ang I to Ang(1–9) and the octapeptide
Ang II to Ang(1–7). A kinetic study evaluating the
comparative roles of ACE and ACE2 in angiotensin
metabolism [14] established that Ang II is hydrol-
ysed two orders of magnitude more efficiently by
Figure 2. The domain structure of somatic and testis ACE,
ACE2, and collectrin. Each protein is a type I integral membrane
protein with a cleaved signal peptide (black), an N-terminal
ectodomain, a transmembrane domain (blue in ACE; red in
ACE2 and collectrin), and a C-terminal cytoplasmic domain.
Somatic ACE contains two HEMGH zinc binding active sites,
while testis ACE and ACE2 contain a single HEMGH motif.
Collectrin lacks a HEMGH motif. The ectodomain of ACE2
(yellow) is more similar to the N-terminal domain of somatic
ACE, while its juxtamembra e stalk, and transmembrane and
cytoplasmic domains are more similar to collectrin. The
numbers indicate the amino acid residues in each prot in.
Modified from Turner and Hooper [102], with permission
ACE2 than Ang I. Hence, the major role of ACE2
in angiotensin metabolism seems to be the production
of Ang(1–7), whose actions oppose those of Ang II.
Different in vivo studies strongly support the concept
that a major role of ACE2 is indeed the generation
of Ang(1–7) from Ang II and that its conversion of
Ang I to Ang(1–9) is not normally of physiological
importance [15–20], except possibly under conditions
that raise Ang II levels, eg ACEi or ARB treatment
[21].
Although most studies have focused on the role
of ACE2 in angiotensin metabolism, the enzyme
has broad substrate specificity. In addition to Ang I
and Ang II, ACE2 hydrolyses apelin-13, neurotensin-
(1–11), dynorphin A-(1–13), β-casomorphin-(1–7),
and ghrelin [22]. Although the ACE substrate brady-
kinin is not hydrolysed by ACE2, its metabolite des-
Arg [9]-[bradykinin], which is an agonist for the B1
bradykinin receptor, is hydrolysed and a role for ACE2
in bradykinin metabolism cannot yet be dismissed. It
is likely that other potential physiological substrates
for ACE2 will emerge.
Cell biology and shedding of ACE2
Knowledge of the basic cell biology of ACE2 still
remains limited, partly because few cell models
expressing ACE2 at high levels are available [23].
ACE2 is expressed as a cell-surface non-raft protein
with little intracellular localization, and the protein
does not readily internalize. However, binding of the
SARS viral spike protein to ACE2 does trigger enzyme
internalization, down-regulating activity from the cell
surface. In polarized cells, ACE2 is exclusively tar-
geted to the apical surface [23,24], in contrast to ACE
J Pathol 2007; 212: 1–11 DOI: 10.1002/path
Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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and B0AT1-mediated AA transport into Xenopus laevis oocytes was increased upon co-
expression of ACE2. In comparison to collectrin knock-out animals[46], kidney proximal 
tubule B0AT1 expression was unchanged in ACE2 knock out mice[5].  
Whereas collectrin has no peptidase function, its functional homologue in small intestine 
hydrolyzes single C-terminal amino acids from small peptides and therefore fulfills two 
functions, trafficking B0AT1 to the brush-border membrane and digesting nutrient peptides. 
These two processes were considered separately for many years, but seem to be linked 
together and are referred to as digestive complexes by Broer and co-workers[36] (Figure 6).  
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Figure 6 
 
 
 
Figure 6. B0AT1 and ACE2 build a digestive complex. ACE2 is required for luminal 
membrane B0AT1 expression. Whether hydrolysis of luminal peptides via ACE2 also 
increases neutral amino acid supply for B0AT1 was not known, when this figure was made 
and is therefore shown with a question mark (from [47]). 
 
3.3.4.3. ACE2(–(accessory(protein(of(SIT1?(
 
A functional interaction of ACE2 and SIT1 has been suggested by the study of the ACE2 
knock out mouse model since sodium-dependent L-proline uptake in everted intestinal rings 
likely reflecting the secondary active transport via SIT1 was absent. A reduced small intestinal 
SIT1 expression in these mice could not been shown due to lack of a specific antibody[9].  
On study showed that L-proline uptake in X. laevis oocytes expressing the mouse orthologue 
of SIT1 was not changed upon co-expression of ACE2, whereas co-expressing B0AT1 and 
ACE2 increased transcellular L-leucine (Leu) transport[53]. 
 
 
3.3.4.4. Other(ACE2(functions(
 
Non-peptide roles of ACE2 include being the functional receptor for the SARS coronavirus, a 
function that is attributed to the transmembrane domain of ACE2[47]. 
 
3.3.4.5. Regulation(of(ACE2(expression(
 
Whereas ACE-inhibitors (ACEIs) including captopril and lisinopril do not affect ACE2 
activity[47], ACEIs and angiotensin II AT1 receptor blockers (ARBs) increase the expression 
of ACE2 mRNA in different organs and tissues, including heart, kidney and the aorta[6-8]. A 
clear explanation for this observation could not been found yet[54].  
 
 )
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3.4. )Intestinal)monosaccharide)absorption)
 
After digestion by the pancreatic α-amylase and brush-border membrane-bound 
disaccharidases including lactase, sucrase and maltase, dietary carbohydrates are absorbed 
exclusively (and unlike dietary proteins that may be absorbed as tri-, dipeptides and single 
amino acids) as monosaccharides D-glucose (Glu), D-galactose (Gal) and D-fructose 
(Frc)[16,55]. Three different intestinal transporters, SGLT1 (SLC5A1), GLUT2 (SLC2A2) and 
GLUT5 (SLC2A5) are well known to provide intestinal monosaccharide absorption[2,3]. 
SGLT1 is a high affinity, low capacity sodium-dependent brush border membrane (BBM) 
glucose and galactose transporter. GLUT2 and 5 are facilitated diffusion proteins with GLUT2 
being expressed in the basolateral enterocyte membrane (but see also 3.3.1.), transporting 
Glu, Gal and Frc and GLUT5 transporting Frc across the BBM[15-17] (Figure 7).  
More recently, another monosaccharide transporter predominantly localizing to the intestinal 
BBM, GLUT7 (SLC2A7), was identified, providing transmembrane glucose and fructose, but 
not galactose transport. Similarly as shown in rodents, this transporter seems also to be 
expressed in the human small intestine[56,57] (Figure 7).  
 
3.4.1. Intestinal)localization)of)monosaccharide)transporter)GLUT2)
 
In experimental diabetes, but also in fructose- and/or glucose rich diets in rodents, the 
basolateral high-capacity, low-affinity facilitative glucose, fructose and galactose transporter 
GLUT2 also shows expression in the apical enterocyte membrane[18].  
Of course small intestinal biopsies in humans are sampled during the fasting state (since the 
lumen has to be empty of food), a fact that might explain, that GLUT2 was detected only in 
the basolateral enterocyte membrane when human biopsies were examined for many 
years[18] until Ait-Omar et al. showed apical GLUT2 expression for the first time in morbidly 
obese human subjects in the year 2011[19]. This finding is in accordance with the fact that 
glucose absorption in humans rises at concentrations far above than required to saturate the 
high affinity, low capacity glucose and galactose transporter SGLT1, suggesting that high 
glucose diet leads to apical GLUT2 expression also in humans[18] (Figure 7). 
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Figure 7 
 
 
 
Figure 7. Schematic representation of monosaccharide absorption in a small intestinal 
enterocyte (from [57]). 
 
3.4.2. Current)definition)of)nonQinsulinQdependent)diabetes)mellitus)
 
Non-insulin-dependent diabetes mellitus refers to a group of chronic metabolic diseases 
characterized by hyperglycemia, caused by a reduction of insulin secretion by pancreatic β-
cells and/or peripheral (i.e. fat- and muscle tissue) insulin resistance[10]. According to the 
World Health Organization (WHO), since 1997 diabetes mellitus is defined as fasting plasma 
glucose levels ≥ 7.0 mmol/l (126 mg/dl) and/or plasma glucose levels ≥ 11.1 mmol/l 
(200 mg/dL) two hours after a 75 g oral glucose load as part of a glucose tolerance test[58]. 
Since 2009, glycosylated hemoglobin (HBA1c) levels with a cut-off point of ≥ 6.5% have been 
added to these diagnostic criteria[58,59].  
 
3.4.3. Metformin)treatment)of)nonQinsulinQdependent)diabetes)mellitus)
 
The biguanide metformin is the most widely used drug to treat NIDDM[14,60] and was 
developed from galegine, a derivative of guanidine found in Galega officinalis  (French lilac or 
goats rue) (Figure 8). According to the American Diabetes Association and European 
Association for the Study of Diabetes – if not contraindicated and if tolerated – metformin is 
the preferred first-line treatment for NIDDM[11]. The glucose-lowering effect of metformin is 
mainly attributed to decreased hepatic glucose output and increased peripheral glucose 
uptake. Other mechanisms that may contribute are reduced fatty-acid oxidation and 
increased intestinal use of glucose[12,13]. Furthermore, metformin treatment exerts an 
inhibitory effect on intestinal glucose absorption as shown in rodents[14] but inconsistent 
effects of metformin on intestinal monosaccharide transporter (SGLT1, GLUT2 and GLUT5) 
expression were found in non-diabetic rats[61,62]. 
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Figure 8 
 
   
 
Figure 8. Chemical structure of metformin[60].  
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3.4.4. Effects)of)dietary)carbohydrates)and/or)(experimental))diabetes)on)
intestinal)monosaccharide)transporter)gene)expression)
 
Several studies show dietary effects on intestinal monosaccharide transporter expression. 
Dietary fructose and sucrose increased jejunal hexose transporter (including SGLT1, GLUT2 
and GLUT5) transcript expression in non-diabetic rats[17]. Whereas expression of the 
fructose transporter GLUT5 seems to be specifically responsive to fructose, intestinal 
expression of SGLT1 and GLUT2 also depend on dietary glucose[63]. The regulation of 
intestinal hexose transporters in diabetic subjects seems to be complex and elicits 
contradictory findings: Whereas one study in humans shows increased gene and protein 
expression of intestinal hexose transporters GLUT2, GLUT5 and SGLT1 in humans with 
NIDDM[16], another study performed in Zucker rats – reflecting a model of type 2 diabetes – 
shows no effect on intestinal monosaccharide transporter GLUT2, GLUT5 and SGLT1 
expression[20]. Surveys in rodents with streptozotocin-induced type 1 diabetes show 
increased small intestinal GLUT2 and SGLT1 expression[64,65] with inconsistent findings 
concerning small intestinal GLUT5 expression[63,65].  
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3.5. Parkinson’s)disease)and)intestinal)levodopa)absorption)
 
3.5.1. Parkinson’s)disease)
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder (following 
Alzheimer’s disease). It is caused by cell loss in different brain regions, mainly by damage to 
dopaminergic neurons in the substantia nigra[66] (Figure 9a). Histo-morphologically, PD is 
characterized by the presence of Lewy bodies, representing eosinophilic cytoplasmic 
inclusions of fibrillar structure showing a dense core, surrounded by a halo (Figure 9b). 
Figure 9a                   Figure 9b 
 
Figure 9a. Substantia nigra. The substantia nigra from a control patient (left side; green 
arrow) and from a Parkinson’s disease patient (right side; blue arrow) are shown. In 
parkinson’s disease, the substantia nigra is almost totally pallid due to loss of pigmented 
neurons. Figure 9b. Lewy body. An eosinophilic Lewy body surrounded by a slight halo 
(blue arrow) within a pathologic neuron is shown. Pictures were adapted from a power point 
presentation from James B. Leverenz, MD, Associate Professor Neurology and Psychiatry 
and Behavioral Sciences, University of Washington School of Medicine. 
 
PD typically manifests above the age of 60 years and displays characteristic clinical 
symptoms including bradykinesia, resting tremor and rigidity[21]. At its onset, PD patients 
show slowly starting and often misinterpreted symptoms of fatigue and stiffness. A lugubrious 
stiff face and postural changes may follow[21] (Figure 10).  
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Figure 10 
 
Figure 10. Illustration of a typical Parkinson’s disease patient showing a frozen face and 
characteristic postural changes (from [21]). 
 
3.5.2. Levodopa)–)the)main)therapeutic)agent)in)Parkinson’s)disease)
 
First introduced in 1968, the dopamine precursor levodopa (L-Dihydroxyphenylalanine, L-
Dopa) is still the main therapeutics for the treatment of Parkinson’s Disease[22]. After passing 
the Blood Brain Barrier (BBB) via the L-type amino acid transporter 1 (LAT1)/4F2 heavy chain 
(4F2hc) complex[67], levodopa is converted into dopamine by the dopa-decarbocylase[23]. 
To prevent levodopa metabolism prior to its transport across the BBB, orally administered 
levodopa is routinely given in combination with a DDC inhibitor (DDCI) (as e. g. carbidopa or 
benserazide) that may be combined with a COMT inhibitor (such as entacapone) in addition 
to avoid levodopa methylation into 3-0-methyldopa[22]. 
The clinical response to levodopa therapy may be categorized into short- and long-term 
response. Whereas the short-duration response seems to be preserved during disease 
progression, the long-term response progressively deteriorates, clinically manifesting in daily 
fluctuating motor responses, referred to as ‘on-off’ phenomenon[23,68]. This phenomenon 
has been attributed to an unsteady delivery of levodopa to the dopamine-lacking substantia 
nigra together with the inability to compensate in end-stage disease with depleted dopamine 
stores[68].  
 
Seminar
www.thelancet.com   Vol 373   June 13, 2009 2057
appearance, a fl exion of one arm with lack of swing, a 
monotonous quality to the speech, and an extreme 
slowing down. These changes are rarely noticed by the 
patient. The early physical signs are often erroneously 
ascribed to old age, misery, introspection, or rheumatism, 
and a lag of 2–3 years from the fi rst symptoms to 
diagnosis is not unusual.
Once the diagnosis has been confi rmed, patients and 
their families often start to remember potentially relevant 
symptoms and signs going back more than a decade. 
Early diﬃ  culties with coordination might have been 
blamed on faulty equipment, such as a keyboard that 
keeps typing a letter twice; a towel that does not dry 
properly; or a self-winding watch that keeps stopping 
despite reassurances from the manufacturer. Each 
neurologist has his anecdotes about unusual clinical 
presentations. Kinnier Wilson, a distinguished 
neurologist who worked at the National Hospital for 
Nervous Diseases (Queen Square, London) and whose 
name has been associated with hepatolenticular 
degeneration, described the case of a colleague who 
remained abnormally still in his seat during a medical 
conference, and another of a friend who commented that 
his fi rst symptom was that he could walk more easily on 
a pebbled beach than in a crowded street.39 Loss of sense 
of rhythm and a tendency to swim in circles are two 
personal recollections. Early motor symptoms can be 
subtle and easily missed. A change in a patient’s writing 
can be present for several years before diagnosis, with a 
tendency to slope usually in an upward direction and for 
the writing to get progressively smaller and more 
cramped after a line or two.
Careful assessment of the family history of patients 
with Parkinson’s disease might also help to identify other 
aﬀ ected fi rst-degree relatives. Early loss of smell is 
occasionally spontaneously reported but many patients 
are unaware of hyposmia until they are formally tested.40 
Disturbed sleep—including shouting out, fl ailing 
movements of arms and legs, and falling oﬀ  the bed 
during dreaming—might only be noticed if the patient’s 
spouse is specifi cally questioned. These symptoms 
suggest rapid eye movement (REM) sleep disorder and, if 
severe, might need to be treated with clonazepam.41
Complaints within the fi rst 2 years of the disease of 
falls (especially backwards), fainting, urinary inconti-
nence, prominent speech, disturbed swallowing, 
amnesia, or delirium should raise the possibility of an 
alternative diagnosis.
The use of dopamine antagonists, such as pro-
chlorperazine for giddiness, metoclopramide for dys-
pepsia, chlorpromazine for bipolar depression, 
calcium-channel blockers, such as fl unarizine, cinn ari-
zine, and sodium valproate used to control epilepsy or 
migraine, should be limited because all these 
medications can cause reversible parkinsonism. Herbal 
remedies such as the western Pacifi c sedative kava 
kava42 or the Indian snake root Rauwolfi a serpentina can 
also cause parkinsonism.43 The increasing purchase of 
herbal medications over the internet and the rise of 
generic formulations of dubious purity have exposed 
people to a greater risk of noxious unregulated 
products.44
The patient’s occupation, and smoking, caﬀ eine, and 
alcohol habits should be noted together with any history 
of illicit drug use. A past history of severe head injury, 
encephalitis, toxin exposure, or hypertension and 
cerebrovascular disease might be important as secondary 
causes.
In the late stages of Parkinson’s disease, the face of 
patients is masked and expressionless, the speech is 
monotonous, festinant, and slightly slurred, and posture 
is fl exed simian with a severe pill rolling tremor of the 
hands (fi gure 1). Freezing of gait for several seconds can 
happen when attempting to enter the consulting room 
and, when starting to move again, the patient tends to 
move all in one piece with a rapid propulsive shuﬄ  e. 
These motor blocks lead to falls. All dextrous movements 
are done slowly and awkwardly, and assistance might be 
needed for dressing, feeding, bathing, getting out of 
Figure 1: Illustration of the slightly anxious frozen face and characteristic 
fl exed posture of a Parkinson’s disease patient (courtesy of Nathalie Lees)
! 
25!
3.5.3. Small)intestinal)levodopa)absorption)
 
Levodopa is a large neutral amino acid (LNAA) that shows structural homology to aromatic 
amino acids (AAs) L-phenylalanine (Phe) and L-tyrosine (Tyr). Therefore, levodopa has been 
suggested to being absorbed by neutral amino acid transporters in the small intestine[69]. 
Hence, as shown in 2000, levodopa is transported via the cysteine and dibasic AA exchanger 
b0,+AT-rBAT (SLC7A9-SLC3A1)[24] that is expressed in the luminal enterocyte membrane. 
b0,+AT is the catalytic unit, that is covalently linked to the glycoprotein rBAT forming a 
heteromeric AA exchanger[70]. Whereas at the luminal enterocyte membrane only one 
transporter (b0,+AT-rBAT) was identified transporting levodopa, three different AA transporters 
were shown to carry levodopa across the basolateral membrane, namely the Na+-
independent L-type amino acid exchangers LAT1 (SLC7A5) and LAT2 (SLC7A8)[25], as well 
as the aromatic AA uniporter TAT1 (SLC16A10)[26]. Similarly as b0,+AT and the heavy chain 
rBAT, also the light chains LAT1 and LAT2 (that form the transmembrane domains) are 
covalently linked to a glycosylated type II membrane protein, the heavy chain 4F2hc 
(SLC3A2) that traffics and stabilizes the associated light chains[70]. In addition to b0,+AT-
rBAT, other luminal AA transporters including the broad neutral amino acid transporter B0AT1 
have been proposed to transport levodopa[24]. 
In patients with end-stage parkinsonism and fluctuating motor response to levodopa 
treatment, it has been hypothesized, that dietary proteins may affect small intestinal levodopa 
absorption due to competition of levodopa with dietary amino acids for its transport across the 
brush border membrane[68]. 
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4. Aims)
 
Several factors affect small intestinal SLC transporter expression and function, including diet, 
(gastrointestinal) diseases, medications, circadian rhythm, functional interactions among 
different transporters and the presence of accessory proteins. The aim of this PhD work was 
to assess the effect of certain medications (ACE-inhibitors, angiotensin II AT1 receptor 
blockers and metformin), diseases (type 2 diabetes mellitus), and of transporters’ substrates 
(levodopa, glucose, amino acids) on amino acid and monosaccharide transporters expression 
in human small intestine.  
In a first study we aimed to assess the effect of antihypertensive drugs (ACE-inhibitors and 
angiotensin II AT1 receptor blockers) on small intestinal ACE2 and associated transporters 
(B0AT1, etc.) expression. Furthermore, a putative functional interaction of ACE2 and system 
IMINO transporter SIT1 was investigated.  
In a second project, we aimed to test whether type 2 diabetes mellitus and/or metformin 
treatment affects small intestinal monosaccharide transporter (GLUT2, GLUT5 and SGLT1) 
expression. In addition, the putative luminal expression of basolateral GLUT2 in non-treated 
diabetic patients was assessed (results pending when the present report was written). 
 
In a third project, we studied the intestinal absorption mechanism of the amino acid and main 
Parkinson’s disease therapeutical levodopa. Because different AAs may compete for its 
intestinal absorption, we further tested the effect of routinely co-administered carbidopa and 
bensirazide and of dietary amino acids on intestinal levodopa absorption.  
 
 )
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5. Manuscript:)‘Human(intestine(luminal(ACE2(and(amino(
acid(transporters(are(regulated(by(ACE:inhibitors’(
 
This section contains the manuscript entitled ‘Human intestine luminal ACE2 and amino acid 
transporters are regulated by ACE-inhibitors’ that was sent to the American Journal of 
Physiology – Gastrointestinal and Liver Physioloy the 12th of December 2013 and returned for 
further correction. 
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Human intestine luminal ACE2 and amino acid transporters are regulated by ACE-
inhibitors 
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Abstract (248 words) 
 
Sodium-dependent neutral amino acid transporter B0AT1 (SLC6A19) and imino acid (proline) 
transporter SIT1 (SLC6A20) are expressed at the luminal membrane of small intestine 
enterocytes and proximal tubule kidney cells where they exert key functions for amino acid 
(re)absorption as documented by their role in Hartnup disorder and iminoglycinuria, 
respectively. Expression of B0AT1 was shown in rodent intestine to depend on the presence 
of the carboxypeptidase angiotensin converting enzyme 2 (ACE2). This enzyme belongs to 
the renin-angiotensin system and its expression is induced by treatment with ACE-inhibitors 
(ACEIs) or angiotensin II AT1 receptor blockers (ARBs) in many rodent tissues. We show here 
in the Xenopus laevis oocytes expression system that human ACE2 also functionally interacts 
with SIT1. To investigate in human intestine the potential effect of ACEIs or ARBs on ACE2, 
we analyzed intestinal biopsies taken during routine gastroduodenoscopy and 
ileocolonoscopy from 46 patients of which 9 were under ACEI and 13 ARB treatment. 
Analysis of transcript expression by real-time PCR and of proteins by immunofluorescence 
showed a co-localization of SIT1 and B0AT1 with ACE2 in the brush-border membrane of 
human small intestine enterocytes and a distinct axial expression pattern of the tested gene 
products along the intestine. Patients treated with ACEIs displayed in comparison with 
untreated controls increased intestinal mRNA levels of ACE2, peptide transporter PEPT1 
(SLC15A1) and AA transporters B0AT1 and PAT1 (SLC36A1). This study unravels in human 
intestine the localization and distribution of intestinal transporters involved in amino acid 
absorption and suggests their regulation by ACEIs. 
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INTRODUCTION 
 
Protein digestion refers to the hydrolysis of dietary proteins by stomach and pancreas 
proteases and by brush-border membrane-bound peptidases into absorbable units, namely 
tri-, dipeptides and amino acids (AA) [39]. Transepithelial absorption across enterocytes 
involves then sequential transport across the luminal brush-border and basolateral 
membrane. The luminal step is mediated by the peptide transporter PEPT1 and various AA 
transporters [37-40]. From enterocytes, amino acids  are then released into the extracellular 
space by another set of AA transporters located in the basolateral membrane [41,71].  
The major small intestine luminal transporter for neutral AAs B0AT1 (broad neutral AA 
transporter 1, SLC6A19) is also expressed in kidney proximal tubule and its defect was 
shown to cause Hartnup disorder [72,73]. Intestinal B0AT1 expression and function depends 
on the presence of the accessory protein ACE2 (angiotensin converting enzyme 2) [5,53]. 
This membrane-anchored monocarboxypeptidase is a structural homologue of ACE and is 
expressed in various tissues, including heart, kidney, testes, lung and intestine, where it 
negatively regulates the renin-angiotensin system by degrading angiotensin I and II into Ang-
(1-9) and Ang-(1-7), respectively [47]. At the brush-border membrane of small intestine 
enterocytes, ACE2 displays a high expression level and is suggested to participate to peptide 
digestion [53,74]. The catalytic domain of ACE2 is fused to a membrane anchor domain that 
shows high structural similarity with the renal protein collectrin (TMEM27) [47] which 
interestingly functions as B0AT1-associated protein in kidney proximal tubule [46]. 
The sodium-dependent imino transporter 1 (SIT1,SLC6A20) is a high affinity luminal L-proline 
(Pro) transporter, expressed – among other tissues – in small intestine enterocytes and 
proximal kidney tubule cells [48,75]. Mutations of its gene has been suggested to cause – in 
combination with polymorphisms of other proline and glycine transporters – the metabolic 
disorder Iminoglycinuria [49]. SIT1 (SLC6A20) is structurally closely related to B0AT1 
(SLC6A19) but an analogous functional interaction with ACE2 and/or collectrin has not been 
demonstrated, although suggested by the observation that mice lacking the ACE2-related 
protein collectrin display reduced proximal tubule SIT1 expression and significant prolinuria 
[46]. Similarly, ACE2 knock-out mice show decreased intestinal Pro absorption; however, 
effects on SIT1 protein expression could not be tested due to lack of a specific antibody [9]. 
Drugs interfering with the renin angiotensin system (RAS), such as ACEIs and ARBs have 
become first-line medications to treat arterial hypertension [76]. Interestingly, both types of 
drugs have been shown in rodents to increase the expression of ACE2 mRNA in different 
organs and tissues, including heart, kidney and the aorta [6-8]. However, it is not known, 
whether ACEIs or ARBs also affect the expression of small intestine ACE2, which is involved 
– as a carboxypeptidase – in protein digestion and – by interacting with B0AT1 and potentially 
SIT1 – in AA absorption. Additionally, the knowledge about the axial distribution of AA- and 
peptide transporters along the intestine is sparse and mainly originates from animal studies 
[70,77].  
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In this study we (i) addressed the question whether human ACE2 can interact functionally 
with the proline transporter SIT1 using the Xenopus laevis oocyte expression system and (ii) 
whether it co-localizes with SIT1 as with B0AT1 at the luminal surface of human intestinal 
mucosa. Furthermore, we (iii) analyzed the axial distribution of ACE, ACE2, amino acid- and 
peptide transporters in human intestine and (iv) assessed whether ACEIs and ARBs 
potentially impact on ACE2 and AA transporter expression in the intestine of human patients. 
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MATERIALS AND METHODS 
 
Transport Studies in Xenopus laevis oocytes 
Transport studies using radiolabeled amino acid tracers were performed as described 
previously [78]. Briefly, after cRNA injection (SIT1 alone: 5ng, SIT1 and ACE2: 5ng and 20ng, 
SIT1 and collectrin: 5ng and 5.4ng) oocytes were incubated 2 – 3 days in ND96 solution at 
16°C. Thereafter, 6 – 10 oocytes per condition were washed 3 - 4 times at room temperature 
(RT) with uptake buffer (pH 7.4, 10mM HEPES, 100mM NaCl, 2mM KCl, 1mM MgCl2, and 
1mM CaCl2) and pre-incubated at 25°C for 2 minutes. The uptake solution containing 
radiolabeled amino acids (2µCi of radiolabeled tracer per group of oocytes) was added for 10 
minutes and uptake was ended by washing oocytes 4 times with uptake buffer at 4°C. 
Oocytes were then dissolved separately in SDS (2%) for 60 minutes. Finally, 3ml of 
scintillation solution (Emulsifier-Safe TM) was added to each oocyte and radioactivity was 
determined using a scintillation counter (TRI-CARB 2900TR, Packard Instrument Co., 
Meriden, CT). Data were expressed as pmol/h/oocyte, and values obtained for non-injected 
oocytes were subtracted. Kinetic experiments were performed with five different amino acid 
concentrations ranging from 3.3 to 330µM. 
 
Study population 
A total number of 46 (21 male and 25 female) patients was included in the current study, with 
9 (20%) patients treated with ACE-Inhibitors, 13 (28%) patients treated with AT1-receptor 
blockers and 24 control patients (Table 1). Medical supply was independent from the present 
study or hereby obtained results. 24 (52%) control patients were not on medication that 
affected the Renin-Angiotensin system. All patients were examined at one single institution. 
Patients underwent either gastroduodenoscopy only (n = 34), a combined 
gastroduodenoscopy and ileocolonoscopy (n = 10) or ileocolonoscopy only (n = 2) as part of 
a routine medical checkup. During this procedure, mucosal biopsies were taken at four 
different parts of the gastrointestinal tract: Duodenum parts II (descending) and III 
(inferior/horizontal), terminal ileum and ascending colon. Blood and urine samples were 
collected from all patients in order to quantify amino acid levels using HPLC (High 
Performance Liquid Chromatography) measurements. Laboratory values of the RAS (ACE-
activity, renin, aldosterone, angiotensin I and II; measured at the Institute of Clinical 
Chemistry, University Hospital of Zurich), as well as different physiologic parameters, such as 
body mass index (BMI), mean arterial blood pressure (MAP = (systolic blood pressure + 2x 
diastolic blood pressure) /3) and heart rate were assessed. The age of included patients 
ranged from 18 to 80 years and patients BMI was between 18 and 35kg/m2. Patients with 
severe pathologies of the gastrointestinal tract, such as coeliac disease, Crohn’s disease and 
ulcerative colitis, as well as patients with carcinomas, kidney- or hepatic insufficiency, 
bleeding disorders, infectious diseases, oral anticoagulation, drug- or alcohol abuse or mental 
retardation, were excluded from the present study. 
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Mean age of treated patients (65 years) was higher than of non-treated controls (52 years). 
Body mass index (BMI), mean arterial pressure, angiotensin I and II and renin plasma levels 
were not different between groups. Plasma ACE-activity was significantly lower in patients 
treated with ACEIs when compared to non-treated controls  (Table 1). 
 
Intestinal biopsies 
Mucosal biopsies were taken at four different intestinal localizations (duodenum part II, part 
III, terminal ileum and ascending colon). After removal, tissue specimens were immediately 
frozen in liquid nitrogen and stored at -800C until RNA extraction or cryosection was 
performed.  
 
Immunofluorescence 
Cryosection 
Harvested biopsies were embedded in optical coherence tomography (OCT) cryostat medium 
(Medite Medizinaltechnik AG, Switzerland) and put into tubes containing liquid propane. 
Tubes were transferred into liquid nitrogen for quick freezing. Obtained blocks were stored at 
-80°C until further processing. A cryotome, (Leica CM 1850 Cryostat, Switzerland) was used 
to produce 5µm sections that were immediately transferred onto polylysine slides (O. Kindler 
& CO GmBH, Germany). The slides were stored at -20°C until later processing. 
 
Immunostaining 
Immunostaining of frozen tissue sections was performed as described previously [79]. Briefly, 
samples were defrosted at RT for 5 minutes in a wet chamber. For fixation, slides were 
immersed in Methanol (70%) for 90 seconds. After fixation, slides were washed (1 x 15min, 2 
x 5min) with phosphate buffered saline (PBS, 0.1M) (137.0mM NaCl, 2.7mM KCl, 12.0mM 
HPO42−/H2PO4−). To reduce unspecific antibody binding, tissues were kept in 2% bovine 
serum albumin (BSA) diluted in PBS (0.1M) for 1h at RT. The following primary antibodies 
were applied to the section samples for 1 hour at RT: 1. Affinity purified mouse anti human 
polyclonal SIT1 (Abnova, Taipei, Taiwan), 2. affinity purified goat anti human polyclonal ACE2 
(R&D Systems, Minneapolis, USA), 3. affinity purified rabbit anti human polyclonal B0AT1 
(Pineda, Berlin, Germany). Antibodies were diluted 1:100 in PBS (0.1M) enriched with 2% 
BSA and 0.04% Triton X-100. Thereafter, sections were rinsed again in PBS (0.1M) (3 x 
5min) before incubation with the secondary antibodies (Alexa Fluor® 594 donkey anti-mouse 
IgG, dilution 1:500, Alexa Fluor® 488 donkey anti-mouse IgG, dilution 1:500, Alexa Fluor® 
594 donkey anti-goat IgG, dilution 1:500, Alexa Fluor® 488 donkey anti-goat IgG, dilution 
1:500, Alexa Fluor® 594 donkey anti-rabbit IgG, dilution 1:500, Alexa Fluor® 488 donkey anti-
rabbit IgG, dilution 1:500) and 4’, 6’-diamidino-2-phenyl- indole (DAPI, Merck, NJ) (0.1mg/ml) 
(diluted 1:5’000) for 1 hour at RT. Sections were washed with PBS (0.1M) (3 x 5min) before 
mounting with DAKO fluorescence mounting media (DakoCytomation, Baar, Switzerland). 
Sections were examined using a Nikon Eclipse TE300/200 inverted microscope fitted with a 
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DS-5M Standard charge-coupled device camera. Pictures were captured with NIS-Elements 
software (Nikon Instruments Inc, Melville, NY) and processed using Adobe Photoshop 
software. Incubation of sections with secondary antibodies only did not result in a detectable 
signal (data not shown). 
 
Intestinal gene expression 
RNA extraction 
RNA extraction was performed by disrupting tissue in 350µl RLT-Beta-Mercapto-Ethanol 
buffer (10µl β-ME / 1ml RLT-buffer) with MagNALyser Green Beads (Roche, Switzerland) for 
30 seconds at 6000rpm using a Precellys® 24 tissue homogenizer (Bertin Technologies, 
France). The solution was centrifuged at 10’000g for 5 minutes at 10°C. The supernatants 
were directly used for RNA isolation with the QiagenRNeasy mini kit (QIAGEN, Switzerland), 
which was employed according to the manufacturer’s instructions.  
RNA concentrations were determined using the NanoDrop 1000 Spectrophotometer (Witec 
AG, Switzerland) at 260nm wavelength. Beside RNA concentrations, purity of the extractions 
was assessed. 
 
Reverse transcription 
For reverse transcription, Applied Biosystems Taq Man RT-PCR reagents and the Biometra T 
Gradient Thermocycler (Biolabo Scientific Instruments SA, Switzerland) were used. Final 
concentrations in the reaction mix were: RT buffer (1x), MgCl2 (5mM), random hexamers 
(2.5µM), deoxyNTP mix (500µM each), RNAse inhibitor (0.4Uxµl-1), multiscribe reverse 
trancriptase enzyme (1.25Uxµl-1), RNA template (33ngxµl-1) and RNAse free water. All 
reactions were executed with negative controls (RT-) using the same protocol without adding 
the multiscribe reverse trancriptase enzyme to the reaction mix. Until further analysis, 
samples were stored at -20°C. 
 
Primers and probes 
Primers and probes were designed according to a previous report [80] or using the software 
Primer Express 3.0 (Applied Biosystems, Switzerland). Self-designed primers were chosen to 
generate amplified fragments of 70 to 140 base pair length spanning intron-exon boundaries 
to avoid contaminating genomic DNA. Primer specificity of all primers was tested using mRNA 
from human intestine and/or human kidney and resulted in a single product of expected 
length (data not shown). Probes were labelled with the fluorescent reporter dye FAM at the 5’ 
end and the quencher dye TAMRA at the 3’ end (Microsynth AG, Switzerland) 
(Supplementary Table 1).  
 
Real time PCR 
Quantitative Real Time PCR (qRT-PCR) was performed as described previously [70,79]. 
Briefly, a 20µl PCR reaction volume was prepared using cDNA (1µl), TaqMan Universal PCR 
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Master Mix (10µl) (Applied Biosystems AG, Switzerland), Primers (0.8µl each), Probe (0.4µl) 
and DEPC-Water (7µl). Final concentrations in the reaction volume were: Primers (1µM each) 
and Probe (0.1µM). Reactions were run in 96-well optical reaction plates using the 7500 Fast 
Real-Time System Termocycler (Applied Biosystmes AG, Switzerland). 45 thermal cycles 
were set at 95°C (10 minutes), 60°C (15 seconds) and 72°C (1 minute). For analyzing data, 
an individual threshold was set for each gene in the linear range of the amplicon curves. All 
reactions were run in triplicates and mean values were used for further processing. Negative 
controls (RT-) were run for each gene. If maximal cycle difference within triplicates was ≥ 1 
cycle or if the difference between the mean value of the triplicates and the negative control 
was ≤ 5 cycles, obtained results were discarded and not used for further analysis. Abundance 
of target mRNA was calculated relative to a Villin mRNA, which is commonly used as 
reference gene for epithelial content in human intestinal samples [81]. In order to verify non-
varying Villin mRNA expression along the human digestive tract, target and Villin mRNA was 
calculated relative to a second reference gene (HPRT, encoding the Hypoxanthine 
phosphoribosyltransferase) (data not shown) [82]. Relative gene expression values were 
determined using the ΔCt method (relative expression = 2-ΔCt, ΔCt = average Ct value of 
target – average Ct value of reference). 
 
Comparative promoter analysis 
The proximal promoter regions of human ACE2, B0AT1 and PEPT1 genes were retrieved 
using the software Gene2Promoter (Genomatix). The proximal promoter regions used were 
generally defined as 500 nucleotides upstream and 100 nucleotides downstream from the 
transcription start site (TSS). TSSs were automatically assigned to genes based on 5′ cap site 
databases integrated into promoter identification programs (Eldorado, Genomatix). Promoter 
sequences of relevant transcripts and in a second analysis of relevant transcripts plus 
CompGene promoters (promoters with no transcript listed) were included in the analysis. 
Genomatix FrameWorker database was used to identify new TFBS modules [83]. A module is 
defined as a set of two or more TFBSs with a specific order, strand orientation, and distance 
range between the individual TFBSs. A threshold of 100% genes containing the module, a 
distance of 5 – 200 bp and an intersite variability of 15 bp or less were permitted between 
TFBSs. The software ModelInspector (Genomatix) was used with the default settings to 
identify the previously characterized TF binding modules in additional promoter regions of the 
Genomatix Human Promoter Database (Version Eldorado 12-2012) [84].  
 
Statistical analysis 
For data representation and statistical analysis, the statistical software Graphpad Prism 5 
(GraphPad Software, San Diego, CA) and R, an open-source language and environment 
for statistical computing. ( http://www.R-project.org/) was used. Shown error bars 
correspond to standard error of the mean (SEM). p-values of 0.05 or less were considered 
statistically significant. 
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Ethics 
Human experiments 
Written informed consent was obtained from each patient. The study was conducted 
according to Good clinical practice guidelines and was approved by the local ethics 
committee (reference number: EK-1744).  
Animal experiments 
Animal experiments (i.e. removal of oocytes from Xenopus laevis frogs) were performed 
according to the Swiss Animal Welfare Laws and as approved by the local Veterinary 
Authority (Kantonales Veterinäramt Zürich). 
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RESULTS 
 
Functional interaction of human L-proline transporter SIT1 with ACE2 and collectrin in 
Xenopus laevis oocytes 
To test whether human ACE2 and human collectrin functionally interact with SIT1 – as shown 
for B0AT1 [53] – we co-expressed these proteins in Xenopus laevis oocytes and assayed their 
transport function using L-proline as substrate. Pro uptake rate was increased more than 2-
fold, when ACE2 or collectrin were co-expressed with SIT1, whereas no significant Pro 
uptake was observed when ACE2 or collectrin RNA was injected alone (Figure 1A). To test 
whether these two accessory proteins modulate SIT1 transport kinetics differentially, the 
concentration dependence of L-proline uptake was measured. The apparent affinity of SIT1 
alone (K0.5: 40.5 µM)  was similar in oocytes co-expressing ACE2 (K0.5: 47.9 µM) or collectrin 
(K0.5: 42.1 µM), respectively, as shown by the K0.5 derived from Michaelis-Menten curves fitted 
to the experimental points. In contrast, the maximal transport capacity (Vmax) was about 3-fold 
higher in oocytes co-injected with ACE2 or collectrin, respectively (Figure 1B). 
 
 
Localization of amino acid transporters B0AT1 and SIT1 and of ACE2 in human small 
intestine 
The distribution of the AA transporters B0AT1 (Figure 2A; green) and SIT1 (Figure 2D; green) 
and of ACE2 (Figure 2B and E; green) along the villi (V) and in the crypts (C) was visualized 
by immunohistochemistry. The two transporters co-localized with ACE2 along the brush-
border membrane of duodenum (Figures 2C and F) and terminal ileum (not shown) 
enterocytes on villi. The signal of AA transporter B0AT1 (Figure 2A) appeared to be stronger 
towards the tips of the villi and weaker in the crypts, whereas no clear statement about the 
expression along the crypt-to-villus axis of SIT1 and ACE2, respectively may be made based 
on the present pictures. Some cells lining the small intestine lumen showed a diffuse labeling 
with all antibodies and represent presumably goblet cells that are non-specifically stained. 
Whereas in the colon B0AT1 was not detected by immunofluorescence, ACE2 and SIT1 were 
labeled within colonic crypts where they co-localized to the apical membrane of epithelial cells 
(data not shown). 
 
Axial expression of AA- and peptide transporters as well as of ACE and ACE2 mRNAs 
along human intestine 
Using mucosal biopsies taken from 10 patients referred for combined gastroduodenoscopy 
and ileocolonoscopy, real-time PCR was performed to measure the relative abundance of 
SLC transporter mRNAs in the epithelial layer of duodenum parts II and III, terminal ileum and 
ascending colon. As internal standard, the transcript of the small intestine enterocyte 
housekeeping gene Villin was used [81]. No statistical tests were applied to the transporters’ 
distribution: terms like higher, lower and equal only qualitatively describe the data and do not 
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refer to statistical significant differences. These measurements revealed distinct axial gene 
expression patterns (Figure 3): (i) All tested transporter mRNAs were more abundant in small 
than large intestine with the exception of that of the AA antiporters ASCT2 (SLC1A5) and 
y+LAT2 (SLC7A6) (catalytic subunit of 4F2hc (SLC3A2)) that displayed a higher gene 
expression in the ascending colon. (ii) The luminal transporter mRNAs showed equal 
expression levels along the duodenum and terminal ileum except the one of the cationic AA 
and cystine exchanger subunit b0,+AT (SLC7A9) that was higher in the terminal ileum (Figure 
3A). (iii) Basolateral transporter subunit mRNAs of LAT1 (SLC7A5), y+LAT1 (SLC7A7) and 
y+LAT2 were equally expressed along the duodenum and terminal ileum, whereas the 
mRNAs of the transporters/transporter subunits LAT2 (SLC7A8), 4F2hc (SLC3A2), LAT4 
(SLC43A2) and TAT1 (SLC16A10), showed a lower gene expression level in the distal ileum 
than in the duodenum (Figure 3B). (iv) The mRNA encoding ACE was higher in the terminal 
ileum, whereas that of ACE2 was equal along the small intestine (Figure 3A). 
 
Intestinal gene expression of ACE2, B0AT1, SIT1, PAT1 and PEPT1 in patients treated 
with ACEIs 
Mucosal biopsies from 42 patients referred for gastroduodenoscopy were analyzed. Nine of 
these patients were treated with ACE-Inhibitors, 13 with AT1-receptor blockers, 22 had no 
RAS-active treatment and none was treated with both medications.  
Levels of mRNA expression of all gene products assessed were very similar in duodenum 
parts II and III, whereas clear differences between duodenum and terminal ileum and 
between small and large intestine were observed for several genes (Figure 3). The impact of 
ACEI and ARB treatment on mucosal gene expression was assessed for duodenal samples 
(means of all available biopsies). In patients treated with ACEIs the mean duodenal mRNA 
expression level of ACE2 was increased 1.9-fold when compared to non-treated controls and 
that of the SLC transporters B0AT1, PEPT1 and PAT1 1.7-, 1.6- and 1.6-fold, respectively. No 
significant differences in ACE2, B0AT1, PEPT1 or SIT1 expression levels were observed in 
patients treated with ARBs (Figure 4A). None of the other genes assessed, including SIT1, 
showed significant differences between groups (data of the other genes not shown). 
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To test whether the ACEI-induced regulation of intestinal ACE2, B0AT1, PAT1 and PEPT1 
expression are correlated with each other, we determined the Pearson correlation of 
respective mean duodenal mRNA levels in all patients (n = 44) quantifying the strength of the 
linear association. Gene expression of intestinal ACE2 strongly correlated with that of B0AT1 
(correlation coefficient 0.83, confidence interval 0.70 – 0.90, p < 0.0001), and PEPT1 
(correlation coefficient 0.80, confidence interval 0.63 – 0.89, p < 0.0001). The correlation of 
ACE2 with PAT1 (correlation coefficient 0.34, confidence interval 0.02 – 0.60, p < 0.05) is 
quite small and only weakly significant (Figure 4B-D).  
 
Promoter analysis 
As the mRNA expression of ACE2, B0AT1, and PEPT1 correlated with each other, we 
performed a comparative promoter analysis to identify common regulatory sequences. 
Comparison of the proximal promoter regions of relevant transcripts of these three genes 
revealed a common promoter module with three conserved transcription factor binding sites 
(TFBS) (SORY_EBOX_MIZ1_modules). Screening of the human promoter database for the 
occurrence of this module revealed its presence only in six other genes, namely HUS1, HIP1, 
CASR, GALC, ZNF555, and VPS13C. A second analysis including all potential promoter 
regions of ACE2, B0AT1, and PEPT1 detected a single additional module with five conserved 
TFBS (HOXC_FKHD_HOMF_HOMF_RORA_module) that was found in a single other gene 
(CDV3). The expression and potential co-regulation of these genes sharing promoter 
modules with ACE2, B0AT1 and PEPT1 was tested in the small intestine biopsies. Only four of 
these seven genes displayed an mRNA expression level reliably quantifiable by qPCR and 
none of them was increased in ACI-treated patients (data not shown), indicating that the 
effect described above for ACE2, B0AT1 and PEPT1 transcripts is selective for these luminal 
membrane proteins. 
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DISCUSSION 
The ACE2 carboxypeptidase is an important player of the systemic RAS and is also 
expressed at the surface of the small intestine [5,53]. In enterocytes, ACE2 is required for the 
expression of the major neutral amino acid transporter B0AT1 the defect of which causes 
Hartnup disorder. A similar interaction with ACE2 has been proposed for the L-proline 
transporter SIT1 the defects of which contributes to iminoglycinuria [49]. The deficiency of 
ACE2 impairs amino acid absorption in the mouse, in particular of tryptophan, and thereby 
increases susceptibility to intestinal inflammation [85]. In rodent heart, kidney and aorta, 
treatment with ACEIs and/or ARBs was shown to increase ACE2 expression [6-8].  
This study addressed the question of the role of ACE2 in human intestine. First we 
characterized its functional interaction with the proline transporter SIT1 in Xenopus laevis 
oocytes. Then we demonstrated the axial expression of ACE2 along human intestine and also 
that of ACE, AA- and peptide transporters. Finally we showed that patients treated with ACE-
inhibitors express higher transcript levels of intestinal ACE2, amino acid transporters B0AT1 
and PAT1 and peptide transporter PEPT1, a novel finding that suggests the possibility that 
ACEI impact on the absorption of other drugs and amino acids.  
 
Intestinal ACE2 and its role as accessory protein for luminal amino acid transporters  
ACE2 has multiple roles in the human body [47]. It is an enzyme that is expressed in various 
cells of many organs and is key to the regulation of local and systemic angiotensin II levels. 
Next to its role within local and systemic renin angiotensin systems, ACE2 has also the 
function of an intestinal brush-border peptidase involved in protein digestion, similarly to ACE. 
Indeed, high ACE2 expression levels are found at the luminal surface of small intestinal 
enterocytes [5] and also of kidney proximal tubule cells [53]. In small intestine, its role at the 
brush-border membrane is that of cleaving single carboxy-terminal AAs from nutrient 
proteins/peptides and also of interacting within digestive complexes comprising AA 
transporters, such as B0AT1 [74]. Whereas intestinal B0AT1 surface expression depends on 
the presence of ACE2 [5], its interacting partner in the kidney, collectrin [46], does not have a 
peptidase domain [47]. It is possible that B0AT1 evolutionary first interacted with ACE2 within 
a complex of proteins involved in intestinal absorption named ‘metabolon’ by Broer and co-
workers [74]. If this was the case, the newer kidney structural partner collectrin could have 
become necessary to separate the AA transport associated function from that of degrading 
kidney proximal tubule angiotensin II. Similarly to B0AT1, the system IMINO transporter SIT1 
has been suggested to depend on intestinal ACE2 and proximal tubule collectrin expression 
[9,46]. Indeed, high-affinity intestinal L-proline absorption was shown to be reduced in ACE2 
knock-out mice [9], and collectrin knock-out mice showed reduced proximal tubule SIT1 
expression and consequently prolinuria [46]. We hereby show, using the Xenopus oocyte 
expression system, a functional interaction of human SIT1 with both accessory human 
proteins ACE2 and collectrin, as previously demonstrated for human B0AT1 [53]. A functional 
interaction of SIT1 with ACE2 had previously not been observed when using the mouse 
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orthologs in Xenopus oocytes, presumably because of the high transport activity induced by 
mouse SIT1 in the absence of an exogenous accessory protein[53]. An analogous species 
difference had been previously observed for the functional expression of B0AT1 in Xenopus 
oocytes[72]. 
Digestive complexes may alter transport kinetics of AA transporters, as shown for the 
aminopeptidase N and B0AT1. Such an effect can be explained by a change in local AA 
concentration, but was not observed in the case of the monocarboxypeptidase ACE2 and 
B0AT1 [74]. Similarly, we show here that the apparent affinity of SIT1 for L-proline was not 
changed by co-expression of either ACE2 or collectrin. Maximal transport rate (Vmax) was 
higher upon co-expression of these accessory proteins, probably reflecting an increase in 
transporter expression at the oocytes’ surface. Interestingly, the apparent affinity of human 
SIT1 for L-proline was 5 -10 times higher than previously reported for the mouse [86], rat [48] 
or opossum [87] orthologues, a species-specific difference for which we have no explanation. 
 
Axial distribution of intestinal ACE, ACE2, amino acid and peptide transporters 
Whereas the gene expression along the human intestine has been described for some 
transporters [77,81,88], to date information about the axial distribution of AA transporters 
along the digestive tract has been derived from animal studies [48,70,79]. Moreover, the data 
that is available from the human gut is difficult to interpret, since tissue specimens from 
different axial localizations originated from different patients and thus local expression 
differences might reflect discrepancies between patient groups [77]. This is the first study 
summarizing the longitudinal gene expression of several luminal and basolateral peptide and 
AA transporters and of ACE and ACE2 along the human digestive tract within one single 
group of patients. We show that the mRNA expression level of most luminal transporters is 
equal along the small intestine (duodenum (parts II and III) and terminal ileum) with the 
exception of the cysteine and dibasic AA exchanger subunit b0,+AT. Together with the 
glycoprotein rBAT, this catalytic subunit forms a heteromeric AA exchanger composed of two 
subunits covalently linked together [40,89]. In murine intestine, both transporter subunits were 
shown to be expressed at a higher level in ileum than in jejunum and duodenum [70]. 
Similarly, we found higher levels of the transporter subunit b0,+AT mRNA in the distal small 
intestine in humans. In contrast, mRNA levels of the heavy chain rBAT were equal all along 
the small intestine. Basolateral 4F2hc (CD98) and luminal rBAT are the only members of the 
SLC3 family of heteromeric AA transporter heavy chains that (as glycoprotein subunits) 
associate with different members of the SLC7 family (of catalytic subunits; also called light 
chains), including luminal b0,+AT and basolateral LAT1, LAT2, y+LAT1 and y+LAT2 [90,91]. In 
small intestine enterocytes and proximal tubule kidney cells, the heterodimer b0,+AT-rBAT 
mediates the apical entry of L-cystine [92] and cationic AAs including L-arginine (Arg). Here 
we show that the basolateral antiporter y+LAT1 that exchanges cationic AAs against neutral 
AAs and Na+ is highly expressed all along the human small intestine up to the ileum and thus 
most likely represents the exit pathway for transcellular cationic AA transport. In contrast, the 
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expression of the other y+L-type transporter y+LAT2 is very low, suggesting that this catalytic 
subunit is not of functional importance for the transepithelial cationic AA absorption. 
Furthermore, the mRNA expression of the basolateral AA transporters considered to be part 
of the neutral AA transport machinery (LAT2, LAT4 and TAT1) [93] appear to be expressed at 
a lower level in the terminal ileum than in the duodenum and presumably the jejunum, in 
contrast to y+LAT1. This differential expression may reflect the fact that the largest load of 
neutral AAs is already absorbed before the ileum such that the efflux capacity of ileal 
enterocytes for neutral AAs is not anymore that high. In contrast, the cationic AA absorption 
via luminal b0,+AT-4F2hc and basolateral y+LAT1 is highly developed in the terminal ileum, an 
observation for which we have no good explanation. 
 
Luminal transporters - with the exception of the low affinity small neutral amino/imino acid 
transporter 1 (PAT1) [94] - showed very low or negligible transcript expression values in the 
large intestine. From the tested basolateral amino acid transporters, only the neutral and 
cationic AA exchanger y+LAT2-4F2hc [95] and small neutral AA and L-glutamine (Gln) 
antiporter ASCT2 [37] were considerably expressed in the large intestine. Epithelial colonic 
cells show rapid renewal and transport large amounts of water and electrolytes. Colonocytes 
therefore need high amounts of energy and use AAs (especially Gln and L-glutamate (Glu)) 
from the circulation to supply the citric acid cycle [96,97]. Thus, it seems likely that basolateral 
exchangers ASCT2 and y+LAT2-4F2hc provide colonocytes with Gln and other amino acids 
for their energy needs.  
Whereas the dipeptidase ACE showed highest gene expression in the terminal ileum, mRNA 
levels of the monocarboxypeptidase ACE2 and of its interaction partners B0AT1 and SIT1 
were equal along the human small intestine. ACE2 protein co-localized with the transport 
proteins B0AT1 and SIT1 to the brush-border membrane of small intestinal enterocytes on 
villi. Staining of B0AT1 appeared to be stronger on top of the villi when compared to the signal 
in the crypts, supporting the notion that this surface protein is important for the function of 
mature enterocytes. This finding agrees with previous observations made in the rodent small 
intestine, showing a clear crypt-to-tip expression gradient along the villi for various AA 
transporters, including B0AT1 [5,70,98]. 
 
ACE-inhibitors increase expression of ACE2 and luminal amino acid and peptide 
transporters 
The regulation of SLC transporter expression in intestine has not been studied extensively. 
Physiological factors including developmental stage, diet, starvation, circadian rhythm and 
pathophysiological situations such as inflammatory bowel disease have been suggested to 
modulate intestinal SLC transporter mRNA expression. Regulatory mechanisms that may 
mediate these changes include transcriptional activation, RNA stabilization and epigenetic 
regulation [99-102]. 
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In the present study we show that the administration of ACE-inhibitors increases small 
intestinal ACE2 gene expression. As yet, ACE2 up-regulation by ACEI has been reported 
only for other organs and in rodents [6,51]. Small intestinal ACE2 mRNA was not different in 
patients treated with ARBs when compared to controls. In contrast, gene expression of small 
intestinal ACE2 was increased in ACEI treated patients. Interestingly, gene expression levels 
of luminal AA transporters B0AT1, PAT1 and of the peptide transporter PEPT1 were also 
increased in patients treated with ACE-inhibitors. The up-regulation of ACE2 mRNA 
correlated with that of B0AT1, PEPT1 and PAT1 gene expression, indicating that these four 
gene products are regulated in parallel. Comparative promoter analysis detected two 
common promoter modules, which however appear not to suffice for mediating the observed 
co-regulation (data not shown). This ACEI-induced regulation did not impact on steady state 
blood plasma and urine AA concentrations (data not shown).  
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This study shows the brush-border membrane co-localization of the carboxypeptidase ACE2 
and the amino acid transporters B0AT1 and SIT1, as well as the axial distribution of ACE, 
ACE2 and most known amino acid and peptide transporters expressed in the small intestine. 
The gene expression levels of B0AT1, PAT1 and PEPT1 are additionally shown for the first 
time to be regulated by treatment with ACE-inhibitors. Since the AA transporter PAT1 and the 
peptide transporter PEPT1 are known to transport different drugs including Vigabatrin, 5-
aminolevulinic acid (PAT1) [94], Betalactam antibiotics and Valacyclovir (PEPT1) [103], we 
may speculate that treatment with ACE-inhibitors might impact on the absorption kinetics of 
these medications. Additionally, since ACE2-deficient mice lacking brush-border membrane 
B0AT1 expression were shown to be more susceptible to intestinal inflammation because of 
impaired local L-tryptophan (Trp) homeostasis [85], it also may be that treatment with ACEIs 
and consecutive up-regulation of intestinal ACE2 and B0AT1 reduces susceptibility to 
intestinal inflammation, especially in conditions of low plasma Trp levels such as observed in 
states of malnutrition as in anorexia nervosa [104]. 
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Figure Legends 
 
Figure 1. Functional interaction of amino acid transporter SIT1 with accessory proteins 
ACE2 and collectrin. A. Xenopus laevis oocytes were injected with human SIT1 (white bar), 
human SIT1 plus human ACE2 (dark grey bar), human SIT1 plus human collectrin (black 
bar), human ACE2 (third last bar; light grey), or human collectrin (second last bar; light grey) 
cRNA. The last bar (light grey) represents non-injected oocytes. L-proline transport was 
determined 2 - 3 days after injection. Each bar represents the mean transport rate ± SEM. (n 
= total of 40 oocytes analysed in 4 independent experiments). * p < 0.05 (Bonferroni 
corrected p values for the indicated comparisons were calculated using a mixed model 
including the experiment number as random factor to take into account the grouping structure 
of the data caused by the data acquisition in 4 independent experiments). B. The half 
maximal uptake rate K0.5 and maximal transport capacity Vmax of L-Proline by human SIT1 was 
assessed in the absence (SIT1; squares; dashed line) or presence of human ACE2 (SIT1 + 
ACE2; triangles; dotted line) or human collectrin (SIT1 + collectrin; diamonds; continuous 
line). Uptake rates using 3 - 4 different L-proline concentrations, ranging from 3.3 – 100 µM, 
were determined 2 - 3 days after injection. Each data point represents the mean transport 
rate ± SEM. (n = total of 24 oocytes from 4 independent experiments). K0.5 was similar in all 
three groups (K0.5 SIT1: 40.5 ± 17.8 µM, K0.5 SIT1 + ACE2: 47.9 ± 19.2 µM, K0.5 SIT1 + 
collectrin: 42.1 ± 19.3 µM). Maximal transport capacity (Vmax) was about 3-fold higher in 
oocytes co-injected with ACE2 or collectrin, respectively (Vmax SIT1: 34.6 ± 6.1 pmol/h/oocyte, 
Vmax SIT1 + ACE2: 93.0 ± 15.9 pmol/h/oocyte, Vmax SIT1 + collectrin: 91.7 ± 
17.3pmol/h/oocyte). The difference of the respective Vmax is significant on a significance level 
of 5% which can be deduced from the non-overlapping 95% confidence intervals. 
 
Figure 2. Immuno-localization of ACE2 with B0AT1 and SIT1 in human small intestine. 
Representative tissue specimens from duodenum show B0AT1 (A; green) and ACE2 (B; red) 
co-localizing (C; yellow) at the brush-border membrane of enterocytes lining small intestinal 
villi. The imino transporter SIT1 (D; green) and ACE2 (E; red) co-localize (F; yellow) at the 
apical membrane of epithelial cells lining duodenal villi. Cellular DNA (A, B, D, E; DAPI) is 
shown in blue to display the nuclei. Pictures were taken at 20x magnification. The white bars 
represent 100µm (A, B, C) or 20 µm (D, E, F), respectively. V = villi. C = crypts. 
 
Figure 3. Relative mRNA abundance of AA- and peptide transporters, ACE and ACE2 
along the human intestine. A. Apical (facing the lumen of the gut) AA- and peptide 
transporters, ACE and ACE2. B. Basolateral (facing the extracellular space) AA transporters. 
Each bar indicates the mean relative mRNA expression ± SEM (normalized to villin (2Ct(Villin)-
Ct(target))). mRNA expression of each gene is shown at four different intestinal localizations: 
duodenum, part II (white bars), part III (light grey bars), terminal ileum (dark grey bars) and 
ascending colon (black bars).  
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Figure 4. A. Effect of ACEIs and ARBs on human duodenal ACE2 and transporter gene 
expression. Mean duodenal mRNA expression (normalized to villin (2Ct(Villin)-Ct(target))) of ACE2, 
AA transporters B0AT1 and PAT1 and peptide transporter PEPT1 in control patients (control; 
white bars) vs. patients treated with ACE-inhibitors (ACEI; grey bars) vs. patients treated with 
angiotensin II AT1 receptor blockers (ARB; black bars). * p < 0.05; ** p < 0.01 (Bonferroni 
corrected p values from a mixed mode including the experiment number as random factor to 
take into account the grouping structure of the data caused by the data acquisition in 4 
independent experiments) . B-D. Correlation analysis of ACE2 with B0AT1, PEPT1 and 
PAT1 mRNA expression. Mean duodenal gene expression of ACE2 with B0AT1, PEPT1 and 
PAT1, respectively was correlated. ACE2 & B0AT1: correlation coefficient 0.83, confidence 
interval 0.70 – 0.90, p = 1.38 x 10-11 (Figure 4B). ACE2 & PEPT1: correlation coefficient 0.80, 
confidence interval 0.63 – 0.89, p = 8.56 x 10-9 (Figure 4C). ACE2 & PAT1: correlation 
coefficient 0.34, confidence interval 0.02 – 0.60, p = 0.037 (Figure 4D).  
 
Supplementary Figure 1. Gene expression of intestinal genes with common promotor 
modules to ACE2, B0AT1 and PEPT1. Mean duodenal mRNA expression (normalized to 
villin (2Ct(Villin)-Ct(target))) of HUS1, GALC, HIP1 and CDV3 in control patients (control; white bars) 
vs. patients treated with ACE-inhibitors (ACEI; black bars). * p < 0.05 (student’s unpaired two-
tailed t-test). 
 
Supplementary Figure 2. Blood plasma and urine amino acid levels in treated and 
control patients. Blood plasma (A) and urine (B) amino acid levels from control patients 
(white bars) vs. patients treated with ACE-inhibitors (ACEI; grey bars) vs. patients treated with 
angiotensin II AT1 receptor blockers (ARB; black bars). AA concentrations in the urine are 
given relative to creatinine. No significant differences between groups were detected. 
(ANOVA with post-hoc Dunnett’s multiple comparison test). 
 
! 
47!
REFERENCES  
 
1. Daniel H. Molecular and integrative physiology of intestinal peptide transport. Annu 
Rev Physiol 2004;66:361-84. 
2. Broer A, Juelich T, Vanslambrouck JM, et al. Impaired nutrient signaling and body 
weight control in a Na+ neutral amino acid cotransporter (Slc6a19)-deficient mouse. J 
Biol Chem 2011;286:26638-51. 
3. Broer S, Palacin M. The role of amino acid transporters in inherited and acquired 
diseases. Biochem J 2011;436:193-211. 
4. Chillaron J, Font-Llitjos M, Fort J, et al. Pathophysiology and treatment of cystinuria. 
Nat Rev Nephrol 2010;6:424-34. 
5. Daniel H, Kottra G. The proton oligopeptide cotransporter family SLC15 in physiology 
and pharmacology. Pflugers Arch 2004;447:610-8. 
6. !!! INVALID CITATION !!! 
7. Seow HF, Broer S, Broer A, et al. Hartnup disorder is caused by mutations in the 
gene encoding the neutral amino acid transporter SLC6A19. Nat Genet 
2004;36:1003-7. 
8. Kleta R, Romeo E, Ristic Z, et al. Mutations in SLC6A19, encoding B0AT1, cause 
Hartnup disorder. Nat Genet 2004;36:999-1002. 
9. Kowalczuk S, Broer A, Tietze N, et al. A protein complex in the brush-border 
membrane explains a Hartnup disorder allele. FASEB J 2008;22:2880-7. 
10. Camargo SM, Singer D, Makrides V, et al. Tissue-specific amino acid transporter 
partners ACE2 and collectrin differentially interact with hartnup mutations. 
Gastroenterology 2009;136:872-82. 
11. Kuba K, Imai Y, Ohto-Nakanishi T, et al. Trilogy of ACE2: a peptidase in the renin-
angiotensin system, a SARS receptor, and a partner for amino acid transporters. 
Pharmacol Ther 2010;128:119-28. 
12. Fairweather SJ, Broer A, O'Mara ML, et al. Intestinal Peptidases Form Functional 
Complexes with Neutral Amino Acid Transporter B0AT1. Biochem J 2012. 
13. Danilczyk U, Sarao R, Remy C, et al. Essential role for collectrin in renal amino acid 
transport. Nature 2006;444:1088-91. 
14. Takanaga H, Mackenzie B, Suzuki Y, et al. Identification of mammalian proline 
transporter SIT1 (SLC6A20) with characteristics of classical system imino. J Biol 
Chem 2005;280:8974-84. 
15. Romeo E, Dave MH, Bacic D, et al. Luminal kidney and intestine SLC6 amino acid 
transporters of B0AT-cluster and their tissue distribution in Mus musculus. Am J 
Physiol Renal Physiol 2006;290:F376-83. 
16. Broer S, Bailey CG, Kowalczuk S, et al. Iminoglycinuria and hyperglycinuria are 
discrete human phenotypes resulting from complex mutations in proline and glycine 
transporters. J Clin Invest 2008;118:3881-92. 
! 
48!
17. Singer D, Camargo SM, Ramadan T, et al. Defective intestinal amino acid absorption 
in Ace2 null mice. Am J Physiol Gastrointest Liver Physiol 2012. 
18. Werner C, Poss J, Bohm M. Optimal antagonism of the Renin-Angiotensin-
aldosterone system: do we need dual or triple therapy? Drugs 2010;70:1215-30. 
19. Igase M, Strawn WB, Gallagher PE, et al. Angiotensin II AT1 receptors regulate 
ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive 
rats. Am J Physiol Heart Circ Physiol 2005;289:H1013-9. 
20. Chappel MC, Ferrario CM. ACE and ACE2: their role to balance the expression of 
angiotensin II and angiotensin-(1-7). Kidney Int 2006;70:8-10. 
21. Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron 
function. Am J Physiol Renal Physiol;298:F1297-305. 
22. Dave MH, Schulz N, Zecevic M, et al. Expression of heteromeric amino acid 
transporters along the murine intestine. J Physiol 2004;558:597-610. 
23. Terada T, Shimada Y, Pan X, et al. Expression profiles of various transporters for 
oligopeptides, amino acids and organic ions along the human digestive tract. 
Biochem Pharmacol 2005;70:1756-63. 
24. Meier C, Ristic Z, Klauser S, et al. Activation of system L heterodimeric amino acid 
exchangers by intracellular substrates. EMBO J 2002;21:580-9. 
25. Ramadan T, Camargo SM, Summa V, et al. Basolateral aromatic amino acid 
transporter TAT1 (Slc16a10) functions as an efflux pathway. J Cell Physiol 
2006;206:771-9. 
26. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-
binding cassette and solute carrier transporter superfamilies. Drug Metab 
Pharmacokinet 2005;20:452-77. 
27. Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA 
expression along the human intestinal tract. Drug Metab Dispos 2007;35:590-4. 
28. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's 
disease are associated with diminished mucosal alpha-defensin expression. Gut 
2004;53:1658-64. 
29. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis 
based on transcription factor binding sites. Bioinformatics 2005;21:2933-42. 
30. Frech K, Danescu-Mayer J, Werner T. A novel method to develop highly specific 
models for regulatory units detects a new LTR in GenBank which contains a 
functional promoter. J Mol Biol 1997;270:674-87. 
31. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to 
microbial ecology and intestinal inflammation. Nature 2012;487:477-81. 
32. Kowalczuk S, Broer A, Munzinger M, et al. Molecular cloning of the mouse IMINO 
system: an Na+- and Cl--dependent proline transporter. Biochem J 2005;386:417-22. 
! 
49!
33. Ristic Z, Camargo SM, Romeo E, et al. Neutral amino acid transport mediated by 
ortholog of imino acid transporter SIT1/SLC6A20 in opossum kidney cells. Am J 
Physiol Renal Physiol 2006;290:F880-7. 
34. Kim DK, Kanai Y, Matsuo H, et al. The human T-type amino acid transporter-1: 
characterization, gene organization, and chromosomal location. Genomics 
2002;79:95-103. 
35. Font-Llitjos M, Feliubadalo L, Espino M, et al. Slc7a9 knockout mouse is a good 
cystinuria model for antilithiasic pharmacological studies. Am J Physiol Renal Physiol 
2007;293:F732-40. 
36. Fernandez E, Carrascal M, Rousaud F, et al. rBAT-b(0,+)AT heterodimer is the main 
apical reabsorption system for cystine in the kidney. Am J Physiol Renal Physiol 
2002;283:F540-8. 
37. Verrey F, Meier C, Rossier G, et al. Glycoprotein-associated amino acid exchangers: 
broadening the range of transport specificity. Pflugers Arch 2000;440:503-12. 
38. Feliubadalo L, Font M, Purroy J, et al. Non-type I cystinuria caused by mutations in 
SLC7A9, encoding a subunit (bo,+AT) of rBAT. Nat Genet 1999;23:52-7. 
39. Mariotta L, Ramadan T, Singer D, et al. T-type amino acid transporter TAT1 
(Slc16a10) is essential for extracellular aromatic amino acid homeostasis control. J 
Physiol 2012;590:6413-24. 
40. Anderson CM, Grenade DS, Boll M, et al. H+/amino acid transporter 1 (PAT1) is the 
imino acid carrier: An intestinal nutrient/drug transporter in human and rat. 
Gastroenterology 2004;127:1410-22. 
41. Broer A, Wagner CA, Lang F, et al. The heterodimeric amino acid transporter 
4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem J 
2000;349 Pt 3:787-95. 
42. Blachier F, Boutry C, Bos C, et al. Metabolism and functions of L-glutamate in the 
epithelial cells of the small and large intestines. Am J Clin Nutr 2009;90:814S-821S. 
43. Scheppach W, Dusel G, Kuhn T, et al. Effect of L-glutamine and n-butyrate on the 
restitution of rat colonic mucosa after acid induced injury. Gut 1996;38:878-85. 
44. Tumer E, Broer A, Balkrishna S, et al. Enterocyte-specific regulation of the apical 
nutrient transporter SLC6A19 (B(0)AT1) by transcriptional and epigenetic networks. J 
Biol Chem 2013;288:33813-23. 
45. Douard V, Cui XL, Soteropoulos P, et al. Dexamethasone sensitizes the neonatal 
intestine to fructose induction of intestinal fructose transporter (Slc2A5) function. 
Endocrinology 2008;149:409-23. 
46. Naruhashi K, Sai Y, Tamai I, et al. PepT1 mRNA expression is induced by starvation 
and its level correlates with absorptive transport of cefadroxil longitudinally in the rat 
intestine. Pharm Res 2002;19:1417-23. 
47. Pan X, Hussain MM. Clock is important for food and circadian regulation of 
macronutrient absorption in mice. J Lipid Res 2009;50:1800-13. 
! 
50!
48. Dyer J, Hosie KB, Shirazi-Beechey SP. Nutrient regulation of human intestinal sugar 
transporter (SGLT1) expression. Gut 1997;41:56-9. 
49. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of 
angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of 
cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-90. 
50. Brandsch M. Transport of drugs by proton-coupled peptide transporters: pearls and 
pitfalls. Expert Opin Drug Metab Toxicol 2009;5:887-905. 
51. Attia E, Wolk S, Cooper T, et al. Plasma tryptophan during weight restoration in 
patients with anorexia nervosa. Biol Psychiatry 2005;57:674-8. 
 
  
! 
51!
TABLES AND FIGURES 
Table 1. Patients data. 
 
1patients without RAS-active medication, 2patients treated with ACE-inhibitors, 3patients 
treated with angiotensin II AT1 receptor blockers, 4BMI = body mass index, 5MAP = mean 
arterial pressure. ** p < 0.01; n. s. = not significant (p > 0.05) (ANOVA with posthoc Dunnett’s 
test) 
) )
 
 
Control1 ACEI2 ARB3 ACEI 
vs. 
Control 
ARB vs. 
Control 
Age [years] 51.5 ± 2.7 64.4 ± 3.2 65.2 ± 2.0 ** ** 
Gender (m/f) 13/11 4/5 4/9   
BMI4 [kg/m2] 25.2 ± 0.75 26.4 ± 1.9 26.5 ± 1.5 n. s. n. s. 
MAP5 [mmHg] 87.9 ± 2.5 87.1 ± 3.3 90.3 ± 3.9 n. s. n. s. 
ACE activity [U/l] 35.2 ± 3.4 14.8 ± 1.7 33.0 ± 4.4 ** n. s. 
Renin [mU/l] 12.2 ± 1.8 33.1 ± 9.1 613 ± 392 n. s. n. s. 
Aldosterone [ng/l] 102 ± 14.2 69.6 ±9.5 148 ± 32.9 n. s. n. s. 
Angiotensin I [ng/ml] 0.49 ± 0.083 0.43 ± 0.077 0.59 ± 0.17 n. s. n. s. 
Angiotensin II [pg/ml] 11.3 ± 3.4 9.8 ± 3.7 65.0 ± 40.1 n. s. n. s. 
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Supplementary Table 1. Primers and Probes used for Real-time PCR. 
Name Start Forward  Primer Stop Start Reverse Primer Stop Start Probe Stop 
 
Apical AA- and peptide transporters, ACE and ACE2 
B0AT1 
(SLC6A19) 
1646 
 
GTG TGG ACA GGT 
TCA ATA AGG ACA T 
1670 
 
1719 
 
CCA CGT GAC TTG CCA 
GAA GAT 
1699 
 
1676 
 
TCA TGA TCG GCC ACA 
AGC CCA A 
1697 
 
SIT1  
(SLC6A20) 
5134 
 
GCA TTC CCT CCA 
CGA TAA GC 
5153 
 
5227 
 
GGC AAC GTG TGG CGA 
TTC 
5210 
 
5169 
 
ACC AGG AAA CTA CCT 
CCG CCG TAC ATC T 
5196 
 
PAT1 
(SLC36A1) 
1057 GTC CCG GCT GAG 
ATC ATC A 
1075 1173 GAT GGC CAA GAT GCA 
TGT CA 
1154 1090 TCC CGA GCG CCC GAG 
CAC 
1107 
b0,+AT 
(SLC7A9) 
630 
 
TCC TCA AAT CGT 
TGT GAA ATG C 
651 
 
707 
 
AGC CGC ACG CTC AGT 
GA 
691 
 
662 
 
CCG CCA TCT TGT TCA 
TCT CGA CAG TGA 
688 
 
rBAT 
(SLC3A1) 
1014 
 
CAC GGT CAC ACA 
ATA CTC GGA  
1034 
 
1153 
 
CTT CAG TCC CCA TGA 
ACC TGT  
1133 
 
1036 
 
CTG TAC CAT GAC TTC 
ACC ACC ACG CA 
1061 
 
PEPT1 
(SLC15A1) 
335 
 
TGG ACA AGC AGT 
CAC CTC AGT AA 
357 427 
 
AGC ACC ACG TGC ACA 
GGA A 
409 382 ACA ACC ATG ATG GCA 
CCC CCG A 
403 
ACE 625 ACC GCT GTA CGA 
GGA TTT CAC T 
646 764 CTA GCT GTT GGT AGA 
GGT GTT CCA 
741 665 TAC AAG CAG GAC GGC 
TTC ACA GAC ACG 
691 
ACE2 1536 GGG AGA TGA AGC 
GAG AGA TAG TTG 
1559 1636 TGA GTA ATC ATT AGA 
AAC ATG GAA CAG A 
1609 1580 CAT GAT GAA ACA TAC 
TGT GAC CCC GCA 
1606 
 
Basolateral AA transporters 
LAT1 
(SLC7A5) 
758 
 
CCT ATG GAG GAT 
GGA ATT ACT TGA A 
782 
 
906 
 
GGT GGA CAG GGT GGT 
GAA GTA G 
885 
 
784 
 
TTC GTC ACA GAG GAA 
ATG ATC AAC CCC T 
811 
 
LAT2 
(SLC7A8) 
952 
 
ATG CCC ATT TCT 
GTT GCC C 
970 
 
1084 
 
AGC GCT TCA CGT GGA 
TCA T  
 
1066 
 
987 
 
AGT TAA TGG GTC TCT 
CTT CAC CTC CTC TCG 
G  
1017 
 
LAT4 
(SLC43A2) 
1537 GAC CCT CTG TGG 
GTG AAC GT 
1556 1677 GAT TTT GAG GAA GAG 
TTT GTC ATC CT 
1652 1579 CTG GGC TTC TGC CTC 
CCG CTC 
1599 
y+LAT1 
(SLC7A7) 
1823 
 
CCC TCA AGC TCA 
GCG TTT T 
1842 
 
2316 
 
TAA AGT GGA ACA GCC 
ACC AGG 
2337 
 
1847 
 
CCG ATT GTC TTC TGC 
CTC TGC ACC AT 
1873 
 
y+LAT2 
(SLC7A6) 
1222 
 
CAG CTC TAC CTC 
CGC TGG AA 
1241 
 
1312 
 
ACA CGG AGC ATA TGC 
AGA ACA C 
1291 
 
1256 
 
CCC GGC CTC TCA AGC 
TGA GCG 
1276 
 
4F2hc 
(SCL3A2) 
708 
 
CAG AAG GAT GAT 
GTC GCT CAG A 
729 
 
813 
 
GGA TGC TCT TTT TTT 
TAG CCG ATT 
790 
 
734 
 
CTT GCT GCA GAT CGA 
CCC CAA TTT TG 
759 
 
ASCT2 
(SLC1A5) 
532 
 
AAG GAG GTG CTC 
GAT TCG TTC  
552 
 
615 
 
AGA GTA TGA GCG AAA 
GGC TGC  
595 
 
563 
 
CGA GAA ATA TCT TCC 
CTT CCA ACC TGG TGT 
CA  
594 
 
TAT1 
(SLC16A10
) 
278 TGC TCT TCG TGT 
CCA TGC T 
296 404 AAG ACG CTG ACT ATT 
GGG CAG  
384 299 AAA CCT TCG GCT CCA 
AAG ACG ATG ACA 
325 
 
Housekeeping Genes 
Villin 2002 AGG ATG ATG TGT 
TCC TAC TAG ATG 
TCT G  
2029 2092 GTT TCT GCG GCC TTC 
TTC 
2075 2031 TGT TTC CCA ATC CAG 
AAG AAG ACC TGG TC 
2059 
HPRT 210 TTA TGG ACA GGA 
CTG AAC GTC TTG 
233 323 CCA GCA GGT CAG CAA 
AGA ATT 
303 262 CCATCACATTGTAGCC
CTCTGTGTGCTC 
289 
 
Intestinal Genes with common promoter modules to ACE2, B0AT1 and PEPT1 
HUS1 371 CCG TGG AGC TGT 
TAT CTA TGT CAA 
394 475 CCA CCG GTT CTT GTA 
AGT CCT T 
454 403 CGC ATT GTG ACC 
CAT GAC ATC CCC 
426 
GALC 2065 CAC CAC TCG TAT 
CCT CGG AAA 
2085 2188 TTG GTG CCT CTT TGC 
ATA TTT TAA 
2165 2126 TGC CGT CTG TTG 
TCT GCC CAT CAC 
2149 
HIP1 111 GCG GAC TCA GAC 
TGT CAG CAT 
131 250 GCA GGC GGT TGA CAA 
CAG A 
232 180 CAG AAC GTG CAT 
ACT GGG CAC CCA 
203 
CDV3 546 ACC ACA AGG ACC 
ACC AGA AAT C 
567 633 TTT ATC CTT CCG GCT 
TTC TAC ATG 
610 573 TGA TAC ACA GTT CCC 
ATC CCT GCA GTC A 
600 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Supplementary Figure 1 
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Supplementary Figure 2 
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6. Manuscript:)‘Intestinal(monosaccharide(transporter(
expression(in(diabetic(patients(–(effect(of(metformin(
treatment’(
 
This section contains the manuscript ‘Intestinal monosaccharide transporter expression in 
diabetic patients – effect of metformin treatment’. 
When the present thesis was written, some experiments including the subcellular localization 
of GLUT2 by immunofluorescence and the gene expression of hepatocyte nuclear factors 1α, 
4α and 3β (HNF-1α, HNF-4α and HNF-3β) were still pending. 
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Abstract  
Type 2 diabetes mellitus (T2DM) is a common disease of glucose metabolism characterized 
by hyperglycemia that may cause severe complications. Metformin is the most widely used 
and first-line pharmacotherapy for T2DM. Dietary carbohydrates are absorbed in the small 
intestine as monosaccharides across the epithelial enterocytes, crossing sequentially the 
luminal membrane via either the sodium transporter SGLT1 (SLC5A1) or the facilitated 
diffusion protein GLUT5 (SLC2A5) and the basolateral membrane presumably via GLUT2 
(SLC2A2). Both experimental diabetes mellitus and metformin treatment were shown to affect 
small intestinal monosaccharide transporter expression in rodents. Furthermore one study 
performed in humans indicated that impaired fasting glucose correlated with changed 
mucosal small intestinal hexose transporter expression. To investigate in human small 
intestine the potential impact of type 2 diabetes mellitus with and without additional metformin 
treatment on hexose transporter expression, intestinal biopsies taken by routine endoscopy 
from 46 patients, whereof 10 where diabetics under metformin treatment and 5 were non-
treated type 2 diabetics were tested. GLUT2, GLUT5 and SGLT1 gene expression showed a 
proximal to distal axial decrease along the human digestive tract as assessed by real-time 
PCR. Immunofluorescence staining localized GLUT5 exclusively to the luminal enterocyte 
membrane. GLUT2 mRNA levels were almost 2-fold higher in human small intestine of non-
treated diabetics when compared to metformin-treated diabetics and non-diabetic controls 
respectively. A similar trend was not statistically significant for GLUT5. Taken together this 
study characterized in human intestine the axial and subcellular localization of intestinal 
hexose transporters and suggests that GLUT2 expression is increased in T2DM, an effect 
that is abolished by metformin treatment.  
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Introduction 
 
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia, 
caused by insulin resistance of fat and muscle cells, inadequate suppression of glucose 
production in the liver in response to insulin and by the inability of pancreatic islet β-cells to 
secret adequate amounts of insulin [10,105]. Its increasing prevalence and devastating 
effects on many organs including cardio-vascular disease, renal failure, vision loss and nerve 
damage [102] make it an enormous healthcare and economic burden [105,106]. According to 
the World Health Organization (WHO) and the American Diabetes Association (ADA) 
diabetes mellitus is currently defined as fasting plasma glucose levels ≥ 7.0 mmol/l 
(126 mg/dl) and/or plasma glucose levels ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g 
oral glucose load as part of a glucose tolerance test [58]. Since 2009, glycosylated 
hemoglobin A1c (HBA1c) concentrations higher than 6.5% have been added to these 
diagnostic criteria [58,59]. Currently, various international professional advisory boards and 
healthcare authorities adopted these recommendations [105]. 
Management of type 2 diabetes mellitus relies on lifestile approaches (consisting of increased 
physical activity, reduction of dietary carbohydrate intake and loss of body weight) and the 
use of hypoglycemic agents lowering blood glucose levels [107]. The biguanide metformin 
hereby is the most widely used and first-line pharmacotherapy for type 2 diabetes mellitus 
[11,14,60]. The glucose-lowering effect of metformin is mainly attributed to decreased hepatic 
glucose output and increased peripheral (i.e. fat and muscle tissue) glucose uptake. Other 
mechanisms of metformin function are reduced fatty-acid oxidation and increased intestinal 
use of glucose [12,13]. Furthermore, metformin treatment seems to exert an inhibitory effect 
on intestinal glucose absorption as shown in rats [14], but inconsistent effects of metformin on 
intestinal monosaccharide transporter expression were found in non-diabetic rodents [61,62]. 
After enzymatic digestion by the pancreatic α-amylase and brush-border membrane (BBM)-
bound disaccharidases, dietary carbohydrates are absorbed exclusively as monosaccharides 
including D-glucose (Glu), D-galactose (Gal) and D-fructose (Frc). Three different intestinal 
transporters, SGLT1 (SLC5A1), GLUT2 (SLC2A2) and GLUT5 (SLC2A5) are known to 
mediate intestinal monosaccharide absorption [2,3]. SGLT1 refers to a high affinity, low 
capacity sodium- dependent BBM glucose and galactose symporter. GLUT2 and 5 are 
facilitated diffusion protein uniporters with GLUT2 being expressed in the basolateral 
enterocyte membrane, transporting Glu, Gal and Frc and GLUT5 transporting Frc across the 
BBM. In experimental diabetes, but also in fructose- and/or glucose rich diets in rodents [18], 
as well as in morbidly obese human subjects [19] the basolateral high-capacity, low-affinity 
facilitative glucose, fructose and galactose transporter GLUT2 is also expressed in the apical 
enterocyte membrane [18]. This finding is in accordance with the fact that glucose absorption 
in humans increased at luminal concentrations far above those required to saturate the high 
affinity, low capacity glucose and galactose transporter SGLT1 [18], but remains selective in 
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these conditions, such that it is likely transporter-mediated and not due to a paracellular leak. 
Both, specific diets and (experimental) diabetes affect small intestinal monosaccharide 
transporter expression. Dietary fructose and sucrose increase small intestinal SGLT1, GLUT2 
and GLUT5 expression in non-diabetic rats [17]. Whereas expression of the fructose 
transporter GLUT5 seems to be specifically responsive to fructose, intestinal expression of 
SGLT1 and GLUT2 also depend on dietary glucose [63]. The regulation of intestinal hexose 
transporter in diabetic subjects seems to be more complex and led to contradictory findings: 
Whereas one study in humans showed increased gene and protein expression of intestinal 
hexose transporters GLUT2, GLUT5 and SGLT1 in humans suffering from impaired fasting 
glucose levels [16], another study performed in Zucker rats – reflecting a model of type 2 
diabetes – shows no effect on intestinal monosaccharide transporter GLUT2, GLUT5 and 
SGLT1 expression [20]. By contrast, surveys in rodents with streptozotocin-induced type 1 
diabetes showed increased small intestinal GLUT2 and SGLT1 expression [64,65] with 
inconsistent findings concerning small intestinal GLUT5 expression [63,65].  
The present study aimed at investigating the potential impact of type 2 diabetes mellitus on 
small intestinal monosaccharide transporter GLUT2, GLUT5 and SGLT1 expression with 
respect to metformin treatment. Additionally, the differential gene expression of these 
transporters along the human digestive tract was analyzed, as well as the subcellular 
localization of GLUT2 in fasting human subjects suffering from type 2 diabetes mellitus. 
(Remark: Results of GLUT2 localization were pending when the present thesis was written) 
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Materials and Methods 
 
Study population 
All patients included in the present study were examined at one single institute as a part of a 
routine medical checkup. Selected patients underwent gastroduodenoscopy only (n= 34), 
ileocolonoscopy only (n= 2) or a combined gastroduodeno-/ileocolonoscopy (n= 10) in the 
morning after overnight fasting in order to avoid short-time dietary- or day-time effects on 
intestinal monosaccharide gene expression. During endoscopy, 8 mucosal biopsies were 
obtained at 4 different intestinal localizations, namely from the descending (part II) and 
inferior (part III) duodenum as well as from the terminal ileum and from the ascending colon. 
In total, 46 patients (26 female, 20male) were included the current study. 12 patients had a 
positive history for diabetes mellitus type II and 3 patients exhibited HbA1c levels ≥ 6.5%. 10 
of 15 diabetic patients were under metformin treatment. 31 patients with negative history for 
type 2 diabetes mellitus, HbA1c levels < 6.5% and spontaneous blood glucose levels < 11.1 
mmol/l served as non-diabetic controls. Patient’s treatment was independent from the present 
study or hereby obtained results. Following endoscopy, blood samples were drawn from the 
patient’s cubital vein in order to assess laboratory values of glucose metabolism 
(spontaneous plasma blood glucose and HbA1c levels), and kidney function (plasmatic uric 
acid- and –creatinine levels as well as the calculated GFR). Physiologic parameters, including 
body mass index (BMI) and mean arterial blood pressure were further assessed. Included 
patient’s age ranged from 18 to 80 years and patient’s Body Mass Index (BMI) was 18 to 35 
kg/m2. Patients with severe pathologies of the GI- tract, such as coeliac disease, Crohn’s 
disease and ulcerative colitis, as well as patients with carcinomas, kidney- or hepatic 
insufficiency, bleeding disorders, infectious diseases, oral anticoagulation, drug- or alcohol 
abuse, mental disability or type 1 diabetes mellitus, were excluded from the present study 
(Table 1). 
 
Intestinal biopsies 
After removal, tissue specimens were immediately (within 10 seconds) frozen in liquid 
nitrogen and stored at -800C until further processing.  
 
RNA extraction 
RNA was extracted by disrupting the tissue with MagNA Lyser Green Beads (from Roche, 
Switzerland) for 30 seconds at 6000 rpm (utilizing a Precellys® 24 tissue homogenizer from 
Bertin Technologies, France) in 350 µl RLT-Beta-Mercapto-Ethanol buffer (10µl β-ME/1 ml 
RLT-buffer). The obtained dilution was then centrifuged at 10°C for 5 minutes at 10000g. 
RNA was isolated from the supernatant using the Qiagen RNeasy mini kit (from QIAGEN, 
Switzerland).  
RNA concentrations at 260nm wavelength and purity of the extractions were measured with 
spectrophotometry applying the NanoDrop 1000 Spectrophotometer (from Witec AG, 
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Switzerland).  
 
Reverse transcription 
Reverse transcription was performed using the Biometra T Gradient Thermocycler (from 
Biolabo Scientific Instruments SA, Switzerland) and Applied Biosystems Taq Man RT-PCR 
reagents and at final concentrations in the reaction mix of: Random hexamers (2.5µM), MgCl2 
(5mM), RT buffer (1x), deoxyNTP mix (500 µM each), RNAse inhibitor (0.4 U µl-1), multiscribe 
reverse trancriptase enzyme 1.25 U µl-1), RNA template (33 ng µl-1) and RNAse free water. In 
parallel to all reactions negative control experiments were performed by omitting the 
multiscribe reverse trancriptase enzyme. Finally, samples were stored at -20°C until further 
processing. 
 
Primers and probes 
Primers and probes were designed using the software Primer Express 3.0 (from Applied 
Biosystems, Switzerland) or according to a previous report[80]. Self-designed primers bridged 
intron-exon boundaries to avoid a contamination by genomic DNA and amplified fragments 
base pair length was 70 to 100. PCR of all used primers was performed and resulted in a 
single product of expected base pair length using (data not shown). Probes were labelled at 
the 5’ end with the fluorescent reporter dye FAM and at the 3’ end with the quencher dye 
TAMRA (from Microsynth AG, Switzerland) (Table 2).  
 
Real time PCR 
Quantitative Real Time PCR (qRT-PCR) was perfomed by preparing a 20µl PCR reaction 
volume containing TaqMan Universal PCR Master Mix (10µl) (from Applied Biosystems AG, 
Switzerland), Primers (0.8µl each; final concentration: 1µM each), Probe (0.4µl; final 
concentration: 0.1µM) cDNA (1µl), and DEPC-Water (7µl). 96-well optical reaction plates and 
the 7500 Fast Real-Time System Termocycler (from Applied Biosystmes AG, Switzerland) 
were utilized. In total 45 thermal cycles were performed (set at 95°C for 10 minutes, 60°C for 
15 seconds and 72°C for 1 minute). Individual thresholds were chosen for each gene within in 
the linear range of the amplicon curves. All reactions were operated three times in parallel 
and if the maximal difference between obtained results was less than one cycle mean values 
were calculated. Furthermore, negative controls were run in parallel for each gene and 
obtained results were only used, if the difference between the reaction (mean value of three 
measurements) and negative controls was more than 5 cycles. The gene expression of 
targed mRNA was calculated relative to villin mRNA (relative expression = 2-ΔCt, ΔCt = 
average Ct value of target – average Ct value of villin), which was used as housekeeping 
gene[81]. HPRT (Hypoxanthine phosphoribosyltransferase) was used as a secondary 
housekeeping gene to verify the exspected consistency of villin mRNA expression along the 
human digestive tract (data not shown)[82].  
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Immunofluorescence 
Cryosection 
Intestinal biopsies were embedded in optical coherence tomography cryostat medium (from 
Medite Medizinaltechnik AG, Switzerland) that was put into tubes containing liquid propane. 
Tubes were then transferred into liquid nitrogen and blocks were cut or stored at -80°C. Slices 
of 5 µm thickness were cut using a cryotome (from Leica CM 1850 Cryostat, Switzerland) and 
transferred onto polylysine slides (from O. Kindler & CO GmBH, Germany). Slides were kept 
at -20°C until immunostaining. 
 
Immunostaining 
After defrosting the samples at room temperature for 5 minutes in a wet chamber, slides were 
immersed in 70% Methanol for 90 seconds for fixation. Thereafter 3 washing steps (1 x 
15min, 2 x 5min) with phosphate buffered saline (PBS, 0.1M) (137.0 mM NaCl, 2.7 mM KCl, 
12.0 mM HPO42−/H2PO4−) were performed. The tissue was then kept in 2% bovine serum 
albumin (BSA) diluted in PBS (0.1M) for 1 hour at room temperature in order to reduce 
unspecific antibody binding. Subsequently, primary antibodies were added to the samples for 
another 1 hour at room temperature. Hereby, the following two antibodies were used: 1. 
Affinity purified rabbit anti human polyclonal GLUT2 (from Abcam, United Kingdom)) and 2. 
Affinity purified rabbit anti human polyclonal GLUT5 (Alpha Diagnostic, San Antonio, Texas). 
Primary antibodies were diluted 1:100 in PBS (0.1M) enriched with 2% BSA and 0.04% Triton 
X-100. Then, the  sections were washed again with PBS (0.1M) (3 x 5min) and subsequently, 
the secondary antibody (Alexa Fluor® 488 donkey anti-rabbit IgG, dilution 1:500 and 4’, 6’-
diamidino-2-phenyl- indole (DAPI, Merck, NJ) (0.1mg/ml) (diluted 1:5’000) was added for 1 
hour at room temperature. Sections were rinsed again in PBS (0.1M) (3 x 5min) before 
mounting with DAKO fluorescence mounting media (Dako Cytomation, Baar, Switzerland). 
The tissue specimens were finally examined utilizing a Nikon Eclipse TE300/200 inverted 
microscope fitted with a DS-5M Standard charge-coupled device camera. Pictures were 
captured using the NIS-Elements software (from Nikon Instruments Inc., Melville, New York) 
and processed with the Adobe Photoshop CS5 software. In parallel – as a negative control – 
sections were processed the same way without adding a primary antibody not yielding a 
detectable signal (data not shown). 
 
Statistical analysis 
For data representation, descriptive statistics and statistical analysis, the statistical software 
Graphpad Prism 5 was used. Data are shown as mean ± SEM (standard error of the mean). 
For multiple comparisons, an ANOVA (one-way analysis of variance) with post-hoc 
Bonferroni’s Multiple Comparison test was used. p-values ≤ 0.05 were considered statistically 
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significant. 
 
Ethics 
The present study was performed according to Good clinical practice guidelines and was 
approved by the local ethics committee. Patients were informed at least 24 hours before 
endoscopy about the present study and written informed consent was obtained from each 
patient. 
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Results 
Patients characteristics 
In total, 46 patients (10 patients suffering from type 2 diabetes mellitus with metformin 
treatment, 5 non-treated diabetics and 31 non-diabetic controls) were included in the present 
study. 12 of 15 diabetic patients had a positive history of diabetes mellitus type 2 and 3 of 15 
patients were rated as ‘diabetic’ based on HbA1c values of 6.5 or higher. Blood glucose levels 
were significantly higher in metformin-treated diabetics when compared to non-diabetic 
controls and to diabetics without metformin treatment. HbA1c levels were significantly higher in 
metformin-treated type 2 diabetic patients when compared to non-diabetic controls. Plasma 
urea levels were higher in diabetics without metformin treatment when compared to non-
diabetic control patients. Other parameters assessed, including body mass index, patient’s 
age and blood creatinine levels were not different between groups (Table 1).  
 
Monosaccharide transporter gene expression along the human digestive tract 
Relative gene expression of monosaccharide transporters GLUT2, GLUT5 and SGLT1 to the 
housekeeping gene villin was assessed at four different localizations of the human intestine 
(duodenum parts II and III, terminal ileum and ascending colon) using mucosal biopsies from 
10 patients referred for combined gastroduodenoscopy and ileocolonoscopy. Gene 
expression of facilitated diffusion protein GLUT2 was slightly, but non-significantly lower in the 
terminal ileum, when compared to duodenum parts II and III. Its expression in the ascending 
colon was below the detection limit in all 10 patients assessed. Similarly, but more 
pronounced, gene expression of GLUT5 was similar in duodenum parts II and III, and non-
sognificantly lower in the terminal ileum. A very low GLUT5 mRNA level was seen in only 1 of 
10 patients, whereas in 9 of 10 patients the GLUT5 gene could not be detected in the 
ascending colon. Sodium-dependent glucose and galactose transporter SGLT1 mRNA was 
significantly higher in duodenum parts II and III when compared to the terminal ileum and the 
ascending colon (p< 0.0001 for all four comparisons). Furthermore, gene expression of 
SGLT1 in the ascending colon was above the detection limit in most patients assessed and 
showed significantly lower expression levels than in the terminal ileum (p< 0.01) (Figure 1).  
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Duodenal monosaccharide transporter expression in metformin-treated type 2 diabetics vs. 
type 2 diabetics without metformin treatment vs. non-diabetic controls  
Mucosal biopsies from 44 patients referred for gastroduodenoscopy were analyzed. Fifteen of 
these patients were diabetic and 10 of these 15 patients were under metformin treatment. 
Since mRNA expression levels of all 3 monosaccharide transporters (GLUT2, GLUT5 and 
SGLT1) assessed were not different between duodenum parts II and III (as assessed by a 
paired two-tailed t-test for each gene; data not shown), the impact of type 2 diabetes mellitus 
and of metformin treatment was measured in duodenal samples (means of all available 
biopsies) only.  
The mean duodenal gene expression level of GLUT2 in non-metformin-treated type 2 
diabetics was increased 1.9- and 1.7-fold, when compared to metformin-treated diabetics and 
non-diabetic controls, respectively (Figure 3a). Similarly, non-metformin treated patients 
showed a trend to increased duodenal GLUT5 mRNA levels when compared to metformin-
treated diabetics and non-diabetic controls, respectively, without yielding significant 
differences (Figure 3b). In contrast, SGLT1 showed equal duodenal gene expression levels 
among groups (Figure 3c).  
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Discussion 
Type 2 diabetes mellitus is a common disease of glucose metabolism that may result in 
severe morbidity [10]. The dimethylbiguanide metformin is the first-line antihyperglycemic 
medication in T2DM treatment [11]. Metfromin increases insuline-stimulated glucose uptake 
in muscle cells and decreases hepatic Glc output [12,13]. Furthermore, metformin treatment 
has an inhibitory effect on intestinal glucose absorption as shown in rodents [14]. Three 
different small intestinal hexose transporters, SGLT1, GLUT2 and GLUT5 provide intestinal 
monosaccharide absorption. Whereas SGLT1 and GLUT5 are expressed exclusively in the 
brush-border membrane, GLUT2 localizes to the basolateral enterocyte membrane, but 
shows luminal expression in conditions of experimental diabetes and in fructose- or glucose 
rich diets in rodents [18], as well as in in morbidly obese human subjects [19]. Whereas 
specific fructose and sucrose rich diets affect small intestinal SGLT1, GLUT2 and GLUT5 
expression [17], the changes in small intestinal hexose transporter expression as a result of 
diabetes mellitus seems to be more complex [16,20].  
We could show in the present study an increase in small intestinal GLUT2 mRNA expression 
in non-metformin treated human type 2 diabetics, an effect that was abolished uppon 
metformin treatment. Whereas SGLT1 expression was equal among groups (i.e. metformin-
treated type 2 diabetics, non metformin-treated type 2 diabetics and non-diabetic controls), 
also GLUT5 gene expression was potentially increased in diabetic patients without metformin 
treatment (non-significant increase). We could further demonstrate for the first time the 
longitudinal gene expression of hexose transporters along the human digestive tract in a 
single cohort of patients, as well as protein localization of facilitated diffusion proteins GLUT2 
and GLUT5. Whereas the latter exclusively localized to the BBM as expected, 
immunolocalisation of uniporter GLUT2 was still pending, when the present thesis was 
written. In experimental diabetes, as well as in fructose-/glucose rich diets in rodents, GLUT2 
also showed, besides its basolateral localization, expression in the apical enterocyte 
membrane. We hence hypothesize that this increased translocation to the luminal enterocyte 
membrane might be for GLUT2, next to its raised gene expression an additional mechanism 
by which it contributes to fast glucose absorption in non-treated type 2 diabetics 
 
 
 
Axial distribution of intestinal hexose transporters GLUT2, GLUT5 and SGLT1 in human 
subjects 
To the author’s knowledge, this is the first study summarizing the longitudinal gene 
expression of intestinal hexose transporters GLUT2, GLUT5 and SGLT1 along the human 
digestive tract in one single cohort of patients. Unlike amino acid transporters showing 
variable transporter expression alongside of the human digestive tract (Vuille-dit-Bille et al, 
unpublisched data) all three hexose transporters exhibited at similar gene expression pattern 
along the human intestine: Whereas GLUT2 and GLUT5 showed a trend to decreasing 
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mRNA levels (without yielding statistical significance) from proximal to distal along the human 
small intestine with undetectable (GLUT2) or almost undetectable (GLUT5) gene expression 
in the large intestine, SGLT1 mRNA was significantly lower in the terminal ileum when 
compared to duodenum parts II or III, respectively and significantly lower in the large intestine 
when compared to the duodenum and the terminal ileum. This indicates that most of the 
monosaccharide absorption occurs already in the proximal small intestine. Concerning 
glucose transport along the luminal membrane - unlike in intestine - in kidney proximal tubule, 
the re-uptake of D-glucose from the glomerular filtrate along the brush border membrane is 
mainly mediated by the low affinity, high capacity transporter SGLT2 (SLC5A2) that is 
essentially expressed in the more proximal convoluted segments S1 and S2. High affinity, low 
capacity transporter SGLT1 is primarily expressed in the more distal straight segment S3 and 
enables the uptake of remaining luminal glucose [108]. Since in intestine only SGLT1 and 
GLUT2 provide transepithelial glucose transport and therefore mediate glucose absorption 
[109], it is not surprising, that transporter expression is highest in proximal segments, where 
presumably most of the glucose uptake occurs and lower in the more distal parts, there 
probably enabling the uptake of the remaining luminal glucose content. 
  
Diabetes mellitus affecting small intestinal hexose transporter expression 
Several studies show dietary effects on intestinal monosaccharide transporter mRNA 
expression [110]. Dietary fructose and sucrose indeed increased jejunal hexose transporter 
(including SGLT1, GLUT2 and GLUT5) expression in non-diabetic rats [17]. Whereas 
expression of the fructose transporter GLUT5 seems to be specifically responsive to fructose, 
intestinal expression of SGLT1 and GLUT2 also depends on dietary glucose [63]. The 
regulation of intestinal hexose transporter in diabetic subjects seems to be complex and 
elicited contradictory findings: Whereas one study in humans shows increased gene and 
protein expression of intestinal hexose transporters GLUT2, GLUT5 and SGLT1 in humans 
with fasting blood glucose levels being above 5.5 mM and/or random blood glucose 
concentrations above 10.5 mM [16], another study performed in Zucker rats – reflecting a 
model of type 2 diabetes – shows no effect on intestinal monosaccharide transporter GLUT2, 
GLUT5 and SGLT1 expression [20]. Surveys in rodents with streptozotocin-induced type 1 
diabetes show increased small intestinal GLUT2 and SGLT1 expression [64,65] with 
inconsistent findings concerning small intestinal GLUT5 expression [63,65].  
In the present study we show, that patients with diabetes mellitus type 2 (without metformin 
treatment) exhibit increased duodenal GLUT2 mRNA expression levels when compared to 
non-diabetic control patients. Similarly, but not statistically significant, also the luminal 
fructose transporter GLUT5 shows a tendency to elevated gene expression in diabetics 
(without metformin treatment) when compared to controls. Interestingly mRNA levels of the 
secondary active brush border membrane glucose and galactose transporter SGLT1 were not 
different between these 2 groups of patients. To the author’s knowledge, the study by Dyer 
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and co-workers [102] reflects the only investigation assessing small intestinal hexose 
transporter expression in human subjects suffering from type 2 diabetes mellitus. In 
comparison to our findings, Dyer and colleagues observed increased gene expression of all 3 
hexose transporters GLUT2, GLUT5 and SGLT1 and raised protein expression levels of 
GLUT5 and SGLT1 in subjects with impaired fasting glucose (denominated ‘diabetic’ by Dyer 
et al.). This discrepancy might be explained by the fact, that Dyer and co-workers allocated 
patients with fasting blood glucose levels > 5.5 mM and/or random blood glucose 
concentrations > 10.5 mM to the ‘diabetic’ group, whereas in the present study, the current 
recommendations from the World Health Organization and the American Diabetes 
Association [58] (i.e. fasting plasma glucose levels ≥ 7.0 mmol/l (126 mg/dl) and/or HBA1c 
concentrations > 6.5%) were applied to assign patients to the ‘diabetic’ group. Furthermore, 
the results presented by Dyer and coworkers might also reflect in part the differential 
nutritional state of diabetics and controls, since the latter individuals consumed normal diets 
whereas diabetic patients were on reduced carbohydrate diets in this survey.  
Most studies in rodents assessing the effect of experimental diabetes on intestinal hexose 
transporter expression were performed in animal models of type 1 diabetes mellitus (i.e. 
streptozotocin-induced) [64,65]. An exception constitutes the study by Corpe and co-workers 
using an animal model of type 2 diabetes mellitus (i.e. Zucker Diabetic Fatty Rats). Corpe et 
al. hereby found no difference in hexose transporters GLUT2, GLUT5 and SGLT1 gene and 
protein expression in diabetic rats when compared to non-diabetic control animals. It is 
questionable, whether the discrepancy between the findings by Corpe and collaborators and 
our results (and also those of Dyer et al.) might reflect species differences or potentially 
biasing (and unknown) influencing factors, that may not be controlled in a cohort of human 
subjects. It is further remarkable that the study by Dyer et al. – next to the present work – 
reflects the only known investigation testing the effect of T2DM on intestinal hexose 
transporters expression in humans. This indeed raises the suspicion of non-publication of 
negative results by others and could hence also reflect a possible publication bias [111].  
Transcription factors reported to participate in the regulation of kidney GLUT2 in diabetic 
animals are hepatocyte nuclear factors 1α, 4α and 3β (HNF-1α, HNF-4α and HNF-3β) 
[112,113]. Hence, the gene expression of these transcription factors was assessed, 
revealing… (Remark: The results of these experiments were pending when the present thesis 
was written) 
Currently, most patients suffering from diabetes mellitus type 2 are treated with the biguanide 
metformin that reflects the first-line pharmacotherapy for T2DM. As metformin treatment was 
shown to exert an inhibitory effect on intestinal glucose absorption in rodents [14] and 
inconsistent effects of metformin on intestinal monosaccharide transporter (SGLT1, GLUT2 
and GLUT5) expression were found in non-diabetic rodents [61,62], we analyzed the diabetic 
patients under metformin treatment separately. Interestingly, the increase in duodenal GLUT2 
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gene expression and the tendency to elevated small intestinal GLUT5 mRNA in diabetic 
patients without metformin treatment was completely abolished in patients under biguanide 
therapy. This could signify, that – among other metformin actions (i.e. decreased hepatic 
glucose output, increased fat and muscle tissue glucose uptake, reduced fatty-acid oxidation 
and increased intestinal use of glucose [12,13]) – also the opposing effect of metformin to 
T2DM on small intestinal GLUT2 (and probably also GLUT5) transporter expression could be 
an additional mode of action of metformin therapy. In contrast to our findings, 8 of 25 patients 
in the diabetic group reported by Dyer et al. were under metformin treatment and no 
information was available for 5 of 25 diabetic patients, meaning that metformin treatment in 
about one third of patients did not mask the increase in small intestinal hexose transporter 
expression observed their study. 
Taken together, our study indicatess that T2DM patients have an increased GLUT2 mRNA 
expression, possibly an increase of GLUT2 expression in the luminal enterocyte membrane,  
as well as a non-significant increase in GLUT5 transcript expression, and that these effects 
are reversible under metformin. Since an increase in low affinity luminal diffusion pathways 
such as the GLUT hexose transporters presumably leads to accelerated luminal hexose 
absorption, this will also lead to stronger postprandial (or post softdrink) hyperglycemia. In 
view of the fact that such glucose excursions are considered to account for a large fraction of 
the HbA1c[114] increase and that they additionally represent an independent risk factor for 
adverse cardiovascular outcomes[115,116], it appears that the reported effects of T2DM on 
GLUT expression and its reversibility under metformin may play an important 
pathophysiological role. 
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Figure legends 
 
Figure 1. Relative mRNA abundance of hexose transporters along the human intestine. 
The gene expression levels of GLUT2, GLUT5 and SGLT1 in 10 patients with combined 
gastroduodeno- and ileocolonoscopy are shown. The bars indicate mean relative mRNA 
expression ± SEM (normalized to villin (2Ct(Villin)-Ct(target))). Gene expression of each transporter 
is shown at four different intestinal localizations: duodenum, part II (white bars), part III (light 
grey bars), terminal ileum (dark grey bars) and ascending colon (black bars).  
 
Figure 2. Effect of diabetes mellitus type 2 with and without metformin-treatment on 
small intestinal hexose transporter expression. Duodenal mRNA expression (mean ± 
SEM) of monosaccharide transporters GLUT2 (A), GLUT5 (B) and SGLT1 (C) (normalized to 
villin (2Ct(Villin)-Ct(target))) in type 2 diabetic patients under metformin treatment (T2DM + 
metformin; black bars; n= 10) vs. diabetic patients without metformin therapy (T2DM – 
metformin; grey bars; n= 5) vs. non-diabetic control subjects (controls; white bars; n= 31) is 
shown. **, p< 0.01, ANOVA with post-hoc Bonferroni’s multiple comparison test for all pairs of 
columns.  
 
Figure 3. Immuno-localization of GLUT5 in human intestine. Representative tissue 
specimens from duodenum part II (A), duodenum part III (B), terminal ileum (C) and 
ascending colon (D) are shown. GLUT5 (green) localizes tot he brush border membrane of 
small intestinal enterocytes (A-C) and is not expressed in the large intestine (D). Cellular DNA 
(lower line; DAPI) is shown in blue to display the nuclei. Pictures were taken at 20x 
magnification. The white bar represents 100µm. 
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Tables and Figures 
 
Table 1. Patient’s data. 
 Control (n=31) DM II + 
metformin 
(n=10) 
DM II, no 
metformin (n=5) 
C vs. 
D+M 
C vs. D-M D+M vs. 
D-M 
Gender (f/m) 19/12 5/5 2/3 n. a. n. a. n. a. 
Age [years] 56.2 ± 2.4 61.4 ± 4.0 59.6 ± 4.0 n. s. n. s. n. s. 
BMI [m/kg2] 25.2 ± 0.9 26.6 ± 1.3 28.6 ± 0.6 n. s. n. s. n. s. 
Glucose [mmol/l] 6.2 ± 0.2 9.8 ± 1.1 7.1 ± 0.4 *** n. s. * 
HbA1c (NGSP) 
[%] 
5.8 ± 0.06 7.1 ± 0.5 6.6 ± 0.1 *** n. s. n. s. 
Creatinine [µmol/l] 74.2 ± 2.6 64.7 ± 4.7 80.0 ± 10.2 n. s. n. s. n. s. 
Urea [mg/dl] 4.5 ± 0.2 4.7 ± 0.4 5.9 ± 0.5 n. s. * n. s. 
 
Table 1. Control; C; Control patients. DMII; Diabetes mellitus type II. DM II + Metformin; D+M; 
Diabetes mellitus type II treated with metformin. DM II, no metformin; D-M; Diabetes mellitus 
type II without metformin treatment. BMI; body mass index. N. s.; not significant; p> 0.05. N. 
a.; not assessed. *; p< 0.05. **; p< 0.01. ***; p< 0.0001. ANOVA with post-hoc Bonferroni’s 
Multiple Comparison test. 
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Table 2. Primers and Probes used for Real-time PCR. 
Protein/Gene Type Sequence 
GLUT2/SLC2A2 Forward primer AGC ATT TTT CAG ACG GCT GG 
 
 Reverse primer TAG AAA GAG AGA ACG TCG CCC 
 Probe ACC TGT TTA TGC AAC CAT TGG AGT TGG C 
 
GLUT5/SLC2A5 Forward primer TCA TTG TCT TCG CCG TGA TC 
 Reverse primer TCT ATG AAC GTC TTG GCC TTG 
 Probe CTC CTC ACC ACC ATC TAC ATC TTC TTG ATT GTC C 
SGLT1/SLC5A1 Forward primer TGC CGG AAG GTT GTT TAT CC 
 Reverse primer GTT GCC CAC TTT GTG CTG ACT 
 Probe CAT CAG CAT CGC CTG GGT GCC 
Villin Forward primer AGG ATG ATG TGT TCC TAC TAG ATG TCT G 
 Reverse Primer GTT TCT GCG GCC TTC TTC 
 Probe TGT TTC CCA ATC CAG AAG AAG ACC TGG TC 
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Figure 1 
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Figure 2  
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Figure 3 
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7. Manuscript:)‘The)molecular)mechanism)of)intestinal)
levodopa)absorption)and)its)possible)implication)on)
treatment)of)Parkinson’s)disease’)
 
This section contains the manuscript ‘The molecular mechanism of intestinal levodopa 
absorption and its implications on treatment of Parkinson’s disease’. 
 
Dr. Simone M. R. Camargo significantly contributed to this research article and performed the 
experiments in rodents and in cell culture.  
 
My contribution to the manuscript concerned the creation of the fusion protein human b0,+AT – 
human rBAT and  the experiments performed in Xenopus laevis oocytes.   
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Abstract 
Levodopa (L-DOPA) is the naturally occurring precursor amino acid of dopamine and the 
main therapeutic agent for neurologic disorders of dopamine depletion, such as Parkinson’s 
disease. Levodopa absorption in small intestine has been suggested to be mediated by the 
large neutral amino acids transport machinery, but the identity of the involved transporters is 
unknown. Clinically, co-administration of levodopa and dietary amino acids is avoided to 
decrease competition for transport in intestine and at the blood brain barrier. Another 
common practice is the co-administration of levodopa metabolism inhibitors (dopa 
decarboxylase and cathechol-o-methyl transferase inhibitors), which also share structural 
similarity with levodopa. In this systematic study involving Xenopus laevis oocytes and MDCK 
epithelia as expression systems and ex vivo preparations from wild type and knock out mice 
we identified the neutral and dibasic AA exchanger (antiporter) b0,+AT-rBAT (SLC7A9-
SLC3A1) as the luminal intestinal levodopa transporter whereas the major luminal 
cotransporter (symporter) B0AT1 (SLC6A19) was not involved. L-leucine and L-arginine 
competed with levodopa for transport across the luminal enterocyte membrane as expected 
for b0,+AT-rBAT substrates whereas dopa decarboxylase and cathechol-o-methyl transferase 
inhibitors had no effect. The presence of amino acids in the basolateral compartment 
mimicking the postprandial phase increased transepithelial levodopa transport by stimulating 
its basolateral efflux via antiporter LAT2-4F2 (SLC7A8-SLC3A2). Additionally, the aromatic 
amino acid uniporter TAT1 (SLC16A10) was shown to play a major role. These results 
identify the molecular mechanisms mediating small intestinal levodopa absorption and might 
lead to optimization of strategies for delivery and absorption of this important pro-drug.   
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Introduction 
Parkinson’s disease (PD) [117] is a neurodegenerative disorder mainly caused by dopamine 
depletion in the substantia nigra, clinically manifesting by different symptoms including its 
hallmark, the trias of bradykinesia, resting tremor and rigidity [23,118,119]. Since its 
introduction in 1968, levodopa (L-Dihydroxyphenylalanine, L-Dopa) is the major therapeutic 
agent in treating PD [120]. After passing the Blood Brain Barrier (BBB), levodopa is converted 
into dopamine by the dopa-decarbocylase (DDC) [23]. To prevent levodopa metabolism prior 
to its transport across the BBB, orally administered levodopa is given in combination with a 
DDC inhibitor (DDCI) (as e. g. carbidopa or benserazide) [22]. It may be additionally 
combined with a cathechol-o-methyltransferase (COMT) inhibitor (such as entacapone) to 
avoid levodopa methylation into 3-o-methyldopa.  
Levodopa is a large neutral amino acid structurally very similarto the aromatic amino acids 
(AAs) L-phenylalanine (Phe) and L-tyrosine (Tyr). Levodopa is believed to compete with other 
neutral amino acids for its active transport across the blood-brain barrier, as well as across 
small intestinal enterocytes. In the brain, levodopa has been suggested to be transported by 
the neutral amino acid heterodimeric transporter LAT1-4F2hc (SLC7A5-SLC3A2) 
[118,121,122]. Intestinal levodopa transport has been also suggested to be mediated by 
neutral amino acid transporters [69], but the identity of the transporters involved in its 
intestinal absorption is still unknown. Several luminal and basolateral AA and peptide 
transporters located at the luminal and basolateral enterocyte membrane have been shown to 
be responsible for neutral AA absorption [1,38,123]. B0AT1 (SLC6A19) is the major 
transporter for neutral amino acids in the apical enterocyte membrane [73,75,124,125]. The 
neutral and dibasic amino acid exchanger (antiporter) b0,+AT-rBAT (SLC7A9-SLC3A1) is the 
transporter responsible for cystine reabsorption in the kidney, but as well cationic and neutral 
amino acids across the luminal enterocyte membrane [70,126-130]. Among the basolateral 
enterocyte transporters the AA exchangers y+LAT1-4F2hc and LAT2-4F2hc (SLC7A8-
SLC3A2) [131-133], and the aromatic AA uniporter TAT1 (SLC16A10) [26,79,93,134,135] 
were shown to promote accumulation or efflux of amino acid from the enterocytes to the 
extracellular space. In addition the functional interaction between different transporters can 
affect the net flux of amino acids [1,135,136]. 
In the present study, we first intended to identify the levodopa transporter(s) of the luminal 
membrane of small intestinal enterocytes. Several candidate transporters were identified by 
means of structural homology of their transported substrates to levodopa and tested. Second, 
the transepithelial transport involving apical and basolateral transporters in cells and along 
the murine small intestine was assessed using a polarized cell system and intestinal everted 
sacs. Additionally, the impact of luminal neutral amino acids (reflecting digested dietary 
proteins) and routinely co-administered DDCIs and COMT inhibitors on intestinal levodopa 
transport was evaluated as well the impact of gender and circadian rhythm on intestinal 
transporter expression. Concisely, the particular role of the apical b0,+AT1-rBAT and 
basolateral TAT1 in intestinal levodopa transport was elucidated. 
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Materials and Methods 
Oocytes  
Expression studies and influx assays using radiolabeled amino acid tracers were performed 
in Xenopus laevis oocytes. The oocytes were injected with cRNA encoding transporters 
known or suggested to be expressed in the apical membrane of small intestinal enterocytes. 
B0AT1-ACE2 (SLC6A19-ace2), SIT1-ACE2 (SLC6A20-ace2), PAT1 (SLC36A1), ASCT2 
(SLC1A5) and b0,+AT-rBAT (SLC7A9-SLC3A1, fusion protein) cRNA respectively were 
therefore injected. The transport rate of levodopa (100 µM, 20 µCu / ml 3H-levodopa, 
containing 100 µM citric acid (in order to inhibit levodopa oxidation)) was measured and 
compared to specific substrate uptake rates for each transporter (as further described on the 
Figure legends). Data obtained for non-injected oocytes were subtracted, and levodopa 
uptake rates were normalized to those of the known substrates. Competition experiments of 
levodopa or leucine (100 µM) transport were conducted in the presence of 5 mM L-leucine or 
levodopa, respectively. For the DDC and COMT inhibitors, uptake was conducted with 1 µM 
levodopa (20 µCu / ml 3H-levodopa, 100 µM citric acid, for 1 minute) in the presence of 50 µM 
bensirazide, carbidopa or entacapone, respectively. For the main neutral amino acid 
transporter B0AT1-ACE2, the transports of levodopa, L-leucine, L-phenyalanine, and L-
tyrosine (1mM) were further measured using the two-microelectrode voltage clamp (TEVC) 
technique. Recordings were carried out as previously described [137] at a membrane holding 
potential (Vh) of −50 mV. Pooled data were shown as mean ± SEM with n representing the 
number of pooled cells.  
Construction of the hrBAT-hb0,+AT Fusion Protein 
To assure b0,+AT-rBAT transport analyzed in X. laevis oocytes was due to human protein, a 
fusion protein of human b0,+AT and human rBAT was used. Briefly, we utilized the previously 
described fusion protein [130] and substituted mouse b0,+AT by the human ortologue. Human 
b0,+AT was amplified by PCR adding with XmaI at 5’ and NsiI at 3’ ( primer: sense’: CAA AAC 
CCC GGG ATG GGG GAT ACT GGC CTG AGA AAG; antisense: CCG GAG GAA GAC CCT 
GAG GGT GCT GCT CCT GAT GGT GCT CCT GGA TGC ATT CAA). The encoding 
fragment was introduced in frame into the vector containing hrBAT and linker previously 
linearized using SmaI (compatible with XmaI) and NsiI. For expression in Xenopus oocytes 
the human b0,+AT-rBAT-pSport plasmid was linearized with Hind III (Promega) and used as 
template for RNA synthesis from the T7 promoter (mMESSAGE mMACHINE, Ambion, Austin, 
Tex., USA). 
Cells 
MDCK (Madine Darby canine Kidney) cells (strain II) were cultured at 37°C in Dulbecco’s 
modified Eagle’s medium (Invitrogen, Basel, Switzerland) with 2 mM L-glutamine, 1% non-
essential amino acids (Invitrogen) and 10% fetal calf serum (FCS). Cell lines previously 
! 
88!
described by Bauch and collaborators [138] were used. A further transduction on these cells 
was performed as previously described to introduce the basolateral transporter TAT1 
(SLC16A10). Four different cell lines were used: Wild type cells (1); cells expressing the 
apical transporter b0,+AT-rBAT alone (2); cells expressing apical b0,+AT-rBAT in the presence 
of the basolateral transporters LAT2-4F2hc (Slc7a8-Slc3a2) and y+LAT1-4F2hc (Slc7a7-
Slc3a2) (3); and cells additionally (to cell line 3) expressing the basolateral uniporter TAT1 
(4). The wild type and stably transfected cell lines were plated at density of 1.6 x106 cells / 24 
mm Corning Costar Transwell filters and cultivated for 7 days. b0,+AT-rBAT expression was 
induced 24h prior to the experiment with 1 µM dexamethasone. Integrity of the monolayers 
was checked by resistance measurements using the Millicell device (Millipore, Bedford, MA). 
At the experiment day, cells were incubated for 30 minutes with the dopa decarboxylase 
(DDC) inhibitor Bensirazide (50µM Bensirazide, 100 µM citric acid) in 150 mM NaCl, 10 mM 
HEPES pH 7.4, 1 mM CaCl2,5 mM KCl, 1 mM MgCl2, 10mM glucose at 37°C. After this 
period, the uptake solution (100 µM levodopa, 50 µM Bensirazide, 100 µM citric acid) was 
added to both compartments. The filter compartment, facing the apical membrane of the 
cellular monolayer, was supplemented with 0.5 µCi/ml 3H-levodopa. In the competition 
experiments, L-leucine or L-lysine (1 mM) was additionally added to the apical compartment. 
To analyze the effect of basolateral amino acids on transepithelial levodopa transport 
(mimicking post-absorptive states with high plasma amino acid levels), L-leucine or L-lysine 
(1 mM) were added to the basolateral compartment.  
After 30 minutes, apical and basolateral solutions were collected. Transwells were washed in 
both compartments with Na+-free buffer at 4°C. Cells were disrupted by incubation with Na+-
deoxycholate and rocking for 30 minutes. After neutralizing with 0.1 M HCl, cells were added 
to vials and supplemented with a scintillation solution (Perking Elmer). The solution facing the 
cells in the filter compartment and the solution in the basolateral compartment were 
measured the same way. Pooled data are shown as mean ± SEM with n representing the 
number of filters used. For each experiment the values for wild type cells were subtracted 
from the overexpressing cells and data were expressed in nmol/hour/cm2. 
Animals 
Wild type and tat1 knockout mice were housed in standard conditions and fed a standard diet. 
A tat1 knockout mouse model was produced by the ENU (N-ethyl-N-nitrosurea) mutagenesis 
(Ingenium Pharmaceuticals AG, Germany). After 10 backcrossings in a C57Bl/6J 
background, the animals were used on the described experiments [93]. All procedures for 
mice handling were performed according to the Swiss Animal Welfare laws Zurich, 
Switzerland. 
Intestinal ring uptake 
Uptake of radiolabeled amino acids was performed as previously described [5,139] on 
duodenal, jejunal and ileal segments. Briefly, everted small intestinal segments were 
incubated in oxygenated (Oxycarbon) Krebs-Tris buffer (pH 7.4) containing 100 µM Levodopa 
(0.05 µCi 3H-L-levodopa/mL, 50µM Bensirazide, 100 µM citric acid), for 5 minutes at 37°C or 
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4°C. After washing the rings with ice cold buffer, the segments were dried at 55°C overnight 
on cellulose (Sartorius AG, Goettingen, Germany) and weighed. Segments were then lysed in 
0.75N NaOH for 6 hours and neutralized with 10N HCl, and the radioactivity was determined 
by liquid scintillation. Amino acid transport was expressed as pmol/mg/5min of dry tissue 
weight. Values obtained at 4°C were subtracted from the values of samples assayed at 37°C. 
Everted intestinal sacs  
In order to analyze transepithelial levodopa transport ex-vivo, everted jejunal sacs from wild 
type or tat1 knockout animals were used. Everted sacs were built by constraining the 
extremities of circa 2 cm everted segments with a suture. The sacs were filled with Krebs-Tris 
buffer (pH 7.4) and incubated in a solution containing levodopa (100 µM levodopa, 0.05 µCi 
3H-levodopa/mL) for 10 minutes. After washing with ice-cold solution, the liquid content of the 
sacs (serosa) was collected, the tissue (mucosa) was weight and processed as the intestinal 
rings. The data are shown as mean ± SEM with n representing the number of sacs. The 
transport is expressed as nmol/10 minutes/mg of dry tissue. Values obtained at 37°C were 
subtracted from measurements performed at 4°C.  
Brush border membrane vesicles (BBMV) and Western blot analysis 
BBMV were prepared from small intestine mucosal cells using the Mg2+ precipitation 
technique as described elsewhere [140]. Western blotting was performed as previously 
described [138]. Primary antibodies used were: rabbit affinity purified anti-mouse b0,+AT1 
(diluted 1:500) and monoclonal anti-mouse actin (1:10’000) (Sigma, St Louis, MO). 
Secondary antibodies: donkey anti-rabbit IgG horseradish peroxidase conjugated (Amersham 
Biosciences, Piscataway, NJ) or anti-mouse IgG alkaline phosphatase conjugate (Promega, 
Madison, WI) were diluted 1:5’000. Antibody binding was detected with Immobilon Western 
Chemiluminescent HRP or AP substrate (Millipore, Billerica, MA) and chemiluminescence 
visualized with a DIANA III camera (Raytest, Dietikon, Switzerland). 
Quantitative real time PCR (qPCR) 
RNA was extracted from small intestine scraped mucosa, and real time quantitative reverse 
transcription-PCR was performed as previously described [75]. The abundance of the target 
mRNAs was calculated relative to the housekeeping gene hypoxanthine guanine 
phosphoribosyltransferase (HPRT). Relative expression ratios were calculated as r = 
2(Ct(reference) - Ct(test)), whit Ct representing cycle number at the threshold, and test representing 
tested mRNAs. Primers and probes used have been previously described [70,75,141].  
Data analysis 
Data are shown as mean ± SEM. All assessed data were unpaired and parametric. 
Differences between one ‘control group’ and two or more ‘treatment groups’ were assessed 
using an ANOVA with post-hoc Dunnett’s Multiple Comparison test and differences between 
three or more groups (executing all possible comparisons between groups) were measured 
utilizing an ANOVA with post-hoc Bonferroni’s Multiple Comparison test. For single pairwise 
comparisons, a Student’s two-tailed t-test was performed. P-values of less than 5% were 
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considered significant. Graphs, descriptive statistics and calculations were performed using 
the software GraphPad Prism version 4.0 (GraphPad, San Diego, Calif., USA).  
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Results 
Levodopa is transported by the luminal enterocyte transporter b0,+AT-rBAT but not by 
the major neutral amino acid transporter B0AT1-ACE2 
To determine the apical amino acid transporter(s) responsible for levodopa transport across 
the luminal enterocyte membrane, candidate transporters were expressed in X. laevis 
oocytes. The uptake of levodopa was compared to known substrates (control amino acids) for 
each given transporter. As depicted on Figure 1A, oocytes expressing the amino acid 
transporters ASCT2 (SLC1A5), SIT1 (SLC6A20) and PAT1 (SLC36A1) did not transport 
levodopa. Oocytes expressing the AA exchanger b0,+AT-rBAT (SLC7A9-SLC3A1) transported 
levodopa as efficiently as the control amino acid (L-leucine) used. The major neutral luminal 
AA transporter B0AT1-ACE2 (SLC6A19-ace2) did not transport levodopa. The current 
generated by the co-transport of sodium (Figure 1B) and the accumulation of radiolabeled 
levodopa (Figure 1C) were negligible, despite structural homology of levodopa and B0AT1 
substrates L-phenylalanine and L-tyrosine. b0,+AT-rBAT hence is the only known luminal 
levodopa transporter of small intestine. 
The transport of levodopa by b0,+AT-rBAT can be inhibited by the presence of luminal 
neutral amino acids, but not by carbidopa, entacapone or benserazide.  
To test whether levodopa and the neutral amino acid L-leucine compete for b0,+AT1-rBAT 
mediated transport, radiolabeled levodopa influx experiments in X. laevis oocytes were 
performed in the presence or absence of L-leucine and vice versa. Both, radiolabeled 
levodopa and L-leucine uptake was abolished by the presence of excess of non-labeled L-
leucine and levodopa, respectively (Figure 2A).  
Since DDCIs bensirazide, carbidopa and the COMT inhibitor entacapone display a similar 
structure to levodopa, a potential effect of these substrates on b0,+AT1-rBAT-mediated 
levodopa transport was tested. The presence of bensirazide, carbidopa or entacapone did not 
affect levodopa transport (Figure 2B).  
To analyze the impact of high intracellular neutral amino acid concentrations (mimicking the 
(post-)absorptive state) on AA uptake via the antiporter b0,+AT-rBAT, uptake rates of levodopa 
and L-leucine, were measured after pre-injecting X. laevis oocytes with either L-arginine 
(12.5mM) or water (negative control). Pre-loading cells with L-arginine resulted in a small but 
non-significant rise of levodopa and L-leucine uptake (Figure 2C). 
Transepithelial transport of levodopa depends on expression of b0,+AT-rBAT in the 
apical- and LAT2-4F2hc and TAT1 in the basolateral membrane  
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To analyze the interaction of apical and basolateral membrane AA transporters on 
transepithelial levodopa transport, mammalian MDCK epithelial cell models overexpressing 
various combinations of heterodimeric amino acid antiporter and TAT1 uniporter was used 
[Ref Bauch]. Cells overexpressing only b0,+AT-rBAT accumulated levodopa intracellularly, and 
showed – to some extent – a basolateral levodopa efflux (Figure 3A, white bars). Cells 
additionally expressing the antiporter LAT2-4F2hc in the basolateral membrane showed a 3- 
and 2-fold increase in intracellular levodopa accumulation and transepithelial levodopa 
transport-, respectively (Figure 3A, gray bars). Maximal transepithelial transport was 
observed in cells additionally overexpressing the facilitated diffusion protein TAT1 in their 
basolateral membrane. In these cells, a 5-fold increase in basolateral- and 3-fold decrease in 
intracellular accumulation was observed (Figure 3A, black bars). 
To mimic the absorptive (presence of high amino acid concentrations in the lumen) or post-
absorptive (presence of high amino acid concentrations in the extracellular space) state, 
excess concentrations of L-leucine or L-lysine were respectively added to the apical or 
basolateral compartments. The presence of excess L-leucine (Figure 3B) or L-lysine (Figure 
3C) in the apical compartment reduced intracellular levodopa accumulation, as well as the 
transepithelial transport in all cell lines used. These results suggest that both L-lysine and L-
leucine compete with levodopa, as expected for transport via b0,+AT-rBAT. 
Adding excess L-leucine to the basolateral compartment increased transepithelial transport of 
levodopa in cells expressing LAT2-4F2hc (Figure 3D, gray bars). These result suggests 
basolateral L-leucine stimulated the antiporter LAT2-4F2hc to export intracellularly 
accumulated levodopa to the basolateral compartment. To test whether y+LAT1-4F2hc could 
also be involved in basolateral levodopa efflux, we analyzed the influence of the y+LAT1 
substrate lysine. The presence of excess L-lysine in the basolateral compartment had no 
effect on levodopa transport (Figure 3E), suggesting it does not transstimulated the efflux of 
intracellularly accumulated levodopa via antiporter y+LAT1. Based on these results we 
suggest that LAT2-4F2hc, but not y+LAT1, participates in basolateral levodopa efflux. 
Neutral and cationic amino acids compete with levodopa for its absorption in the 
murine small intestine. 
Levodopa accumulation in intestinal enterocytes was tested using mouse everted rings of 
different small intestinal segments (duodenum, jejunum and ileum). Cellular uptake was 
similar in all three intestinal segments in the condition tested (Figure 4A) and uptake-rates 
were therefore pooled for the competition experiments depicted in Figure 4B. Adding excess 
non-labeled cationic AA L-arginine or neutral AA L-leucine to the uptake solution reduced 
intestinal levodopa uptake (Figure 4B), similarly as observed in the cell culture (Figure 3B, C) 
or in Xenopus laevis oocytes (Figure 2B) for transport via b0,+AT-rBAT. 
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Basolateral uniporter TAT1 affects transepithelial levodopa transport in vivo 
To analyze the role of the basolateral AA uniporter TAT1 on levodopa efflux from mucosal 
cells into the serosal compartment and on its transepithelial transport, levodopa accumulation 
was measured using everted intestinal sacs. Intracellular levodopa accumulation in tat1 
(slc16a10) knockout mice did not differ from wild type animals (Figure 4C), whereas 
transepithelial levodopa transport was significantly reduced in preparation made  from knock-
out animals when compared to wild type mice (Figure 4D). These results suggest the 
aromatic amino acid transporter TAT1 to play a major role mediating levodopa efflux from 
intestinal enterocytes. 
Circadian and gender influence on transporters involved in levodopa absorption.  
Absorption of levodopa in humans follows a circadian rhythm with faster absorption during 
daytime and delayed absorption during night [142]. Furthermore, gender differences in 
levodopa bioavailability and clinical presentation were observed [143] [144]. We hence 
analyzed the expression of transporters involved in levodopa transport in the small intestine 
of male and female rodents during the active (related to daytime in humans) and non-active 
phase (related to nighttime in humans). Intestinal gene expression of transporters involved in 
levodopa absorption (b0,+AT-rBAT, LAT2-4F2hc and TAT1) were not different between male 
and female mice and during active and non-active phase along the small intestine (Figure 
5A). The RNA expression of b0,+AT-rBAT was not different in males and females or during the 
different activity periods (Figure 5A), while protein expression of b0,+AT showed a tendency to 
higher levels during the active phase in male animals when compared to female rodents, but 
did not differ among groups during the non-active period (Figure 5B).   
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Discussion 
In this study we identify the molecular mechanism involved in intestinal levodopa absorption. 
Levodopa is the main therapeutic agent used to treat Parkinson’s disease. It structurally 
belongs to the class of large neutral amino acids, which also includes L-tyrosine, L-
phenylalanine, L-tryptophan, L-leucine, L-isoleucine (Ile) and L-valine [145]. For more than 20 
years it was suggested that levodopa absorption should take place by the same active 
transporters as large neutral amino acids, but the identity of the transporter(s) was not known 
[146]. By using several experimental models, we could show that b0,+AT-rBAT (SLC7A9-
SLC3A1, apical), LAT2-4F2hc (SLC7A8-SLC3A2, basolateral) and TAT1 (SLC16A10, 
basolateral) are the amino acid transporters responsible for small intestinal levodopa 
absorption.   
Levodopa is transported by the luminal enterocyte transporter b0,+AT-rBAT but not by 
the major neutral amino acid transporter B0AT1-ACE2 
In the blood brain barrier (BBB), levodopa was shown to be actively transported by the neutral 
amino acid antiporter LAT1-4F2hc [122]. In the kidney, its apical transport was suggested to 
involve the antiporter b0,+AT-rBAT [134,147]. Several different AA transporters for neutral 
amino acids are expressed in the apical membrane of small intestinal enterocytes [1] and 
might therefore likewise transport levodopa. The broad neutral AA transporter B0AT1 
(SLC6A19) is the main luminal neutral amino acid transporter in the intestine and a likely 
candidate. B0AT1 transports amino acids with close structural homology to levodopa 
(including in particular the aromatic amino acids Phe and Tyr). The IMINO transporter SIT1 
(SLC6A20) and the proton-dependent amino acid transporter PAT1 (SLC36A1) represent 
other AA transporters of the apical enterocyte membrane. Both transporters to some extent 
also transport neutral amino acids [87,148]. The amino acid exchanger ASCT2 (SLC1A5) 
transports neutral amino acids as well, and was suggested to be expressed at the apical 
membrane of small intestinal enterocytes [149]. More recent data suggest however that it 
localizes rather to the basolateral membrane [......Borer]. We thus assayed the potential 
transport of levodopa by these different known or predicted luminal AA transporters, 
specifically B0AT1, SIT1 (SLC6A20), PAT1 (SLC36A1), ASCT2 (SLC1A5) and b0,+AT-rBAT. 
With the exception of the cells expressing the antiporter b0,+AT-rBAT, other transporters listed 
here did not show levodopa transport (Figure 1). Despite the fact that the main neutral amino 
acid transporter B0AT1-ACE2 transports large neutral amino acids (Tyr and Phe) whose 
structure differ from levodopa only by the presence of less hydroxyl groups on the aromatic 
ring, oocytes expressing B0AT1 did not show levodopa transport as evidenced by two-
electrode voltage clamp or accumulation of radiolabeled AA. The hydroxyl group substitution 
seems to reduce B0AT1 affinity to the substrate, but had no effect on b0,+AT-rBAT mediated 
transport. b0,+AT-rBAT transports Phe, Leu, Tyr, as well as methionine, glutamine, histidine, 
ornithine, cationic amino acids and the di-peptide cystine [126,130,150]. Furthermore, the 
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transporter b0,+AT-rBAT was also previously shown to be involved in intestinal drug 
(gabapentin) absorption in rodents [136] and renal levodopa re-absorption [134]. It suggests a 
less rigorous selectivity of the transporter by accepting diverse small molecule structures. 
This broad substrate selectivity makes luminal intestinal and proximal tubule transporter 
b0,+AT-rBAT an interesting pharmacological target. Broad selectivity was also observed for 
the basolateral antiporter LAT2-4F2hc and by the BBB levodopa transporter LAT1-4F2hc. 
LAT2-4F2hc was shown to transports a broad range of proteinogenic neutral amino acids, 
and additionally accepted levodopa, 3-o-methyldopa, T3 and T4 hormones. LAT1-4F2hc was 
shown to accept levodopa, 3-o-methyldopa, α-methylphenylalanine, α-methyltyrosine, α-
methyldopa, phenylalanine methylester (Phe-Me), T3 hormone and gabapentin [121]. 
Interestingly, dopamine formed by the metabolism of levodopa is not transported by b0,+AT-
rBAT [134], LAT2-4F2hc [121], LAT1-4F2hc, TAT1 [79], or B0AT1-ACE2 [137]. Different 
substrates (i.e. amino acids) compete according to their affinity and local concentration for 
their transporter. In humans’ small intestine, the co-administration of Leu was shown to 
decrease the absorption of levodopa [69], an effect that might be explained by competition of 
these two amino acids for transepithelial transport. In our study we reveal the molecular 
mechanism of this competition in the small intestine. By using oocytes and cell cultures 
overexpressing b0,+AT-rBAT we could demonstrate that Leu or cationic amino acids inhibit 
levodopa transport by competing for the apical transporter b0,+AT-rBAT (Figures 2 and 3). 
Furthermore, Leu and cationic amino acids competed with levodopa along the mouse small 
intestine (Figure 4), similarly as reported in humans. The uptake of levodopa was comparable 
in the three segments of mouse small intestine (Figure 5A), even though we observed higher 
expression of b0,+AT RNA and protein levels towards the ileum, as shown previously [70]. In 
humans, we also observed that b0,+AT (SLC7A9) gene expression increases towards the 
more distal segments of the small intestine (Vuille-dit-Bille et al., unpublished data). The fact 
that gene/protein expression and absorption levels did not correlate might be explained by 
other influencing factors, including gastrointestinal motility, gastric secretion and gastric 
emptying [1,123,151,152].  
Taken together, b0,+AT-rBAT appears to be the only luminal enterocyte levodopa transporter, 
and its transport is competitively inhibited by luminal neutral- and dibasic amino acids.  
Levodopa is metabolized to dopamine by the dopamine decarboxylase in different tissues, 
including brain, kidney and intestine [134,147]. To prevent levodopa metabolism prior to its 
transport across the BBB, it is usually administered in combination with a DDCI such as 
carbidopa or bensirazide. Further inhibitors of levodopa metabolism, such as the COMT 
inhibitor entacapone may be included in the formulation [22]. The transport mechanism of 
these substrates in the small intestine is not known. Carbidopa is not transported by LAT1-
4F2hc and LAT2-4F2hc [121,122], however, a possible effect of carbidopa, bensirizide or 
entacapone on b0,+AT-rBAT transport were not yet assayed. Despite the fact that carbidopa, 
entacapone or benserazide have some structural similarity to levodopa, no inhibition of 
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levodopa transport in X. laevis oocytes expressing b0,+AT-rBAT was observed (Figure 2b). 
We thereof conclude that levodopa transport across the luminal enterocyte membrane 
mediated by b0,+AT-rBAT is not affected by the co-administration of carbidopa, entacapone or 
benserazide.  
Since b0,+AT-rBAT is an obligatory amino acid exchanger (antiporter), it was suggested that 
preloading cells with amino acids could increase levodopa uptake. Hence, b0,+AT-rBAT was 
shown to functionally interact with the peptide transporter PEPT1 (Slc15a1). Peptides 
transported inside the cell by PEPT1 and subsequently metabolized to single amino acids 
could be used by b0,+AT-rBAT as exchanger substrates (trans-stimulation). Nguyen and 
colleagues [136] showed that the increased amount of intracellular neutral amino acids 
following PEPT1 mediated peptide uptake and intracellular metabolism to single amino acids 
increased the entry of gabapentin mediated by b0,+AT-rBAT, resulting in increased 
accumulation of the drug in rat jejunum. Using X. laevis oocytes the intracellular concentration 
of amino acids can be directly manipulated, but preloading oocytes with the cationic amino 
acid L-arginine showed only a trend to increased L-leucine and levodopa uptake (Figure 2C) 
that was not statistically significant. The functional interaction of transporters may be more 
complex and other intracellular amino acids may be involved as shown for LAT1-4F2hc and 
ASCT2 functional interaction couples [153]. Important to notice, that the higher intracellular 
concentration of the cationic b0,+AT-rBAT substrate Arg did not inhibit the levodopa 
accumulation in cells. These results suggest that a preload of cells before the ingestion of 
levodopa may not be deleterious.   
Transepithelial transport of levodopa depends on LAT2-4F2hc and TAT1 expression in 
the basolateral membrane  
The basolateral large neutral amino acid antiporter LAT2-4F2hc (SLC7A8-SLC3A2) and the 
basolateral uniporter TAT1 (SLC16A10) [26,134,154] were previously assayed in 
overexpression systems for their ability to transport levodopa. In our epithelial cell culture 
model [Bauch et al.,], labeled levodopa was given to the luminal compartment, but the same 
concentration of unlabeled levodopa was also given in the basolateral compartments. 
Expression of the basolateral antiporter LAT2-4F2hc induced an increase in basolateral efflux 
of labeled levodopa. This suggests that intracellular levodopa was exchanged with 
extracellular one. The apparent affinity of LAT2-4F2hc for levodopa on the extracellular 
compartment was estimated to be in the micromolar range [154], whereas its intracellular 
affinity is not known, but may be lower as observed for other neutral amino acids [78]. The 
fact that additional high basolateral Leu (5 mM), but not Lys (5 mM), further transstimulated 
levodopa efflux ~2-foldindicates that 100 µM extracellular levodopa only approximately half-
maximally activated LAT2-4F2hc function and thus suggests that 100 µM corresponds 
approximately to the K0.5 of this transporter for levodopa. Interestingly, in cells expressing 
additionally TAT1, the same level of labeled levodopa efflux was observed in the absence of 
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high basolateral neutral amino acids. This may be explained by the fact that TAT1 is a 
uniporter (facilitated diffusion pathway) the bidirectional function of which does not depend on 
the presence of contralateral substrate [26,79]. Using this epithelial co-expression system we 
thus showed that both AA transporters LAT2-4F2hc and TAT1 can function as basolateral 
levodopa efflux pathways and consequently participate to its transepithelial transport. 
Interestingly, a functional interaction of these two basolateral enterocyte transporters was 
previously shown [135]. Similarly, as observed for PEPT1 and b0,+AT-rBAT in the apical 
membrane, TAT1 can stimulate the function of the antiporter LAT2-4F2hc. For instance, 
aromatic amino acids exported by the uniporter TAT1 represent high affinity extracellular 
substrates for LAT2-4F2hc that can thus be exchanged by this antiporter with intracellular 
substrates like levodopa, thereby increasing trans-epithelial transport. This functional 
interaction is postulated to be crucial for the net directional transport of LAT2-4F2hc substrate 
amino acids and may thus influence the net levodopa flow. Ex-vivo experiments using everted 
gut sacs of tat1 knockout animals confirmed that TAT1 plays a central role as basolateral 
efflux pathway for levodopa using experimental conditions without basolateral amino acids.  
Levodopa absorption along the small intestine and gender and circadian variation of 
transporters.  
Parkinson patients develop several non-motor symptoms and some have a diurnal 
component suggesting circadian dysfunction [155-157]. Gastrointestinal (GI) dysfunction is 
common in all stages of the disease. Delayed gastric emptying and constipation are the most 
common symptoms [158].!Delayed gastric emptying can influence the absorption of levodopa, 
causing wearing-off symptoms by inducing fluctuations in plasma levodopa levels. Orally 
administered levodopa is usually delivered throughout the day in several doses to avoid the 
wearing-off symptoms, and because the drug was shown to be absorbed faster during the 
active phase [142]. This difference in circadian pharmacokinetics may be a combination of the 
nocturnal delayed gastric emptying, supine position, and daily rhythmicity in gastrointestinal 
enzyme activity and blood flow. Circadian variations in function may be coordinated by a 
combination of a passive response to the daily cycle of food intake and endogenous 
timekeeping system [152]. Furthermore, gene expression levels of some small intestinal 
transporters have been shown to exhibit circadian rhythms. For instance, sugar transporters, 
including the apical Na+ /glucose co-transporter 1 (SGLT1/Slc5a1) and fructose transporter 5 
(GLUT5/Slc2a5) as well as the basolateral hexose transporter GLUT2/Slc2a2 were shown to 
have rhythmic expressions [101,159,160]. Additionally, the expression of amino acid 
transporters involved in drug absorption like the proton coupled peptide transporter 1 
(PEPT1/Slc15a1) also shows a circadian expression cycle [101,160-162]. The mRNA 
expression levels of intestinal transporters b0,+AT, rBAT, 4F2hc, LAT2 and TAT1 during the 
active (reflecting day-time expression in humans) and non-active (reflecting nocturnal gene 
expression in humans) phase of wild-type mice were not significantly different in the present 
study. The expression of the gene encoding the PEPT1 transporter, previously shown to 
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increase in the active phase [101], showed a similar tendency in our experiments that was 
however not statistically significant. In contrast, the protein expression level of the apical 
transporter b0,+AT measured in brush border membrane vesicles was significantly increased 
during the active phase in male animals, but interestingly not in females. Since the changes in 
RNA levels precede the changes at the protein level, as shown for PEPT1 [162], we may 
have missed RNA changes that potentially took place earlier. Differences in the circadian 
cycle of male and females as observed in our study are not yet well understood [163], but 
importantly also in PD patients, gender differences have been indicated to play a major role. 
Men are more affected than women by the disease and its clinical symptoms and also onset 
and treatment outcomes differ [164,165]. Because in subjects receiving the same drug 
formulation a higher plasma concentration was found in females, it was suggested that the 
pharmacokinetics of levodopa would differ although in these studies the dose was not 
corrected to the body weight [144] [166] [167]. The higher plasma concentration in females 
could also be the result of differing metabolism or absorption, the latter parameter depending 
on gastric emptying and secretion, gastrointestinal motility, and transporter expression. The 
question of the influence solute transporter expression for the absorption of drugs is a 
growing field [168], but data related to gender differences are sparse.  
Taken together, this study identifies the intestinal players involved in the absorption of 
levodopa, and detects b0,+AT-rBAT as luminal enterocyte levodopa transporter. Moreover, 
this study also sheds light on the basolateral membrane with new information about the 
transporters involved in the second step of the transepithelial transport. The identification of 
the transporters involved in levodopa absorption, their mechanism of action, knowledge about 
trans-stimulation or competitive inhibition are very valuable information to optimize strategies 
for delivery and absorption of levodopa, the most important therapeutic agent in Parkinson’s 
disease.   
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Legends 
Figure 1: Levodopa is transported by the luminal enterocyte transporter b0,+AT-rBAT, 
but not by the major neutral amino acid transporter B0AT1-ACE2. A) Oocytes 
expressing b0,+AT-rBAT transport levodopa as efficiently as L-leucine. Oocytes were 
injected with cRNA encoding mouse PAT1 (20ng), human SIT1 (5ng) and human accessory 
protein ACE2 (20 ng), human B0AT1 (10 ng) and human accessory protein ACE2 (10ng), 
human ASCT2 (10 ng), or human b0,+AT-rBAT fusion protein (10 ng). Levodopa uptake rates 
(100 µM; white bars) were compared to uptake rates of 100 µM L-glycine (PAT1), 100 µM L-
proline (SIT1-ACE2), 100 µM L-leucine (B0AT1-ACE2 and b0,+AT-rBAT) and 100 µM L-
alanine (ASCT2) (dark grey bars), respectively. The uptakes were performed at 25°C for 10 
minutes. Results are expressed in pmol/oocyte/hour and values of non-injected oocytes were 
subtracted. Uptake results of control amino acids were normalized to 1. Bars represent 
means ± SEM, n= 4-9 injected oocytes per group. **, p < 0.01; ***, p < 0.0001; ns, not 
significant (unpaired two-tailed t-tests). B and C) Oocytes expressing B0AT1-ACE2 do not 
transport levodopa. B) Levodopa does not induce current in oocytes expressing B0AT1-
ACE2: Oocytes expressing B0AT1-ACE2 were superfused with L-leucine, L-phenylalanine L-
tyrosine or levodopa (1 mM each). Results are expressed as current generated by the 
transport at a membrane potential  of -50 mV and are represented as means ± SEM, n= 4 
oocytes per group. *, p < 0.05 (ANOVA with post-hoc Dunnett’s Multiple Comparison test). C) 
Levodopa is not accumulated in oocytes expressing B0AT1-ACE2. The transport of L-leucine, 
L-phenylalanine, L-tyrosine and levodopa was assayed by measuring radiolabeled compound 
accumulation (1 mM, 30 minutes). Results are expressed in pmol/oocyte/hour and values of 
the non-injected oocytes were subtracted. Results are given as means ± SEM, n= 5-6 
oocytes per group. *, p < 0.05 (ANOVA with post-hoc Dunnett’s Multiple Comparison test). 
Figure 2: The transport of levodopa by b0,+AT-rBAT can be inhibited by excess of 
neutral amino acids (and vice versa), but not by DDC inhibitors or COMT inhibitors. 
Transstimulating cells with L-arginine does not significantly increase levodopa uptake. 
A) Competitive inhibition of levodopa and L-leucine transport. Radiolabeled levodopa 
(50 µM, white bars) and L-leucine (50 µM, black bars) uptake in X. laevis oocytes expressing 
b0,+AT-rBAT was assayed in the presence or absence of excess non-labeled L-leucine (5mM) 
and levodopa (5mM), respectively. Results are expressed in pmol/oocyte/hour. Non-injected 
oocytes were subtracted. Results are expressed as mean ± SEM, n= 7-8 injected oocytes per 
group. **, p < 0.01; ***, p < 0.0001 (unpaired two-tailed t-tests). B) DDC inhibitors 
bensirazide and carbidopa and the COMT inhibitor entacapone do not compete with 
b0,+AT-rBAT mediated levodopa transport. The transport of levodopa (1 µM / minute) was 
assayed alone (white bar), in the presence of bensirazide (50 µM, gray bar), carbidopa (50 
µM, crosshatch bar), or entacapone (50 µM, black bar). Results are expressed in 
pmol/oocyte/hour and values of non-injected cells were subtracted. Data are represented as 
means ± SEM, n= 7-8 injected oocytes per group. The comparison of the ‘treatment’ groups 
! 
100!
with the ‘control’ group (levodopa alone) yielded no differences (ANOVA with post-hoc 
Dunnett’s Multiple Comparison test). C) Intracellular L-arginine does not affected 
levodopa uptake into X. laevis oocytes expressing b0,+AT-rBAT. Oocytes were injected 
with the b0,+AT-rBAT antiporter substrate L-arginine (final concentration in the oocyte 
achieved was 12.5 mM) or water (negative control). After 4 hours, the uptake with L-levodopa 
(50 µM; white bars) or L-leucine (50 µM; black bars) was performed. Data are represented as 
means ± SEM, n= 8-9 injected oocytes per experiment. No significant differences were seen 
(unpaired two-tailed t-tests; p > 0.05). 
 
Figure 3: Transepithelial transport of levodopa depends on b0,+AT-rBAT expression in 
the apical and LAT2-4F2hc and TAT1 on the basolateral membrane. MDCK cells 
expressing the apical transporter b0,+AT-rBAT (white bars), the apical transporter b0,+AT-rBAT 
and basolateral transporters LAT2-4F2hc and y+LAT1-4F2hc (gray bars) and (additionally to  
apical b0,+AT-rBAT and basolateral LAT2-4F2hc and y+LAT1-4F2hc)  TAT1 (black bars) were 
assayed in 5 different conditions (3A-E). A) Radiolabeled levodopa was added to the apical 
compartment. B), Radiolabeled levodopa and L-leucine (5 mM) were added to the apical 
compartment. C) Radiolabeled levodopa and L-lysine (5 mM) were added to the apical 
compartment. D), Radiolabeled levodopa in the apical compartment and L-leucine (5 mM) in 
the basolateral compartment. E), Radiolabeled levodopa in the apical compartment and L-
lysine (5 mM) in the basolateral compartment. In the conditions A-E both compartments 
contained solutions supplemented with 100 µM levodopa, 50 µM bensirazide, and 100 µM of 
ascorbic acid. The intracellular (middle panels) and the basolateral accumulation (right 
panels) of levodopa were measured and subtracted from the wild type cell values. Results are 
expressed in nmol/hour/cm2 and given as mean ± SEM, n= 5-6 filters per experiment. *, p < 
0.05 (ANOVA with post-hoc Bonferroni’s Multiple Comparison test). 
Figure 4: Levodopa transport takes place all along the small intestine and can be 
inhibited by addition of luminal L-leucine and L-arginine or by ablation of basolateral 
transporter TAT1. A) Levodopa accumulates similarly in all segments of the small 
intestine. Everted rings from duodenum, jejunum and ileum were incubated with levodopa 
(100 µM) at 37°C (white bars) or 4°C (crosshatched bar). Results are expressed in pmol/mg 
dry tissue/ 5min and given as nean ± SEM, n= 9-11 experiments per group. No significant 
differences between different intestinal localizations were seen (ANOVA with post-hoc 
Bonferroni’s Multiple Comparison test; p > 0.05). B) Neutral and cationic amino acids 
compete with levodopa transport. Excess of L-leucine (1 mM, gray bar) and L-arginine (1 
mM, black bar) were added to the uptake solution. Values obtained at 37°C were subtracted 
from uptakes performed at 4°C. Results are expressed in pmol/mg dry tissue/ 5min and given 
as mean ± SEM, n= 7-9 experiments per group. *, p < 0.05; **, p < 0.01 (ANOVA with post-
hoc Dunnett’s Multiple Comparison test). C and D) The ablation of TAT1 decreases 
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transepithelial levodopa transport. Everted jejunal sacs of wild type (black bars) and TAT1 
knockout animals (gray bars) were assayed for levodopa transport. The accumulation in the 
tissue (mucosa) (4C) and the levodopa accumulation in the sacs resulting from the 
transepithelial transport (serosal) (4D) were quantified. Results are expressed in nmol/mg of 
dry tissue/ 10 minutes. Values at 4°C were subtracted and data are given as mean ± SEM, n= 
11-12 everted sacs per group. Ns, not significant; *, p < 0.05 (unpaired two-tailed t-tests). 
Figure 5: Intestinal b0,+AT-rBAT expression varies with gender and circadian rhythm at 
protein but not at RNA level. A) Expression of mRNA encoding the transporter b0,+AT-
rBAT (Slc7a9-Slc3a1), LAT2-4F2hc (Slc7a8-Slc3a2), TAT1 (Slc16a10) and peptide 
transporter PEPT1 (Slc15a1) in male and female animals during active and inactive 
periods were unchanged. The gene expression of animals in the active (4 hours after the 
dark phase onset) and non-active phase (4 hours after the light phase onset) were analyzed 
by quantitative real time PCR. Results are expressed relative to the housekeeping gene 
HPRT and given as mean ± SEM, n= 3 female (solid bars) and 3 male (hatched bars) 
animals. ns, not significant; *, p < 0.05 (multiple two-tailed t-tests without applying a posttest 
to correct the global α-level). B) The protein level of b0,+AT in male animals is higher 
during the active phase when compared to the inactive phase. B) Expression of b0,+AT in 
the duodenum (white bars), jejunum (gray bars) and ileum (black bars) of female (solid bars) 
and male (hatched bars) mice in the active and inactive phase were analyzed by Western blot 
analysis of brush border membrane vesicles (50 µg). The Western blots were quantified by 
densitometry and normalized to beta actin. The results are expressed relative to actin and 
given as mean ± SEM, n= 3 animals each gender. ns, not significant; *, p < 0.05 (multiple 
two-tailed t-tests without applying a posttest to correct the global α-level).   
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Figure 3 
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8. Conclusion)and)outlook)
 
8.1. Conclusion)
 
SLC family transporters that function as symporters (cotransporters) or antiporters 
(exchangers) use electrochemical gradients of inorganic (or organic) solutes as driving force 
to actively transport specific substrates across cellular membranes. About 400 genes have 
been identified that are grouped according to sequence similarities (of 20% or more) into 52 
SLC families[38,42]. In polarized cells (such as small intestinal enterocytes), solute carriers 
are targeted to the luminal or basolateral membranes, where they mediate substrate influx or 
efflux, respectively. Substrate specificities of SLC transporters may be wide (as for instance 
of B0AT1[37], accepting the bulk of neutral amino acids) or narrow (as for instance of 
SIT1[48]) and several transporters show overlapping substrate specificities. For example, 
both luminal amino acid transporters B0AT1 and SIT1 accept glycine and proline (with low 
affinity to B0AT1) as substrates. Similarly, the monosaccharide transporter GLUT2 which can 
transiently be inserted in the luminal membrane accepts the SGLT1 substrates glucose and 
galactose as well as the GLUT5 substrate fructose[102]. Furthermore, some SLC transporters 
(such as for instance PEPT1, PAT1 or b0,+AT-rBAT) also recognize therapeutic agents as 
substrates. Since membrane permeation across the gastrointestinal tract is one of the critical 
determinants for oral drug bioavailability, it is essential to precisely understand localization 
and function of these SLC transporters.  
The quantity of absorbed nutrients may be modulated to meet body needs. This type of 
intestinal adaption occurs at the physiological, cellular and molecular level and reduces the 
risk of malnutrition in cases of e.g. short bowel syndrome[169]. Different growth factors, 
including Inslulin-like growth factors, Human growth hormone, Epidermal growth factor, etc. 
were shown to mediate this small intestinal adaption[170].  
The regulation of expression and activity of intestinal SLC transporters is poorly 
understood[171]. Factors that may affect SLC transporter expression and function include 
presence or absence of accessory proteins, functional interactions of amino acid transporters, 
transporters’ substrates, gastrointestinal diseases, medications et cetera; The presence of the 
luminal dipeptidase ACE2 for instance is necessary for adequate B0AT1 expression in the 
brush border membrane of intestinal enterocytes as shown in ACE2 knock-out mice exhibiting 
almost abolished luminal membrane B0AT1 expression[5]. Another example of limiting factor 
is the Na+/H+ exchanger NHE3 (SLC9A3) that maintains intracellular pH, and hence the 
transmembrane H+-electrochemical gradient that is necessary to drive the function of H+-
coupled (drug) transporters including PAT1 and PEPT1[43]. SLC transporters were shown to 
functionally interact for the transport of specific substrates using heterologous expression 
systems: for instance, recycling of aromatic amino acids (such as phenylalanine) via T-type 
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aromatic amino acid transporter TAT1 was shown to allow the efflux of other neutral amino 
acids that are not transporterd by TAT1 (such as glutamine) via the L-type amino acid 
exchanger LAT2-4F2hc[135]. It seems expectable that the transporters’ substrates might 
regulate transporter expression, as shown for the substrate fructose regulating transcription of 
fructose transporter GLUT5 expression. This regulation appears to be specific, since only 
GLUT5, but not GLUT2 or SGLT1 expression is affected by dietary fructose[99]. Similarly, 
intestinal amino acid transporter expression is known to be induced by increased dietary 
protein levels[171]. Per contra, AA transporter expression may also increase in response to 
incomplete absorption of dietary proteins[171] such as for instance in short bowel syndrome.  
At the molecular level, different major signaling pathways were shown to regulate gene 
expression within the intestinal epithelium including the Hedgehog family members Forkhead 
Box (FOX) factors and Hepatocyte nuclear factors 1α and 1β[172]. Regulatory mechanisms 
that may mediate these expression changes include regulatory microRNAs binding to mRNA 
transcripts and epigenetic regulations including imprinting, DNA methylation, regulation of 
histone modifications, and chromatin remodeling[172], but the involved sensing mechanisms 
are not known.  
Different diseases and medications were shown to alter intestinal SLC transporter expression 
and function. Diseases affecting the intestinal microclimate pH such as Celiac disease or 
enterotoxin exposure reduce absorption of H+-coupled transporter (i.e. PAT1 or PEPT1) 
substrates including the therapeutic agents salicylate and folate[43]. Furthermore, intestinal 
SLC mRNA levels were shown to be dysregulated in patients suffering from inflammatory 
bowel disease (IBD)[173]. Interestingly, PEPT1 expression was shown to be up-regulated in 
the large intestine of patients suffering from IBD, indicating, that the di- and tripeptide 
transporter plays a role in IBD pathogenesis. PEPT1 hereby transports colonic bacterial di- 
and tripeptides into colonocytes maintaining inflammation[174,175]. Among medications 
affecting intestinal SLC transporter expression and function, especially antidiabetics 
(including rosiglitazone, metformin and insulin) were shown to alter gene and protein 
expression of monosaccharide transporters and also of peptide transporter 
PEPT1[14,60,176]. 
During my PhD I focused on the regulation of intestinal SLC transporter expression in 
humans suffering from certain diseases (such as Parkinson’s disease or type 2 diabetes 
mellitus) and/or in patients treated with certain medications. The transport of dietary contents 
across the small intestinal epithelium displays one of the first steps of interaction between 
ingested solutes (i.e. amino acids, monosaccharides, drugs, etc.) and the human body. 
Several diseases relate to diet (such as for instance type 2 diabetes mellitus) and also the 
absorption of several medications is influenced by dietary compositions. With this PhD work 
we hence intended to assess in humans the effect of medications such as ACE-inhibitors, 
angiotensin II AT1 receptor blockers and metformin), of diseases such as type 2 diabetes 
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mellitus) as well as of dietary transporter substrates (i.e. dietary amino acids and dietary 
glucose overload in type 2 diabetes mellitus) on small intestinal amino acid and 
monosaccharide transporter expression and function. 
 
In one observational study, the effect of chronic ACE-inhibitors and angiotensin II AT1 
receptor blockers intake on intestinal ACE2 and associated transporters expression was 
assessed. This study first confirmed that also in human ACE2 acts as an accessory protein 
for distinct amino acid transporters of the SLC6 family expressed in small intestine and 
interestingly showed that ACE2 gene and protein expression was modified in patients treated 
chronicaclly with these drugs. The underlying observation for another study was that dietary 
monosaccharides, experimental diabetes mellitus and metformin treatment had been shown 
to affect intestinal monosaccharide transporter expression and function in rodents[17,20,61-
65]. We thus tested whether also in human subjects type 2 diabetes mellitus and/or metformin 
treatment also alter small intestinal monosaccharide transporter expression and hence 
probably also intestinal glucose absorption. Starting point for a further study was the fact that 
the main therapeutic agent for Parkinson’s disease, levodopa, is a neutral amino acid. We 
studied its intestinal absorption mechanism and, since different amino acids may compete for 
its intestinal absorption, we tested the effect of routinely co-administered drugs (i.e. carbidopa 
or bensirazide) and of dietary amino acids on intestinal absorption.  
 
We could hereby show that dietary compositions may affect the absorption of specific drugs 
(such as neutral amino acids affecting intestinal levodopa transport), that certain medications 
affect the expression pattern of intestinal SLC transporters (such as ACE inhibitors affecting 
the brush border membrane expression of B0AT1, PAT and PEPT1), and that certain 
diseases (such as diabetes mellitus type 2) affect small intestinal hexose transporter GLUT2 
expression.  
 
8.2. Open)questions)
 
Human)intestine)luminal)ACE2)and)amino)acid)transporters)are)regulated)by)ACEQ
inhibitors)
 
SIT interacts with ACE2 and collectrin. We could show a functional interaction of the 
system IMINO transporter SIT1 and the accessory proteins ACE2 and collectrin (TMEM27), 
similarly as previously shown for the named accessory proteins and neutral amino acid 
transporter B0AT1[5,46]. ACE2 and collectrin hereby seem to increase SIT1-mediated L-
proline transport via increasing the transporters’ cellular surface expression without changing 
the apparent affinity to its transported substrate.  
Does ACE2-deficiency affect small intestinal SIT1 expression? It remains to be 
investigated, whether ACE2-deficiency decreases small intestinal SIT1 expression in vivo. 
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Unfortunately, a specific antibody against mouse SIT1 is still lacking[177] and therefore SIT1 
expression in the ACE2 knock-out mouse could not be measured yet. 
 
Treatment with ACE-inhibitors increases small intestinal gene expression of ACE2, 
B0AT1, PAT1 and PEPT1. Furthermore, our findings show an association of long-term ACE-
inhibitor treatment with an increased gene expression of small intestinal ACE2 and of luminal 
amino acid and peptide transporters B0AT1, PAT1 and PEPT1 and thus suggest a causal 
relationship. The question remains open whetherthe increased gene expression of ACE2, 
B0AT1, PAT1 and PEPT1 upon ACE-inhibitor treatment is functionally relevant in terms of 
amino acid absorption and homeostasis. Indeed, blood plasma and urine amino acid levels as 
detected by high performance liquid chromatography (HPLC) analysis were not different 
between treated and non-treated patients. This is however not surprising, in view of the small 
number of subjects and the interindividual differences and because blood plasma and urine 
AA levels are subjected to many different other influencing factors, including diet as well as 
liver- and muscle metabolism[178]. Follow-up studies performing experiments such as stable 
isotope uptakes in human subjects or animals would have to be executed to answer this 
question. 
 
Does the increased small intestinal gene expression of transporters B0AT1, PAT1 and 
PEPT1 have an effect on drug absorption? Since several drugs are transported via the 
amino acid and peptide transporters PAT1 (as e.g. vigabatrin or 5-aminolaevulinic acid) and 
PEPT1 (as e.g. β-lactams, angiotensin converting enzyme inhibitors or valacyclovir)[43], it 
would be interesting to perform a follow-up study assessing a potential impact of ACE-
inhibitor treatment on intestinal drug absorption. It can be speculated that ACE-I treatment 
affects the pharmacokinetics of these drugs. Labeled drug uptake rates and/or post-intake 
plasma levels of non-labeled drugs or metabolites in patients under ACE-inhibitor treatment 
versus non-treated controls would have to be measured to test this hypothesis. 
 
Why does ACE-inhibitor treatment increase small intestinal ACE2, B0AT1, PAT1 and 
PEPT1 mRNA expression? As discussed in the manuscript, the mechanism by which ACE-
inhibitors might increase the expression of these genes is not clear, but an increase in ACE2 
upon ACE-inhibitor treatment has previously been observed in different organs of rodents 
including heart, kidney and large vessels[6,7,179]. The involved regulatory pathway(s) are not 
known and the possible mechanisms mediating the mRNA upregulation include 
transcriptional activation, RNA stabilization and epigenetic regulations. 
As the mRNA expression of ACE2 correlated with the gene expression levels of B0AT1, 
PEPT1 and PAT1, a comparative promoter analysis was performed in order to identify 
potential common regulatory sequences. Hereby, common promoter modules with conserved 
transcription factor binding sites were found. Screening of the human promoter database for 
the occurrence of these modules revealed its presence only in 7 other genes, whereof only 4 
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genes showed small intestinal mRNA expression levels reliably quantifiable by qPCR. The 
product of none of these genes was increased in ACE-I-treated patients, indicating that these 
modules are per se not sufficient to mediate the ACE-induced regulation, but not excluding 
their involvement.  
Hepatocyte nuclear factors 1a (HNF1a) and 4a (HNF4a) are transcriptional activators 
expressed in different organs including pancreas, liver, kidney, and intestine and are known 
to participate to the regulation of the expression of many tissue-specific genes,in particular for 
their differentiation-induced expression in enterocytes. Furthermore, both transcription factors 
were shown to induce B0AT1 expression, whereas the ACE2 promoter could be activated 
only by HNF1a[98]. Hence, the expression of HNF1a and HNF4a was assessed in ACE-I 
treated patients and compared. The results of these experiments were pending, when the 
present thesis was written. 
 
Intestinal)monosaccharide)transporter)expression)in)diabetic)patients)–)effect)of)
metformin)treatment))
 
mRNA levels of GLUT2 were increased almost 2-fold in human small intestine in non-
treated diabetics when compared to metformin-treated diabetics and non-diabetic 
controls, respectively. Why is the expression of GLUT2 increased diabetic patients? Of 
course, similar regulatory mechanisms as those involved in ACE2, B0AT1, PAT1 and PEPT1 
gene expression regulation upon ACE-I treatment (including transcriptional activation, RNA 
stabilization and epigenetic regulations) may cause GLUT2 up-regulation in diabetes mellitus 
type 2. 
Since in kidney of diabetic rats, hepatocyte nuclear factors 1a, 3b and 4b (HNF-1a, HNF-3b 
and HNF-4a) were shown to play a substantial role in the overexpression of the GLUT2 
gene[112,113], the expression of these transcription factors was assessed. Results of this 
experiment are pending when the present manuscript was written. 
In experimental diabetes, but also in fructose- and/or glucose rich diets in rodents, the 
basolateral high-capacity, low-affinity facilitative glucose, fructose and galactose transporter 
GLUT2 also shows (transient) expression in the apical enterocyte membrane[18]. Whether 
the increased small intestinal GLUT2 mRNA expression observed in the present study is 
associated with a (transient) luminal transporter expression is being investigated by using 
immunofluorescence to visualize the subcellullar GLUT2 protein localization in the biopsy 
specimens. The results of these experiments were still lacking, when the present report was 
written. 
Metformin-treatment decreased small intestinal GLUT2 mRNA to normal expression 
levels (as measured in non-diabetic controls). Might this effect reflect a new 
mechanism of metformin action? In the present study only the gene expression of GLUT2 
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was measured. Furthermore, protein expression was visualized by immunofluorescence, 
which only allows a semi-quantitative analysis of protein expression (results pending when 
the present report was written). ‘Less’ GLUT2 transporter mRNA as observed in diabetic 
patients under Metformin treatment does not necessarily mean ‘less’ transport, especially not 
in a redundant system such as the small intestine. Hence, follow-up studies assessing the 
absorption of radiolabeled GLUT2-substrates glucose, galactose and/or fructose would be 
necessary to answer this question. Nevertheless, assuming that metformin-treatment affects 
small intestinal monosaccharide absorption as shown in rats, where metformin significantly 
decreased glucose absorption in the perfused intestine[14] we may only speculate whether 
metformin directly affects intestinal SLC transporter expression or whether it is the lower 
plasma glucose levels that influence intestinal monosaccharide transporter expression. 
Interestingly, metformin mostly accumulates in the small intestine after oral administration 
suggesting the digestive tract being a relevant site of metformin action[180]. 
GLUT5 gene expression showed a similar trend as GLUT2 with a tendency of increase in 
non-treated human type 2 diabetics (when compared to non-diabetics and to metformin-
treated type 2 diabetics) without yielding statistical significance. Is GLUT5 expression 
altered in human type 2 diabetics or not? Unfortunately, the present study was a pilot 
study and thus a power analysis was not feasible. The group of non-treated type 2 diabetics 
consisted of only n= 5 individuals because most diabetic patients undergoing 
gastroduodenoscopy during the time of the study were under treatment. Hence the GLUT5 
gene expression would have to be tested in a larger cohort of patients to obtain a clear 
conclusion. 
 
The)molecular)mechanism)of)intestinal)levodopa)absorption)and)its)implications)on)
treatment)of)Parkinson’s)disease))
 
As expected, neutral amino acids competed for b0,+AT-rBAT-mediated levodopa transport 
across the luminal enterocyte membrane. However, preloading cells with dibasic amino acids 
which are exchange substrates for b0,+AT-rBAT mediated levodopa transport, did not 
significantly transstimulate the uptake of levodopa by this obligatory exchanger).  
 
May protein-sensitive fluctuating motor response to levodopa treatment in patients 
with end-stage parkinsonism be explained by competition of levodopa and dietary 
amino acids for small intestinal absorption? As shown in the present study ex-vivo using 
mouse everted rings as well as applying the heterologous expression system X. laevis 
oocytes, b0,+AT-rBAT substrates (Leu, Arg) compete for b0,+AT-rBAT-mediated levodopa 
transport. Accordingly, it was shown, that low-protein diets ameliorate daily motor fluctuations 
in end-stage Parkinson patients with severely depleted dopamine stores. Similarly, perfusion 
of human small intestine with L-leucine decreased intestinal levodopa absorption[69]. We 
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hypothesize that competition for b0,+AT-rBAT mediated levodopa transport across the brush 
border membrane at least in part explains the reduction of fluctuating motor symptoms in end-
stage Parkinson patients upon protein-restricted diets.  
 
May a transstimulation of small intestinal enterocytes with dibasic amino acids (as e.g. 
L-arginine) increase levodopa absorption? Since b0,+AT-rBAT is an amino acid 
heteroexchanger[91], it seems to be evident, that preloading cells (small intestinal 
enterocytes) with dibasic b0,+AT-rBAT-substrates (such as L-arginine) would increase neutral 
amino acid (such as levodopa or L-leucine) uptake by so-called transstimulation. As 
suggested by Pineda and co-workers in 2004 using the two electrode voltage clamp 
technique in X. laevis oocytes[181], preloading oocytes with Arg indeed increased Leu 
transport and vice versa. In contrast, when we preloaded oocytes with L-arginine (as shown 
in the present study), there was only a non-significant increase in L-leucine or levodopa 
uptake measured by radiolabeled intracellular substrate accumulation. Whether these diverse 
findings reflect technical limitations, may not be answered, since Pineda et al. did not 
measure radiolabeled substrate uptake and per contra we did not utilize the by two-electrode 
voltage clamp technique. Of course, X. laevis oocytes endogenously contain dibasic amino 
acids[78,182], and it is not clear to what extent this endogenous level suffices to fully trans-
stimulate the uptake of extracellular substrates. Transferred to Parkinson patients – assuming 
that Pineda and co-workers were right – one might expect that protein-rich meals 1 or 2 hours 
before levodopa intake could increase levodopa uptake by transstimulation. But, (as 
suggested by Pineda et al.[181]) whereas transstimulation with the dibasic amino acid Arg 
increased Leu uptake, L-leucine preload appeared to decrease transcellular Leu transport, 
observations that are supported by our data obtained with ex-vivo mouse everted rings as 
well as using X. laevis oocytes. Hence, a L-arginine-rich- and L-leucine-poor diet would be 
necessary to transstimulate levodopa absorption in vivo, assuming intracellular dibasic amino 
acid levels in small intestinal enterocytes are below the saturation level of b0,+AT-rBAT.  
 
 
8.3. Outlook)and)personal)statement)
 
During my PhD I intended to test the impact of dietary nutrients (i.e. amino acids), of drugs 
(i.e. ACE-inhibitors, angiotensin II AT1 receptor blockers, metformin) and of disease (i.e. type 
2 diabetes mellitus) on small intestinal nutrient (i.e. amino acid and monosaccharide) 
transporter expression. To assess possible regulatory mechanisms underlying the discovered 
changes in expression patterns, expression of transcription factors were assessed (ongoing) 
and/or ex-vivo experiments were performed.  
We hereby found that chronic intake of ACE-inhibitors increases small intestinal expression of 
distinct amino acid transporters and of intestinal ACE2. Furthermore, a functional interaction 
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of IMINO transporter SIT1 and of accessory protein ACE2 was shown for the first time. In 
addition, type 2 diabetic patients were shown to exhibit increased intestinal GLUT2 
transporter mRNA expression, an effect that was annihilated by metformin treatment. Finally, 
we could identify the small intestinal amino acid transporters responsible for absorption of the 
main Parkinson drug levodopa and dietary neutral amino acids were shown to compete small 
intestinal levodopa absorption.  
Due to my personal intention to pursue an academic career in pediatric surgery I aim to 
continue my research career undertaking translational research. Hence, the subsequent two 
follow-up projects were started adjacent to my PhD thesis:  
The first project intends to assess the impact of small intestinal atresia on amino acid and 
monosaccharide transporter expression in the human newborn gut: An interesting 
model to assess the effect of dietary nutrients on intestinal nutrient transporter expression 
constitutes the human newborn suffering from small intestinal atresia. It is hypothesised that 
small intestinal atresia (referring to a complete obstruction of the small intestine) occurs 
secondary to an ischemic insult in the later pregnancy or primary to a malformation in the 
early pregnancy[183]. Intestinal segments distal to congenital small intestinal obstruction 
have been suggested to be immature due to lack of luminal access of amniotic fluid, that 
contains inter alia carbohydrates, amino acids, peptides, proteins, lipids and multiple growth 
factors[184,185]. In collaboration with the Children’s Hospital of Zurich, we started to sample 
tissue samples proximal and distal to the atretic segment. The preliminary analysis of genes 
and proteins assessed in 4 human newborns (aged 1 to 4 days) suffering from small intestinal 
atresia indicates a reduced gene expression of some basolateral amino acid- as well as of 
luminal hexose transporters GLUT5 and SGLT1 in the small intestine distal to the atretic 
segment. 
 
The second project examines the amino acid and monosaccharide transporter 
expression in colorectal cancer and kidney cell carcinoma: Tumor cells require a high 
and constant supply of nutrients to support their characteristic unabated growth. Amino acids 
provide the primary source of cellular nitrogen, which is used for nucleotide-, glutathione-, and 
protein synthesis. Monosaccharides are used as an oxidative fuel source for ATP generation. 
To fulfil these metabolic needs, tumor cells must express large amounts of specific nutrient 
transporters on their cellular membranes[186].  
AA transporter LAT1 (L-type amino acid transporter 1; SLC7A5) is responsible for large 
neutral amino acid transport and has been shown to be highly expressed in different tumors, 
including prostatic-, oesophageal-, gastric-, pancreatic- and pulmonary carcinoma [186,187]. 
It has thereof been indicated, that LAT1 serves as prognostic predictor, diagnostic tool and 
specific molecular target in cancer diagnostics and therapy. In addition, CD98hc (SLC3A2), a 
type II transmembrane cell surface molecule, has been described in different tumors, 
including melanoma, squamous cell carcinoma of the larynx and adenocarcinomas of the 
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lung [188]. 
The diagnostic of colorectal cancer mainly consists of ileo-colonoscopy, whereas kindey cell 
carcinomas are often an incidental finding in abdominal CT scans executed for different 
reasons. The main therapeutic option in both, colorectal cancer and kindey cell carcinoma, 
still consists of complete surgical removal, which may be followed by other therapies, 
including chemotherapy and radiation[189].  
Whereas some amino acid transporters/transporter subunits have been shown to be highly 
expressed in different tumor cells (see above), the “transportome” of colorectal cancer- and 
kidney cell carcinoma cells has not been identified yet. Since amino acid and 
monosaccharide absorption in small intestine and re-absorption in kidney proximal tubule is 
provided by different transport proteins, that must functionally interact in order to guaranty net 
unidirectional amino acid and monosaccharide transport[1,135], we assume several amino 
acid and monosaccharide transporters being highly expressed in colorectal cancer and 
kidney cell carcinoma cells. 
 
In collaboration with the division of Pathology of the University Hospital of Zurich, we hence 
aim to assess the tumor transportome in human colorectal cancer and human kidney cell 
carcinoma. 
  )
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